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INTRODUCTION 
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AND SUSTAINED-RELEASE  
FROM MULTIPARTICULATE  
POLYMERIC DOSAGE FORMS  
 
 
 
Hot-melt extrusion comprises the forcing of material through an opening (extrusion die) by 
means of pressure. During the process, thermoplastic polymer(s), active ingredient(s) and other 
processing aids are fed into a heated barrel and the polymer-drug blend is transferred through the 
machine towards the die: the excipients melt or soften at the elevated temperature and the molten 
mass is continuously kneaded and pressurized, and finally the homogeneous melt is pumped 
through the die attached to the end of the barrel. As material passes through the die, the material 
acquires the shape of the die opening and the material solidifies: the extruded product is referred 
to as the extrudate. When the shape of the die is changed, the final product may take the form of 
a film, cylinder or tube [1-4]. 
 
It is not the aim of this introduction to provide a complete literature review about hot-melt 
extrusion, but the most important aspects about this processing technique as well as its use for 
pharmaceutical applications will be discussed in the next paragraphs, as a motivation why this 
production technique was selected to produce sustained-release mini-tablets. 
 
Materials can be extruded in the molten state or in the solid state. It is called melt-fed 
extrusion when the extruder is fed with molten polymer. Solid-state extrusion occurs when the 
material is fed to the extruder as a solid; the material will melt or soften by the elevated 
temperatures of the extruder screw as it is conveyed from the feed port to the die [2]. 
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Extrusion process technology can be divided into two categories based on their mode of 
operation: ram extrusion (discontinuous) and screw extrusion (continuous). Ram extrusion 
operates with a positive displacement ram capable of generating high pressures to force material 
through a shaping die, while screw extrusion consists of a rotating screw or set of screws inside a 
heated barrel. During ram extrusion, materials are introduced into a heated cylinder. After an 
induction period to soften the materials, a ram (or a piston) pressurizes the soft materials through 
the die and transforms them into the desired shape (Figure 1). High pressure is the operating 
principle of ram extrusion. The major drawback of ram extrusion is the limited melting capacity that 
causes poor temperature uniformity in the extrudate. Also, extrudates prepared by ram extrusion 
have lower homogeneity, in comparison with extrudates processed by screw extrusion [5]. 
 
 
     
 
Figure 1: Ram extrusion using a capillary die [5]. 
 
Unlike ram extrusion, a screw extruder provides more shear stress and intense mixing. A 
distinction can be made based on the number of screws incorporated in the extruder, resulting in 
single-screw, twin-screw and multi-screw extruders. As indicated by the name, the difference 
between a single-screw and twin-screw extruder is whether one or two screws are utilized in the 
machine. Also, they differ in the type of material transport and mixing abilities that take place in the 
extruder: using a single-screw extruder, one screw rotates inside the barrel and is used for 
feeding, melting and pumping the material in the direction of the die (a drag-induced type of 
transport), whereas the transport in a twin-screw extruder is to some extent a positive 
displacement type of transport, with a reduced degree of leakage flow since there is a possibility 
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of exchanging material from one screw to the other. An important implication is that a stagnant 
layer may remain at the screw surface: single-screw extruders are less efficient processors than 
twin-screw extruders, and therefore have generally a longer equipment length. On the other hand, 
single-screw extruders do have the advantage over twin-screw extruders in terms of their 
mechanical simplicity, are less expensive and hence provide high productivity-to-cost ratios [6]. 
 
The twin-screw extruder has two agitator assemblies on parallel shafts and rotate together 
with the same direction of rotation (co-rotating) or in the opposite sense (counter-rotating) (Figure 
2). Co-rotating screws can rotate either clockwise or counterclockwise, and both directions are 
equivalent from a processing point of view. If the two screws rotate in different directions, they can 
either rotate towards the center, or rotate away from the center: using the counter-rotating screw 
designs, the material is squeezed through the gap between the two screws as they come 
together. Generally, counter-rotating screw extruders suffer from disadvantages of potential air 
entrapment and low maximum screw speeds and output: these types of extruders are operated at 
lower speeds because of the pressure which is developed from the outward pushing effect as the 
screws come together in rotation. Co-rotating twin-screw extruders can be operated at higher 
screw speeds and achieve higher outputs, while maintaining good mixing and conveying 
characteristics. Both rotational designs with twin-screw extruders have the basic processing 
advantages of positive conveying and effective mixing as compared with single-screw extruders 
[6-9]. 
 
 
 
 
Figure 2: Twin-screw configurations: (top) intermeshing co-rotating twin-screw extruder, (bottom) 
intermeshing counter-rotating twin-screw extruder [6]. 
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These two types can be further separated into non-intermeshing and fully intermeshing. 
For the latter, each agitator element wipes both the surface of the corresponding element on the 
adjacent shaft and the internal surfaces of the mixing chamber, thereby preventing material from 
rotating with the screw which is a significant advantage over single-screw extruders, where the 
material is not being conveyed forward in an efficient manner. The agitators are said to be self-
wiping, an arrangement that eliminates stagnation areas within the mixing chamber and ensures a 
narrow and well-defined residence time distribution. If the agitators are chosen not to intermesh, 
the arrangement comes close to a single-screw set-up and have a lower degree of positive 
conveying: the non-meshing types are also described as double-screws as they are not true twin-
screw extruders, they consist of essentially two single-screws side by side and work in a similar 
way as single-screw extruders. In general, co-rotating shafts have better mixing capabilities as the 
surfaces of the screws move towards each other. As the screws rotate, the flight of one screw 
element wipes the flank of the adjacent screw, causing material to transfer from one screw to the 
other. In this manner the material is transported along the extruder barrel [6-9]. Illustrations of the 
two types (co-rotating and counter-rotating), both intermeshing, are shown in Figure 2. 
 
Twin-screw extruders have several advantages over single-screw extruders, such as 
easier material feeding, high kneading and dispersing capacities and less tendency to overheat 
the material. In addition, twin-screw extruders have the advantage of a shorter residence time, 
therefore, a smaller equipment size is required to achieve an equivalent output, and twin-screw 
extruders are currently used to process larger quantities of material [6-10]. 
 
 The extruder is typically composed of a feeding hopper, barrel, screw, die, screw driving 
unit, and a heating/cooling device. Downstream equipment is used to collect the extrudates for 
further processing. Monitoring devices on the equipment, used for performance and product 
quality evaluation, include temperature gauges, a screw speed controller, an extrusion torque 
monitor and pressure gauges. The extrusion channel is conventionally divided into three sections 
along the length of the barrel: the feed zone (solid conveying zone), the transition zone (melting, 
compression) and the metering zone, as shown in Figure 3. 
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Figure 3: Schematic of an extruder illustrating various functional zones including the hopper, solid 
conveying zone, melting zone, metering zone and die [11]. 
 
The starting material is fed from a hopper directly into the feed section, which has deeper 
flights or flights of greater pitch (Figure 4). 
 
 
 
 
Figure 4: Extrusion screw geometry [8]. 
 
This geometry enables the feed material to fall easily into the screw for conveying along 
the barrel; pitch and helix angle determine the throughput. The channel depth is usually widest in 
this section to facilitate mass flow and transfers the solid material forward as a solid plug into the 
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melting section where it is mixed, compressed, melted and plasticized. Compression is developed 
by decreasing the pitch and channel depth, and entrapped air is removed by the increasing 
pressure. The polymer gradually begins to soften and melts as it enters the melting section; 
melting results from the heat transferred to the barrel from the heating devices as well as from 
heat generated because of the shearing effect of the rotating screw(s). The melt moves by 
circulation in a helical path when entering the metering section; the function of the metering zone 
is to reduce the pulsating flow and to ensure a uniform delivery rate through the die cavity (a 
variety of shapes is possible) [7-10]. 
 
Most extruders have a modular design, providing a choice of screw elements or 
interchangeable sections which alter the configuration of the feed, transition and metering zones 
(Figure 5). This makes it possible to modify the process to meet particular requirements and to 
improve the melting process, from standard extrusion with low shear to high shear extrusion [7-9, 
12, 13]. In an extrusion process, the dimensions of the screws are given in terms of L/D ratio, 
which is the length of the screws divided by the diameter [14]. 
 
 
Figure 5: Screw and kneading elements [8]. 
 
 In a hot-melt extrusion process, polymers are subjected to both thermal and shearing 
stresses. The temperature can contribute to depolymerization of polymer chains, whereas 
polymer chain scission may result from the shearing effects of the screw [4]. So one of the major 
drawbacks of hot-stage extrusion is that it can only be applied when the products are thermally 
stable. For a number of drugs, proteins and other excipients, hot-stage extrusion can not be used 
unless a plasticizer is added in order to reduce the viscosity of the mixture in the extruder and 
therefore to lower the process temperature settings [15]. But, as the residence time in the extruder 
is rather short (up to 2-5 min, depending on the feed rate and screw speed) and the temperature 
of all the barrels are independent and can be accurately controlled from low temperatures to high 
temperatures, degradation by heat can be minimized [7]. 
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For pharmaceutical applications, it can be concluded that this technique offers many 
advantages over conventional pharmaceutical production methods. Neither solvents nor water are 
used for processing since the molten polymer can function as a thermal binder; due to the 
anhydrous nature of the process any potential drug degradation from hydrolysis can be avoided. 
Therefore, fewer processing steps are needed and time-consuming drying steps are eliminated. 
When used as a molding technique, there are no requirements on the compressibility of the 
materials used in the formulation, and the entire process is simple, continuous and efficient. The 
intense mixing and agitation during processing cause suspended drug particles to de-aggregate in 
the molten polymer, resulting in a more uniform dispersion of fine particles. Furthermore, the 
bioavailability of the drug substance may be improved when it is solubilized or dispersed at the 
molecular level in hot-melt extruded dosage forms. Its simplicity on an industrial scale makes it 
popular with pharmaceutical manufacturers [16, 17]. The popularity of continuous processes is 
increasing in the pharmaceutical industry [18]. This way of processing offers several advantages, 
such as improved process efficiency due to reduction of costs and time. Furthermore, scale-up is 
avoided as the amount of material processed can be increased by simply prolonging the process 
time [19]. 
 
Hot-melt extrusion originates from the polymer and food industry [7-9, 16], but several 
research teams explored the possibilities of hot-melt extrusion as an alternative method to 
develop pharmaceutical dosage forms such as granules, sustained-release pellets, matrix tablets, 
matrix-in-cylinder systems, capsules and implants. Hot-melt extrusion also has applications in 
topical drug delivery. In Table 1, an overview is given of hot-melt extrusion used as processing 
technique for pharmaceutical applications: it lists the active drug substances, carriers, extruded 
dosage forms and the references to literature sources. Crowley and co-authors also provided a 
partial listing of some of the drug substances and carriers that have been formulated and 
processed with hot-melt extrusion [9, 20]. 
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Oral solid dosage forms are available as single-unit (non-divided formulation) or 
multiple-unit (divided formulation) forms which can be used for immediate- or sustained-
release drug delivery. Multiple-unit dosage forms consist of numerous sub-units which are 
filled into capsules or sachets, or compressed into tablets which disintegrate instantaneously 
[94, 95]. The sub-units of these multiparticulate dosage forms are granules, pellets or mini-
tablets. Mini-tablets are tablets with a diameter equal to or smaller than 2-3 mm [96]. 
Multiple-unit dosage forms offer a high degree of flexibility during the design and 
development of oral dosage forms: they can be divided into desired doses without 
formulation and process changes, and sub-units with different release profiles can be 
administered simultaneously. Multiparticulates also have therapeutic advantages over single-
units, such as a more predictable gastric emptying which is less dependent on the nutritional 
state: particles smaller than 2-3 mm are rapidly emptied from the stomach regardless of the 
feeding state of the patient and the influence of gastric emptying rate on the upper gastro-
intestinal transit time of mini-tablets is minimized. Furthermore, mini-matrices have a high 
degree of dispersion in the digestive tract (minimizing the risk of high local drug 
concentrations which could damage the mucosa), less variance in transit time through the 
gastro-intestinal tract, less inter- and intra-subject variability (owing to the improvement in 
both transit reproducibility and dispersion in the digestive tract), and a lower risk of dose-
dumping [94, 95, 97-100]. 
 
Intensive research work is conducted on developing pellets as multiparticulate dosage 
form by the classical way of extrusion and spheronization [101-108]. Extrusion/spheronization is 
one of the most established techniques for the production of pellets with high quality, but due to 
the fact that it is a multi-step process, a number of process parameters should be controlled. 
Furthermore, formulation development is of special concern since the moistened mass needs to 
possess specific characteristics in order to be successfully extruded and spheronized, dried and 
coated. Therefore, for this thesis, mini-tablets (3 mm diameter, 2 mm height) will be produced 
instead of pellets, using a hot-melt twin-screw extruder as continuous processing technique since 
mixing, melting, homogenizing and shaping are carried out in a single step. The multiple-unit 
dosage forms were obtained by cutting the extrudates manually into small cylinders using surgical 
blades and are called mini-matrices. For larger scale batches, this cutting can also be performed 
mechanically [109]: the strand discharged from the die is collected on a moving belt, eventually 
cooled by air cooling, followed by cutting the extrudate using a sizing machine. If the extrudate 
needs to be cut to a predetermined length, this can be accomplished with several downstream 
equipments such as a guillotine cutter or rotating knife cutter (a blade is mounted to a disc which 
is driven by a servomotor to cycle the blade in rotary motion) (Figure 6). 
 
 
17
INTRODUCTION 
 
             
(a)       (b) 
 
Knife 
Nozzle 
Extruder screw 
Extruder 
Polymer melt 
  
(c)       (d) 
 
Figure 6: Cut-to-length devices: (a) guillotine cutter, (b) chopper to pelletize tablets [9], (c) rotating 
knife cutter after extrudate is cooled on a moving belt, (d) rotating knife cutter immediately after 
extrusion. 
 
With conventional dosage forms, high peak blood concentrations may be reached soon 
after administration with possible adverse effects related to the high concentration. Repeated 
administration of a drug may cause serious side effects, which in many cases necessitates the 
patient to stop taking medication. Sustained-release formulations are usually intended to optimize 
a therapeutic regimen by providing slow and continuous drug delivery over the entire dosing 
interval in combination with reduced side effects, whilst also providing greater patient compliance 
and convenience by reducing the number of daily doses [110]. 
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The classical way to design an oral sustained-release dosage form is by coating capsules, 
tablets or pellets with insoluble, pH-independent polymers (reservoir type), whereby the 
composition and thickness of the coat determine the drug release pattern. However, coating is a 
time-consuming and expensive process with possible problems related to reproducibility of drug 
release and dose-dumping. Therefore, another common sustained drug delivery system is the 
matrix type, whereby the drug is uniformly dissolved or dispersed throughout the rate-controlling 
polymer and drug release is determined by the excipients incorporated into the formulation and 
not by an outer polymeric membrane. The matrix principle can be applied to single-unit as well as 
to multiple-unit dosage forms, the latter having definite advantages, as described above. 
 
Different strategies have been investigated in an attempt to sustain drug release from 
matrix dosage forms. One strategy is to restrict the matrix surface area exposed to the release 
medium, leading to a decreased matrix hydration and swelling rate and consequently a slower 
drug release rate (e.g. multi-layered hydrophilic tablets [111-115], partial coating of the matrix with 
an impermeable film to restrict matrix swelling [116], a core-in-cup tablet (an inert cup into which a 
drug-containing matrix layer was compressed, thus leading to a matrix with only one side in 
contact with the surrounding medium) [117], RingCap®, an oral controlled-release drug delivery 
system consisting of a capsule-shaped matrix tablet to which bands of insoluble material are 
applied circumferentially to the surface of the tablet (these bands modified drug release by 
controlling the surface area, which changed over time as the area around the bands became 
hydrated and eroded creating new surface area) [118-120], matrix-in-cylinder systems or covered-
rod-type formulations (a hydrophilic matrix tablet placed in an impermeable cylinder, reducing drug 
release to the open ends of the cylinder) [61-66, 121], etc.). Varying the geometry is also a 
possible means of altering release kinetics from matrix systems: matrix systems having spherical, 
cylindrical, biconvex, donut shapes, etc. [122-128]. 
 
However, for this thesis, instead of manipulating the surface available for drug release in 
order to have sustained drug release, mini-matrices will be produced. Therefore, the ultimate goal 
of this project is to obtain sustained drug release using polymers which decrease drug dissolution 
and diffusion/erosion since we deal with a large surface area from the multiparticulate dosage 
form under investigation. Matrix tablets composed of drug and the release-retarding material 
(polymer) offer a simple approach to design a sustained-release system. The materials that are 
commonly used include: (a) hydrophobic materials, (b) insoluble, erodible materials or (c) 
hydrophilic polymers [129]. 
 The mechanism of drug release from the first two classes (a and b) of insoluble polymers 
is considered to be diffusion of the drug from the matrix as a result of liquid penetration, therefore 
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hydrophobic matrix carriers (e.g. ethylcellulose, glycerides, waxes) have been investigated as 
drug carriers [21-23, 25, 53, 54, 130-132]. 
In contrast, especially hydrophilic polymer-based dosage forms are very popular and well-
described since drug release from these matrices is controlled by a combination of polymer 
swelling, front movement, drug dissolution and diffusion through the hydrated gel, and matrix 
erosion [133]. Despite their high water solubility, they are very successful in sustaining drug 
release: upon contact with the surrounding medium, the hydrophilic polymer swells and develops 
a highly viscous surface barrier which controls the liquid penetration into and the drug release 
from the system, thus, retarding drug diffusion. Until now, hydroxypropylmethylcellulose has been 
widely studied, reviewed by many authors and is the excipient chosen by most formulators for 
hydrophilic matrix systems [134-143] as well as polyethylene oxides [40, 58, 76, 80, 144-150]. 
Also natural materials were extensively investigated as hydrophilic matrix carrier: xanthan gum 
[44, 151-167], galactomannan [156, 159, 168], guar gum [169-173] and carrageenan [174-178]. 
However, drug release from a hydrophilic matrix is generally characterized by a burst 
effect; the drug present at the surface is quickly released, then with time, as the diffusion path 
length increases the release rate is progressively reduced. Therefore, it is often desirable to mix 
different polymers in an optimum ratio to synchronize the movement of the swelling and erosion 
fronts in the tablets [179-182]. Only few investigators performed research on the mechanism of 
drug release from solid dispersions prepared with water insoluble and water soluble polymers, 
combining ethylcellulose and hydroxypropylmethylcellulose [46, 47, 183]. No detailed 
investigations were conducted on the drug release from matrix tablets formulated with 
ethylcellulose as carrier material with xanthan gum or polyethylene oxides to tailor drug release. 
 
Combining the advantages of hot-melt extrusion as processing technique and sustained-
release multiparticulate dosage forms – to achieve a plasma concentration-time profile within the 
optimal therapeutic range in combination with reduced side effects – resulted in the production of 
a sustained-release multiple-unit matrix dosage form manufactured by hot-melt extrusion. The 
challenge of this doctoral thesis is to sustain drug release from the mini-matrices using a 
combination of hydrophobic (ethylcellulose) and hydrophilic polymers (xanthan gum, polyethylene 
oxides): hydrophilic polymers will be added to obtain zero-order release kinetics with complete 
drug release within 24 h, by making the hydrophobic drug carrier more accessible to the release 
medium, without resulting in burst release. 
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Previous research work showed that sustained-release mini-matrices formulated with a 
combination of ethylcellulose and a hydrophilic polymer (hydroxypropylmethylcellulose, xanthan 
gum) could be manufactured using the hot-melt extrusion technique. The release of ibuprofen, 
selected as model drug, was influenced by the concentration, viscosity grade and substitution type 
of hydroxypropylmethylcellulose, and the investigators only briefly discussed a formulation 
consisting of ethylcellulose, ibuprofen and xanthan gum [1]. No detailed study was performed to 
evaluate the influence of xanthan gum concentration and particle size on ibuprofen release. 
Therefore, CHAPTER 1 further explores the possibilities of xanthan gum as hydrophilic polymer to 
tailor ibuprofen release from ethylcellulose/xanthan gum mini-matrices. The influence of xanthan 
gum concentration and particle size on the in vitro behaviour of the mini-matrices (drug release 
and mechanism, liquid uptake/swelling/erosion, porosity/friability/hardness) was evaluated and a 
stability study over 12 months at different storage conditions was conducted. In addition, the 
ibuprofen bioavailability from these hot-melt extruded mini-matrices was evaluated in dogs. 
Since ibuprofen acts as a plasticizer for ethylcellulose, ibuprofen was substituted in 
CHAPTER 2 by metoprolol tartrate, a non-plasticizing drug. We studied the influence of different 
plasticizers and plasticizer concentrations on the performance of the hot-melt extrusion process, 
the quality of the extrudate and mini-matrices, and the in vitro release properties of metoprolol 
tartrate. The influence of xanthan gum concentration was investigated in order to obtain mini-
matrices with zero-order release kinetics. In addition, the effect of extrusion process parameters 
(screw design, powder feed rate and screw speed) on the extrusion process, extrudate and mini-
matrices quality, drug and polymer crystallinity, drug homogeneity and in vitro release 
characteristics is described.  
 CHAPTER 3 deals with the addition of polyethylene oxides as hydrophilic polymer to tailor 
metoprolol tartrate release from the lipophilic ethylcellulose matrix-cores: the influence of 
polyethylene oxide concentration as well as its molecular weight was investigated on drug and 
hydrophilic polymer release, drug distribution, and drug and polymer crystallinity. An in vivo study 
in dogs was performed and the bioavailability of metoprolol tartrate from 
ethylcellulose/polyethylene oxide and ethylcellulose/xanthan gum mini-matrices was compared.  
CHAPTER 4 reports the modelling of metoprolol tartrate and polyethylene oxide release 
from hot-melt extruded mini-matrices.  Based on time-independent diffusion coefficients, drug 
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release was predicted from mini-matrices with different dimensions. In case the drug release was 
not only diffusion-controlled, a new mathematical model was developed (taking the porosity 
changes during dissolution into account) to better describe drug release and predict drug and 
polymer distribution in the mini-tablets in function of dissolution testing. 
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ABSTRACT  
 
Mini-matrices (multiple-unit dosage form) with release-sustaining properties were 
developed by means of hot-melt extrusion using ibuprofen as model drug and ethylcellulose 
as sustained-release agent. Xanthan gum, a hydrophilic polymer, was added to the 
formulation to increase drug release since ibuprofen release from the 
ibuprofen/ethylcellulose matrices (60/40, w/w) was too slow (20% in 24 h). Changing the 
xanthan gum concentration as well as its particle size modified the in vitro drug release. 
Increasing xanthan gum concentrations yielded a faster drug release due to a higher liquid 
uptake, swelling and erosion rate. Regarding the effect of the xanthan gum particle size, no 
difference was observed for formulations containing 10 and 20% xanthan gum. However, 
using 30% xanthan gum, drug release was influenced by the particle size of the hydrophilic 
polymer due to the susceptibility of the coarser xanthan gum particles to erosion. Drug 
release from the mini-matrices was mainly diffusion-controlled, but swelling played an 
important role to obtain complete drug release within 24 h. Drug release was influenced by 
the ionic strength of the medium as the conformation of xanthan gum molecules is 
determined by the salt concentration. An oral dose of 300 mg ibuprofen was administered to 
dogs (n = 6) either as an immediate-release preparation (Junifen®), as a sustained-release 
formulation (Ibu-Slow® 600 mg (½ tablet)) or as the experimental mini-matrices (varying in 
xanthan gum concentration). Administration of the experimental formulations sustained the 
ibuprofen release. Although a significant difference in dissolution rate of the 20 and 30% 
xanthan gum mini-matrices was detected in vitro, the difference in relative bioavailability 
(using Ibu-Slow® 600 mg as reference) was limited (70.6 and 73.8%, respectively).  
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1. INTRODUCTION 
 
Hot-melt extrusion is becoming a widely used technology in the pharmaceutical industry to 
produce matrix formulations into which a drug is homogeneously embedded. Its major advantage 
over conventional techniques (e.g. direct compression) for manufacturing matrices is the 
continuity of the production process as the different steps (mixing, melting, homogenizing and 
shaping) are carried out on a single machine. This implicates a decrease in investment costs and 
offers more opportunities for automation of the production. Furthermore, this technique has a high 
throughput and limited material loss, yielding material having excellent homogeneity [1-3]. 
The excellent feasibility of ethylcellulose, a polymer with thermoplastic properties, for 
hot-stage extrusion has been established in a variety of applications [4-7]. Previous work [8-
10] has shown that hot-melt extrusion can be used as an appropriate technique to develop 
mini-matrices using ethylcellulose to sustain the release of ibuprofen, selected as the model 
drug. The combination of ethylcellulose and a hydrophilic component such as 
hydroxypropylmethylcellulose (HPMC) offered a flexible system to tailor the drug release by 
changing the viscosity, substitution type and concentration of HPMC. Substituting HPMC for 
xanthan gum yielded formulations having a nearly zero-order drug release without burst 
effect and complete drug release within 24 h. In addition, the incorporation of xanthan gum 
resulted in a longer sustained-release effect, allowing to use a lower concentration of 
hydrophilic polymer [11]. Rheological and drug diffusion studies in hydrated HPMC and 
xanthan gum compacts elucidated the difference in the release-controlling ability of both 
polymers [12-14]. The higher ability of xanthan gum to control drug release in comparison 
with HPMC most probably originates from their different hydrophilicity, hydration properties 
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and swelling behaviour. Whereas a gradual increase in liquid uptake and swelling prevailed 
for the HPMC systems, the maximum liquid uptake and swelling was reached within 2 h for 
the xanthan gum formulation, quickly forming a viscous gel around the matrix core.  
In the present study, sustained-release mini-matrices were developed by hot-melt 
extrusion of an ibuprofen/ethylcellulose mixture with the addition of xanthan gum to tailor 
drug release, whereby the influence of the concentration as well as the particle size of 
xanthan gum on the in vitro characteristics of the mini-matrices was investigated. The in vivo 
performance of these experimental formulations was evaluated in dogs and compared with 
an equivalent dose of a sustained-release ibuprofen matrix tablet (Ibu-Slow® 600 mg).  
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2. MATERIALS AND METHODS 
 
2.1. Materials  
 
2.1.1. Ibuprofen 
 
Ibuprofen (IBP) (average diameter: 25 µm) was received from Knoll Pharmaceuticals 
(Nottingham, UK) and selected as model drug (Figure 1).  
CH3
CH3
CH3
O
OH
 
 
Figure 1: Chemical structure of ibuprofen. 
 
It is a chiral non-steroidal anti-inflammatory drug (NSAID), which is widely used for 
the treatment of acute and chronic musculoskeletal inflammations and the control of mild to 
moderate pain due to its anti-inflammatory, analgesic and antipyretic properties. Ibuprofen is 
administered as a racemic mixture of R-(-)-ibuprofen and S-(+)-ibuprofen. S-(+)-ibuprofen is 
the pharmacological active compound. However, R-(-)-ibuprofen is also related with the 
therapeutic activity of the drug since it is in vivo partially converted to S-(+)-ibuprofen via a 
unidirectional mechanism [15-18], and investigators performed research work on the 
stereoselective disposition of ibuprofen enantiomers [19, 20]. Maximum ibuprofen plasma 
concentrations are achieved within 1-2 h after ingestion of the drug, but due to its short half 
life of approximately 2 h therapeutic blood concentrations can only be maintained if the drug 
is administered frequently (multiple daily dosing). Slowing down the ibuprofen release from 
the formulation could reduce the dose regimen to a once or twice a day scheme, enhancing 
patient compliance and therefore making it a suitable candidate for sustained drug delivery. 
Besides, a slower ibuprofen release could also decrease the occurrence of gastro-intestinal 
(GI) side effects since the main adverse effects are GI disturbances [21]. Hot-melt extrusion 
is a viable method to develop solid dispersions and solid solutions to improve the 
bioavailability of poorly soluble compounds [3, 22-26]. The low aqueous solubility of 
ibuprofen provides a scientific rationale for its incorporation in the dosage form under 
investigation. 
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2.1.2. Ethylcellulose 
 
The matrix consisted of ethylcellulose (EC) (Ethocel® Std 10 FP Premium; particle 
size: 3-15 µm; ethoxyl content: 48-49.5% (w/w); viscosity: 9-11 mPa.s (5% solution in 
toluene/EtOH 80/20, 25°C)), kindly donated by Dow Chemical Company (Midland, USA).  
 
Ethylcellulose, an ethylether of cellulose, is a long chain polymer of β-anhydroglucose 
units, where the number of monomers (n) can vary to provide a wide variety of molecular 
weights (Figure 2; with partially ethoxyl substitution, degree of substitution = 2). 
Ethylcellulose ethers are a family of inert hydrophobic polymers (organosoluble 
thermoplastics) that are essentially tasteless, odourless, colourless, non-caloric and 
physiologically inert. Ethylcellulose is useful in a variety of pharmaceutical applications: as 
rate-controlling polymer in matrix tablets, as tablet binder and cushioning agent, as viscosity-
increasing agent, as coating polymer, as granulation binder and as matrix for solid 
dispersions [27]. In our study, ethylcellulose was applied as sustained-release agent. 
O
OHO
O
O C2H5
C2H5
n
 
 
Figure 2: Chemical structure of ethylcellulose. 
 
 
2.1.3. Xanthan gum 
 
Xanthan gum (XG), available in different particle sizes (Xantural® 75 (XG75), 
Xantural® 180 (XG180) and Xantural® 11K (XG11K) having a mean particle size of 75, 180 
and 1180 µm, respectively) was supplied by CP Kelco (Liverpool, UK).  
 
Xanthan gum (Figure 3) is a high molecular weight extracellular polysaccharide 
produced by the gram-negative bacterium Xanthomonas campestris through a fermentation 
process. The primary structure of this naturally produced cellulose derivative consists of a 
cellulosic backbone (β-D-glucose residues) and a trisaccharide side chain containing two 
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mannose units and one glucuronic acid residue. The terminal D-mannose may carry a 
pyruvate function, the non-terminal D-mannose unit (closest to the backbone) in the side 
chain contains an acetyl function. The degree of acetylation and pyruvylation varies, 
depending on the fermentation conditions. The anionic character of the polymer is due to the 
presence of both glucuronic acid and pyruvic acid groups in the side chain. Next to its use as 
thickening agent in the food and cosmetics industry, it has also applications in 
pharmaceutical formulations to thicken, suspend, stabilize and emulsify. It has also been 
reported by many authors that xanthan gum can be used as an effective excipient for 
sustained-release formulations [27-32]. For our purposes, xanthan gum was incorporated in 
the dosage form to tailor drug release from the lipophilic carrier, ethylcellulose. 
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Figure 3: Chemical structure of xanthan gum (where M+ = Na+, K+ or ½ Ca2+). 
 
 
All other chemicals were at least of analytical grade (VWR, Leuven, Belgium). 
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2.2. Methods  
 
2.2.1. Composition of the mixtures 
 
The ibuprofen content was kept constant at 60% (w/w) and the remaining part of the 
formulation consisted of ethylcellulose and xanthan gum. The xanthan gum concentration 
varied between 10 and 30% (w/w). All formulations are listed in Table 1.  
 
Table 1: Composition (%, w/w) of the hot-melt extruded formulations. 
 10% XG 20% XG 30% XG 
Ibuprofen 60 60 60 
Xanthan gum (XG75, XG180 or XG11K) 10 20 30 
Ethylcellulose 30 20 10 
 
 
2.2.2. Production of mini-matrices 
 
Prior to hot-melt extrusion the formulations were blended in a planetary mixer (15 min, 90 
rpm) (Kenwood Major Classic, Hampshire, UK). Hot-melt extrusion was performed using a lab-
scale intermeshing co-rotating twin-screw extruder (MP19TC-25, APV Baker, Newcastle-under-
Lyme, UK) with a length-to-diameter ratio of 25/1 (Figure 4).  
 
 
Figure 4: Schematic diagram of a twin-screw extruder with (a) control panel, (b) driving unit, 
(c) feeding hopper, (d) barrel with screws and (e) die.  
 
The machine was equipped with a Brabender twin-screw powder feeder, a Technodrives 
DC motor and a Tricool cooling unit. The barrel, containing the screws, is divided into 5 zones of 
which the temperature can be set separately. A control panel is used for setting the temperature, 
the screw speed and the powder feed rate (the process parameters). Some process variables 
such as the pressure, the material temperature and the torque can be recorded from the control 
a b 
e c d 
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panel. A screw with two mixing sections (Figure 5) and a cylindrical die of 3 mm was used for the 
production of the mini-matrices. For all formulations, the following extrusion conditions were used: 
a screw speed of 30 rpm, a powder feed rate of 6 g/min and a temperature of 50°C for the five 
heating zones along the barrel. After cooling down to room temperature, the extrudates (∅ = 3 
mm) were manually cut into mini-matrices of 2 mm length.  
 
 
 
Figure 5: Configuration of the intermeshing co-rotating screws. Screw configuration with 2 
kneading blocks: (1) transport zone, (2) mixing zone, (3) transport zone, (4) mixing zone, (5) 
transport zone, (6) densification zone.  
 
 
2.2.3. In vitro evaluation 
 
2.2.3.1. In vitro drug release 
 
The mini-matrices (approximately 60 mg) were introduced in a basket (USP 27, 
dissolution apparatus 1 [33]). The dissolution was performed in a VK 7010 dissolution system 
combined with a VK 8000 automatic sampling station (VanKel, New Jersey, USA). 
Phosphate buffer KH2PO4 (pH 7.2, µ = 0.11) was used as the dissolution medium. The 
temperature of the medium (900 ml) was kept at 37 ± 0.5°C, while the rotational speed of the 
baskets was set at 100 rpm. Samples of 5 ml were withdrawn at 0.5, 1, 2, 4, 6, 8, 12, 16, 20 
and 24 h and spectrophotometrically analyzed for ibuprofen at 221 nm by means of a Perkin-
Elmer Lambda 12 UV-VIS double beam spectrophotometer (Zaventem, Belgium). The 
ibuprofen concentrations were calculated from a calibration curve between 0 and 50 µg/ml. 
The dissolution was simultaneously performed in 6 dissolution vessels, each vessel 
containing 4 mini-matrices. As the solubility of ibuprofen is pH-dependent, one could think to 
investigate the impact of different pHs on the formulations tested. Phosphate buffer pH 7.2 
was selected for dissolution testing (as recommended by USP for ibuprofen dosage forms 
[33]) since it is most challenging at this pH to develop a sustained-release platform as the 
solubility of ibuprofen is the highest at this pH. 
1 2 3 4 5 6
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Additional rotational speeds of 50 and 200 rpm were used during dissolution testing in 
order to evaluate the influence of matrix erosion on drug release. 
The susceptibility of the mini-matrices to ionic strength was verified by dissolution 
testing in diluted phosphate buffer and phosphate buffer with increasing NaCl concentrations: 
µ = 0.011 (10-fold dilution), µ = 0.022 (5-fold dilution), µ = 0.055 (2-fold dilution), µ = 0.11, µ = 
0.15 and µ = 0.2. Sodium chloride was added to the medium, since these are the main 
electrolytes in the gastro-intestinal fluid [34].  
To determine the in vitro release properties of the formulations used for in vivo 
evaluation, a dissolution was also performed on a hard-gelatin capsule (n° 00) filled with 500 
mg mini-matrices.  
 
To understand the drug release mechanism from swellable matrices, the data (Mt/M∞) 
were fitted to the following exponential equation (equation 1) [35-38]: 
 
nt kt
M
M =
∞
                     (1) 
 
This equation generally holds for the initial phase of the release profile (Mt/M∞ ≤ 60%). Mt/M∞ 
is the percentage drug released at time t, k denotes a constant incorporating the structural 
and geometric characteristics of the release device and the exponent n is a release constant 
used to characterize the transport mechanism. The values of n were obtained by logarithmic 
calculation of equation 1. 
 
Images of the mini-matrices, after immersion in the dissolution medium, were made 
with a digital camera (C3030 Olympus) attached to an image analysis system (analySIS®, 
Soft Imaging system, Münster, Germany).  
 
 
2.2.3.2. Liquid uptake, erosion and swelling measurements 
 
The mini-matrices were introduced into USP dissolution apparatus 1 and submitted to 
a dissolution test (n = 3) under the conditions described above (100 rpm, µ = 0.11), each 
vessel containing one mini-matrix. At predetermined time intervals (dissolution sampling 
points), they were withdrawn from the medium and weighed after removing excess surface 
water.  
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Liquid uptake (expressed as % weight gain of the polymer content (ethylcellulose and 
xanthan gum)) was determined from the weight of the mini-matrices, taking into account the 
drug released (equation 2): 
 
( ) ( )
( )0
0%
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DRWDRWuptakeliquid
i
itw
−
−−−=  x 100                           (2) 
 
where  Ww = weight of the mini-matrix at time ‘t’ after immersion in the dissolution medium 
 Wi = initial weight of the mini-matrix at time ‘0’ 
 DR0 = amount of drug in the mini-matrix at time ‘0’ 
 DRt = amount of drug in the mini-matrix at time ‘t’ 
 
The degree of erosion (expressed as % erosion of the polymer content) was determined 
based on the weight difference between the dried mini-matrix and its initial weight, considering the 
amount of drug released (equation 3): 
 
( ) ( )
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−
−−−=  x 100                                     (3) 
 
where  Wd = dry weight of the mini-matrix at time ‘t’ after immersion in the dissolution medium 
 Wi = initial weight of the mini-matrix at time ‘0’ 
 DR0 = amount of drug in the mini-matrix at time ‘0’ 
 DRt = amount of drug in the mini-matrix at time ‘t’ 
 
The height and diameter of the mini-matrices were measured using a digital calliper 
(Bodson, Luik, Belgium) to determine the axial and radial swelling, respectively.  
 
 
2.2.3.3. Porosity 
 
The porosity of the mini-matrices was calculated, based on the difference between the 
apparent and true volume of the extrudates. After measuring the exact height and diameter of the 
extrudate (∅ = 3 mm, length = 30 mm), the total apparent volume was calculated (n = 10). The 
true volume of 10 extrudates was measured using a helium pycnometer (AccuPyc 1330, 
Micromeritics, Norcross, USA) (one analysis is the mean of 10 measurements, n = 10). The 
porosity was expressed as a percentage of the apparent volume. 
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2.2.3.4. Friability 
 
10 g of mini-matrices together with 200 glass beads (∅ = 4 mm) (to increase the 
mechanical stress) were placed in a friabilator, equipped with an abrasion wheel (Pharma 
Test Type PTF E, Hainburg, Germany). After rotating for 10 min (25 rpm), the glass beads 
were removed. The size fraction > 250 µm was recovered by shaking for 5 min at an 
amplitude of 2 mm using a Retsch VE 1000 Shaker (Retsch, Haan, Germany), and the 
weight loss was expressed as a percentage of the initial weight of the mini-matrices. A 
weight loss of not more than 1% was considered acceptable [33]. 
 
 
2.2.3.5. Crushing strength 
 
The hardness of the mini-matrices was analyzed using a hardness tester (Pharma 
Test Type PTB 311, Hainburg, Germany). 10 tablets were analyzed and the force needed to 
break each tablet was registered. 
 
 
2.2.3.6. Stability study 
 
The XG75 formulations were selected for stability testing according to the USP 
guidelines [33]. Mini-matrices were stored at 25 ± 2°C/60 ± 5% relative humidity (RH) and at 
40 ± 2°C/75 ± 5% RH.  
 
The in vitro drug release, moisture content and hardness of the mini-matrices were 
determined as a function of storage time (12 months), storage conditions and xanthan gum 
concentration.  
 
The moisture content of the mini-matrices was determined using a Mettler Toledo 
DL35 Karl Fisher titrator (Mettler Toledo, Beersel, Belgium) in combination with a Mettler 
DO337 oven operated at 170°C. The samples (approximately 100 mg) were placed in the 
oven and the moisture evaporated from the sample during 10 min was carried to the titration 
vessel by a nitrogen stream (300 ml/min), after which the titration was started. Hydroquant 
Uniquant 2® (Biosolve LTD, Valkenswaard, The Netherlands) with a theoretical titre of 2 mg 
H2O/ml was used as the titrant solution. The analysis was performed in triplicate.  
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Texture profile analysis was conducted on the mini-matrices, stored at the 
aforementioned storage conditions, using a Texture Analyser Model TA.XT.plus (Stable 
Micro Systems, Goldalming, UK). The force of resistance (N) against penetration (maximum 
penetration depth of 1.0 mm) of a flat-tipped cylindrical steel probe (2 mm diameter) under 
increasing load (test speed of 0.8 mm/s) was measured. The maximum recorded force is a 
measure for the hardness of the mini-matrices. Data acquisition and analysis was performed 
using the software Texture Exponent 32® (version 1.0.0.91). The analysis was performed in 
tenfold. 
 
 
2.2.3.7. Statistical analysis 
 
The effect of xanthan gum concentration and particle size on the release mechanism and 
drug release (using the area under the curve of the release profiles) was assessed by a two-way 
ANOVA. To further compare the main effect of the different treatments a multiple comparison 
among pairs of means was performed using a Bonferroni post-hoc test with P < 0.05 as 
significance level. If a significant interaction between both factors was present, the simple effects 
were investigated with a Bonferroni post-hoc test. The normality of the residuals was tested with a 
Kolmogorov-Smirnov test. The homogeneity of variances was tested with Levene’s test. SPSS 
version 12.0 was used to perform the statistical analysis.  
 
 
2.2.4. In vivo evaluation 
 
Although dogs are more sensitive to ibuprofen compared to humans and the 
ulcerogenic activity of ibuprofen after chronic use is related to the plasma concentration of 
the drug [16, 39-41], no gastro-intestinal side effects were expected after the single-dose 
treatment used in this study. 
All procedures were performed in accordance with the guidelines and approval of the 
local Institutional Animal Experimentation Ethics Committee. 
 
 
2.2.4.1. Subjects and study design 
 
A group of 6 male mixed-breed dogs (weight 26.0-45.5 kg) was used in this study. To 
investigate the influence of the xanthan gum concentration in the experimental mini-tablets on the 
bioavailability of ibuprofen, the following drug formulations were administered: 
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F-1: hot-melt extruded mini-matrices, consisting of 60% IBP, 30% EC and 10% XG75 (10% 
XG75) 
F-2: hot-melt extruded mini-matrices, consisting of 60% IBP, 20% EC and 20% XG75 (20% 
XG75) 
F-3: hot-melt extruded mini-matrices, consisting of 60% IBP, 10% EC and 30% XG75 (30% 
XG75) 
F-4: Ibu-Slow® 600 mg (commercially available hydrophilic matrix tablets containing 600 mg 
ibuprofen (Therabel Pharma, Brussels, Belgium)) 
F-5: Junifen® (100 mg/5 ml) (commercially available sugar-free syrup of ibuprofen (Boots 
Healthcare, Wemmel, Belgium)) 
 
The mini-matrices of the experimental formulations were filled in hard-gelatin capsules n° 
00, each capsule containing 300 mg ibuprofen. Ibu-Slow® 600 mg (½ tablet) and Junifen® (15 ml) 
were administered as sustained- and immediate-release reference formulations, respectively. The 
formulations were administered in randomized order with a wash-out period of at least 8 days 
between consecutive sessions. On the experimental days the dogs were fasted for 12 h prior to 
the study period, although water was available ad libitum. Before administration of the 
formulations, an intravenous cannula was placed in the lateral saphenous and a blank blood 
sample was obtained. The formulations were orally administered with 10 ml water. The blood 
samples (2 ml at each sampling) were collected in dry heparinized tubes 1, 2, 4, 6, 8, 12, 24 and 
36 h after intake of F-1, F-2, F-3, F-4, and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 and 36 h after 
administration of F-5. No food was administered to the dogs during the initial 24 h of the test, 
afterwards they resumed their usual diet. Water could be taken freely. Within 1 h after collection, 
the blood was centrifuged for 10 min at 1450g and the plasma was immediately assayed for 
ibuprofen. 
 
 
2.2.4.2. Ibuprofen assay  
 
The plasma ibuprofen concentrations were determined by a validated HPLC-UV 
method. All chemicals were of analytical or HPLC grade.  
 
Fifty microlitres of an internal standard solution (30 µg/ml indomethacin in ethanol), 50 µl 
ethanol and 500 µl plasma were transferred into a borosilicate glass tube. After 1 min of vortexing, 
100 µl HCl (2 N) was added and homogenized by 1 min of vortexing. Consecutively, 4 ml 
hexane/ether mixture (4/1, v/v) was added. After 3 min of vortexing and 5 min of centrifuging at 
2500g, the upper organic layer was transferred into a new glass tube and evaporated to dryness 
 
 
60
 XANTHAN GUM TO TAILOR IBUPROFEN RELEASE: IN VITRO AND IN VIVO EVALUATION  
 
under a nitrogen stream. The residue was dissolved in 200 µl mobile phase and 50 µl of this 
solution was injected onto the column. The ibuprofen plasma concentrations were determined via 
a calibration curve. These standards for the calibration curve were extracted using the same 
procedure as described above: 500 µl blank plasma was spiked with 50 µl of internal standard 
solution and 50 µl of a standard solution with a known concentration of ibuprofen in ethanol (0, 3, 
6, 12, 30, 60, 90, 180 and 240 µg/ml). 
 
The HPLC equipment (Merck-Hitachi, Darmstadt, Germany) consisted of a solvent 
pump (L-7100) set at a constant flow rate of 1.5 ml/min, a variable wavelength UV-detector 
(L-7400) set at 220 nm, a reversed-phase column and precolumn (LiChroCART® 125-4 and 
4-4, LiChrospher® 100 RP-18 5 µm), an auto-sampler injection system (L-7200) with a 50 µl 
loop (Valco Instruments Corporation, Houston, Texas, USA) equipped with an automatic 
integration system (software D-7000 Multi-Manager). The mobile phase consisted of 0.1 M 
KH2PO4 (adjusted to pH 7.0 with 2 M NaOH)/acetonitrile (12/3, v/v).  
 
 
2.2.4.3. Method validation 
 
Based on the guidelines of the International Conference on Harmonisation (ICH) 
about the validation of analytical procedures, the following parameters were evaluated [42]. 
 
 
2.2.4.3.1. Specificity 
 
The specificity can be defined as the ability to measure the analyte accurately in the 
presence of interfering substances such as impurities and plasma components present in the 
sample.  
In our experiment, specificity was determined at 220 nm by comparing the 
chromatograms after extraction of blank plasma, plasma spiked with internal standard 
indomethacin, and plasma spiked with ibuprofen and indomethacin. 
 
 
2.2.4.3.2. Linearity 
 
The linearity of an analytical procedure is its ability to obtain test results which are 
directly proportional to the concentration of the analyte in the samples. 
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During validation of the HPLC method, different calibration curves (n = 10) were 
prepared. For each calibration curve, blank plasma of dogs was spiked with different 
ibuprofen solutions to obtain plasma concentrations from 0 to 20 µg/ml, and internal standard 
(indomethacin, 2.5 µg/ml) to cover the concentration range of the unknown samples. 
Linearity was expressed by the coefficient of determination (R2) and the mean linear 
regression equation (equation 4): 
 
Y = aX + b                                 (4) 
 
where  a = slope 
 b = intercept 
X = ibuprofen concentration (µg/ml) 
Y = absorption of ibuprofen at 220 nm 
 
 
2.2.4.3.3. Precision 
 
The precision of an analytical method expresses the closeness of agreement 
between a series of measurements obtained when the method is applied repeatedly to 
multiple samples of the same homogeneous sample. Precision may be considered at three 
levels: repeatability (intra-assay precision), intermediate precision (within-laboratory 
precision) and reproducibility (between-laboratory precision). Due to the fact that all samples 
were analyzed at the same laboratory by the same person using the same equipment, 
reproducibility was not considered. 
The within-day repeatability was determined using the variation of the peak area of 
samples injected at different times (n = 4) during the same day. The analyses performed over 
five different days can be considered as the intermediate precision or within-laboratory 
precision (between-day repeatability). 
The precision was expressed as the coefficient of variation of a series of 
measurements and was calculated for different ibuprofen concentrations (0.25, 0.5, 1, 2.5, 5, 
7.5, 15 and 20 µg/ml). To have an acceptable precision the coefficient of variation of the 
mean value should not exceed 15% [43].  
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2.2.4.3.4. Accuracy 
 
To determine the accuracy (or trueness) of an analytical procedure, the closeness of 
agreement (expressed as %) between the value accepted as the conventional true value 
(known spiked amount of analyte in the sample) and the mean value (n = 10) obtained using 
the test procedure different times was calculated.  
Accuracy was determined for different ibuprofen concentrations (0.25, 0.5, 1, 2.5, 5, 
7.5, 15 and 20 µg/ml). The mean value should be within 15% of the actual value [43]. 
 
 
2.2.4.3.5. Recovery 
 
The recovery is defined as the extent of agreement (expressed as %) between the 
peak areas of an extracted sample (n = 10) versus the peak areas of a non-extracted sample 
(n = 3).  
The recovery experiments were performed at ibuprofen and indomethacin 
concentrations of 0.25, 2.5, 7.5 and 20 µg/ml and 2.5 µg/ml, respectively. 
 
 
2.2.4.3.6. Limit of detection and limit of quantification 
 
The limit of detection is the lowest amount of analyte in a sample which can be 
detected but not necessarily quantitated as an exact value. The limit of quantification is the 
lowest amount of analyte in a sample which can be quantitatively determined with suitable 
precision and accuracy. 
The limit of detection (LOD) and limit of quantification (LOQ) were calculated based 
on the standard deviation of the intercept and slope of the mean calibration curve (equation 5 
and equation 6): 
 
LOD = 3.3 x σ/S          (5) 
 
LOQ = 10 x σ/S           (6) 
 
where  σ = standard deviation on the intercept (b) of the mean calibration curve 
 S = slope (a) of the mean calibration curve 
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2.2.4.4. Data analysis 
 
The peak plasma concentration (Cmax), the time to reach Cmax (Tmax) and the extent of 
absorption (area under the curve, AUC0-36h) were calculated using the MW-Pharm Program 
version 3.0 (Mediware 1987-1991, Utrecht, The Netherlands). The AUC0-36h was calculated 
using logarithmic and linear trapezoidal rules. The relative bioavailability (Frel, expressed in 
%) was calculated as the ratio of AUC0-36h between a test formulation and the sustained-
release reference formulation (Ibu-Slow® 600 mg). The sustained-release characteristics of a 
formulation were evaluated by the time span during which the plasma concentrations were at 
least 50% of the Cmax value (HVDt50%Cmax, the width of the plasma concentration profile at 
50% of Cmax) [44, 45]. The HVDt50%Cmax values were determined from the individual plasma 
concentration-time profiles. The ratio between the HVDt50%Cmax values of a test formulation 
and the immediate-release reference formulation (Junifen®) (expressed as RD) is indicative of 
its sustained-release effect: a ratio of 1.5, 2 and > 3 indicating a low, intermediate and strong 
sustained-release effect, respectively [44]. 
 
 
2.2.4.5. Statistical analysis 
 
The effect of ibuprofen formulation on the bioavailability was assessed by repeated 
measures ANOVA (univariate analysis). To further compare the effects of the different treatments, 
a multiple comparison among pairs of means was performed using a Bonferroni post-hoc test with 
P < 0.05 as significance level. The normality of the residuals was tested with a Kolmogorov-
Smirnov test. The sphericity of covariances was tested with Mauchly’s test. If the assumption of 
sphericity was not fulfilled, the Huynh-Feldt correction was performed. SPSS version 12.0 was 
used to perform the statistical analysis.  
 
 
64
 XANTHAN GUM TO TAILOR IBUPROFEN RELEASE: IN VITRO AND IN VIVO EVALUATION  
 
3. RESULTS AND DISCUSSION 
 
3.1. In vitro drug release: influence of xanthan gum concentration and particle 
size 
 
Hot-melt extrusion was performed at 50°C and produced smooth extrudates. This 
rather low extrusion temperature, far below the glass transition temperature of EC (130°C), 
can be explained by the plasticizing effect of IBP on EC, favourably affecting the stability of 
both the drug and the polymer [46]. Previous work at the Laboratory of Pharmaceutical 
Technology confirmed the chemical stability of drug and polymers when hot-melt extruded at 
this processing temperature using similar shearing forces [47]. The pressure and torque 
during processing varied between 0 and 3 bar, and 30 and 44%, respectively. Figure 6 
presents an example of an extrudate processed via hot-melt extrusion and of mini-matrices 
obtained after manually cutting the extrudate. 
 
 
Figure 6: Extrudate (left) and mini-matrices (right). 
 
The drug release from the IBP/EC matrix was too slow as only 20% of IBP was 
released in 24 h (Figure 7). The same slow drug release pattern was seen for theophylline 
(40%, w/w) embedded in ethylcellulose tablets [48]. This sustained-release effect was 
attributed to the integrity of the matrix structure which was maintained during the dissolution 
experiment. Hydrophilic polymers such as HPMC [8] and XG had to be added to enhance the 
drug release rate. Changing the XG/EC ratio allowed to modify the drug release rate as 
increasing concentrations of XG (type XG75) enhanced drug release (Figure 7): after 24 h, 
only 50% IBP was released from formulations containing 10% XG, whereas the total drug 
load was released within this time from mini-matrices containing 20 and 30% XG. 
Conventionally, in case of XG as a hydrophilic matrix, the drug release rate from matrices 
decreased at higher XG concentrations, due to an increase in viscosity and thickness of the 
hydrated gel layer, instantly formed around the dosage form upon contact with the dissolution 
medium [11, 49]. This gel barrier restricted water penetration into and drug diffusion from the 
tablet, delaying drug release [12-14, 34, 50-52]. However, as the system under investigation 
is not a pure hydrophilic matrix but a combination of a hydrophobic matrix and a hydrophilic 
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polymer, the higher degree of swelling did not impede drug release as the swelling of XG 
opened the structure of the mini-matrices, creating pores in the lipophilic EC matrix through 
which IBP was released. The XG particle size had no effect on the drug release from 
formulations containing 10 and 20% XG since the XG180 and XG11K formulations (results 
not shown) yielded similar release profiles as presented in Figure 7 for the XG75 mini-
matrices. However, at 30% XG, the drug release was influenced by the particle size of the 
hydrophilic polymer: a faster drug release from the mini-matrices formulated with coarser XG. 
Those data are in agreement with the results reported by Dhopeshwarkar and Zatz [11] on 
XG hydrophilic matrix tablets: a fine particle size of XG produced the slowest and most 
reproducible sustained-release profiles, whereas the coarser XG fractions did not hydrate 
fast enough to form a protective layer and the matrix tablet disintegrated during dissolution 
testing. To evaluate the susceptibility of the coarser XG fractions to erosion, the erosion 
behaviour (including liquid uptake and swelling) of the hydrated mini-matrices was 
determined since these parameters affect the mechanism and kinetics of drug release. 
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Figure 7: Influence of xanthan gum concentration and particle size on the dissolution profiles 
(mean ± standard deviation (S.D.), n = 6) of mini-matrices containing 60% IBP, EC and XG: 
(△) 0% XG, (○) 10% XG75, (□) 20% XG75, (▲) 30% XG75, (■) 30% XG180, (●) 30% 
XG11K. 
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The mean porosity data of the mini-matrices (Table 2) indicated that the initial 
porosity is independent of the composition of the mini-matrices and therefore not responsible 
for any difference in drug release. Other researchers already reported that melt-extruded 
dosage forms had a low porosity since compression and intense mixing of molten materials 
during processing resulted in a product with low free volume [53]. 
 
Table 2: Porosity (%, mean ± S.D., n = 10) of the hot-melt extruded mini-matrices. 
 10% 20% 30% 
XG75 1.4 ± 0.1 1.6 ± 0.1 3.2 ± 0.5 
XG180 2.4 ± 0.7 4.2 ± 0.6 4.6 ± 0.1 
XG11K 3.2 ± 0.1 5.3 ± 0.4 5.5 ± 0.1 
 
 
3.2. Liquid uptake, erosion and swelling 
 
Since the rate of swelling and erosion determines the mechanism and kinetics of drug 
release, matrix swelling, liquid penetration and polymer (hydrophilic/lipophilic) erosion of the 
hydrated mini-matrices were determined. 
 
The influence of XG concentration and particle size on the liquid uptake, swelling and 
erosion is presented in Figure 8. A higher liquid uptake (Figure 8a) was observed at 
increasing XG180 concentrations: as expected from the hydrophilic nature of the polymer, 
the mini-matrices became more accessible to the dissolution medium with increasing XG 
concentration, resulting in a higher weight gain of the mini-matrices after immersion in the 
medium (equation 2). Radial (Figure 8b) as well as axial (data not shown) swelling also 
depended on the concentration of XG and was in all cases directly proportional to the liquid 
uptake. Anisotropic swelling (more swelling in the longitudinal direction than in the radial 
direction) was seen for the 10 and 20% XG formulations, independent of XG particle size. 
However, anisotropic swelling for 30% XG mini-matrices could only be seen using the finest 
XG particle size. When mini-matrices were formulated with 30% XG180 and XG11K, no rigid 
structure could be recovered due to the higher impact of erosion, and therefore the swelling 
in both directions was comparable. Similar phenomena during the swelling of HPMC 
compacts were observed in literature [54, 55]. They related the axial relaxation of the HPMC 
compacts to the relief of stress induced during compaction and the unidirectional swelling to 
the orientation of molecules during compression. Since the hot-melt extrusion process also 
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induces stress on the extrudates, the asymmetric swelling behaviour could also be due to 
this phenomenon. Formulations containing 10 and 20% XG (XG180 grade) did not swell to a 
great extent, in contrast to the swelling capacity of the 30% XG formulation: for the latter, the 
hydrated polymer layer was less cohesive, and therefore more sensitive to erosion (Figure 
8c). After 4 h immersion in the medium, these mini-matrices became brittle and as a 
consequence a higher erosion rate was seen, the matrix was completely eroded after 6 h. 
The liquid uptake, swelling and erosion profiles for the 10 and 20% XG75 and XG11K 
formulations (data not shown) coincided with those presented for the XG180 mini-matrices, 
so no influence of the particle size was observed at these concentrations. However, when 
comparing formulations containing 30% XG, the erosion rate was affected by the XG grade 
(Figure 8c): using the coarser XG types, the mini-matrices were more susceptible to erosion, 
whereas the gelled surface of the mini-matrices formulated with the XG75 grade seemed to 
be stronger and therefore these mini-matrices were more resistant to erosion. The lower 
liquid uptake and swelling of the XG180 and XG11K matrices at 4 h are also due to the 
higher erosion rate of these formulations as a smaller amount of material was recovered.  
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(a)   
 
 
 
 
 
 
 
 
 
 
(b)   
 
 
 
 
 
 
 
 
 
 
(c)   
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Influence of xanthan gum concentration and particle size on (a) liquid uptake, (b) 
radial swelling and (c) erosion (mean ± S.D., n = 3) of mini-matrices containing 60% IBP, EC 
and XG: (○) 10% XG180, (□) 20% XG180, (▲) 30% XG75, (■) 30% XG180, (●) 30% XG11K.  
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The difference in gel strength of XG when using different grades was confirmed by 
visual inspection of the mini-matrices after 4 h immersion in the dissolution medium (Figure 
9): the mini-matrices containing XG75 were embedded in a gel layer, and the inner core was 
not yet fully hydrated. In contrast, the entire matrix was hydrated when using the coarsest XG 
grade (XG11K), only a few non-hydrated individual particles remained. These pictures also 
confirmed a decrease in diffusion path length with increasing XG particle size, resulting in a 
faster drug release from the 30% XG11K mini-matrices (Figure 7). 
 
 
(a)    (b)    (c) 
Figure 9: Mini-matrices containing 60% IBP, 10% EC and 30% XG after 4 h immersion in the 
dissolution medium: (a) XG75, (b) XG180, (c) XG11K.  
 
 
3.3. Analysis of drug release mechanism 
 
To investigate if the XG concentration and particle size had an effect on the IBP 
release mechanism, the exponent characterizing drug release (n) and the area under the 
curve (AUC) were compared. As the ranking of n (Table 3) and AUC (Table 4) in function of 
concentration was independent of particle size, the main effect of XG concentration could be 
analyzed (comparison of the overall mean of each column). However, as the ranking in 
function of particle size depended on XG concentration only the simple effect could be 
analyzed (at each specific XG concentration, i.e. within each column).  
 
When increasing the XG concentration in the mini-matrices (regardless of the XG 
particle size), the drug release tended towards transport by Case II diffusion (i.e., erosion) as 
indicated by a significantly increasing exponent n (Table 3) (coefficient of determination of 
0.9943 ± 0.0076 (n = 162)). This observation was confirmed by the erosion study (Figure 8c) 
and the dissolution profiles (Figure 7) and correlated with the AUC values (Table 4), since a 
higher contribution of erosion resulted in a faster drug release. 
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Table 3: Influence of xanthan gum concentration and particle size on the calculated n values 
(mean ± S.D., n = 6) of the dissolution profiles of mini-matrices (100 rpm). 
For a cylinder, Fickian or Case I diffusion is defined by n = 0.45, zero-order drug release due to erosion or 
relaxation (Case II diffusion) by n = 0.89 and anomalous behaviour or non-Fickian transport is indicated by 
values between 0.45 and 0.89. Super Case II transport is defined by n values > 1.0 [35, 37]. 
 10% 20% 30% 
XG75 0.58 ± 0.08a   0.77 ± 0.03a 0.86 ± 0.07a
XG180 0.64 ± 0.03a   
   
   
0.85 ± 0.09a 1.00 ± 0.07b
XG11K 0.55 ± 0.05a 0.85 ± 0.10a 1.06 ± 0.05b
Main effect concentration 0.59 ± 0.07A 0.82 ± 0.08B 0.97 ± 0.11C
 
a, b: means in the same column with different superscript are different at the 0.05 level of significance 
A, B, C: means in the same row with different superscript are different at the 0.05 level of significance 
 
 
Table 4: Influence of xanthan gum concentration and particle size on the calculated AUC 
values (mean ± S.D., n = 6) of the dissolution profiles of mini-matrices (100 rpm). 
 10% 20% 30% 
XG75 794 ± 32a   1637 ± 27a 1993 ± 36a
XG180 792 ± 31a   
   
   
1412 ± 28b 2136 ± 33b
XG11K 981 ± 23b 1469 ± 12c 2236 ± 25c
Main effect concentration 856 ± 95A 1506 ± 101B 2122 ± 107C
 
a, b, c: means in the same column with different superscript are different at the 0.05 level of significance 
A, B, C: means in the same row with different superscript are different at the 0.05 level of significance 
 
Regarding the effect of XG particle size, the IBP drug release mechanism did not 
differ significantly for the 10 and 20% XG formulations, although a significant, but not 
relevant, higher AUC value was obtained for the XG11K and XG75 formulations, 
respectively. Both formulations followed a similar release pattern: in all cases anomalous 
transport with n values from 0.55 up to 0.85. As the core of these mini-matrices could be 
recovered after 24 h, there is a strong indication that the drug release mechanism is not 
primarily erosion-controlled. However, for the 30% XG formulation, anomalous transport was 
seen for the XG75 type (n = 0.86), whereas the release mechanism was mainly erosion-
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controlled for the mini-matrices with a coarser XG particle size (n = 1.06). This observation 
was expected based on the erosion study (Figure 8c and 9) since a higher erosion rate was 
seen for the XG180 and XG11K mini-matrices.  
 
 
3.4. In vitro drug release: influence of hydrodynamics 
 
The influence of the hydrodynamic stress on the release rate is negligible for a 
diffusion-controlled system, but has a great influence on an erosion-based system [56]. 
Therefore, dissolution experiments were carried out at different stirring rates (50, 100 and 
200 rpm). The n and AUC values for IBP release (50 and 200 rpm data not shown) clearly 
indicated that for all formulations, regardless of the XG concentration and particle size, the 
drug release mechanism was not affected by the rotational speed. For the 30% XG 
formulations, this was surprising in view of the high erosion rates observed for the XG11K 
formulations (Figure 8c and 9). As an example, the mean dissolution profiles of 30% XG11K 
mini-matrices at different rotation speeds are shown (Figure 10).  
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Figure 10: Dissolution profiles (mean ± S.D., n = 6) of mini-matrices containing 60% IBP, 
10% EC and 30% XG11K at different stirring speeds: (▲) 50 rpm, (■) 100 rpm, (○) 200 rpm. 
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Since drug release was unaffected by the hydrodynamic conditions, we concluded 
that, although erosion of the mini-matrix is contributing to faster drug release from the 30% 
XG formulations, the drug release mechanism from the mini-matrices was mainly diffusion-
controlled. The faster drug release observed using a coarser particle size (XG11K type) for 
the 30% XG formulations was more related to the faster hydration of the polymer particles. 
 
 
3.5. In vitro drug release: influence of ionic strength of the dissolution medium 
 
The susceptibility of the 20% XG75 containing matrices to the ionic strength of the 
dissolution medium is shown in Figure 11. The slowest drug release was seen at the lowest 
ionic strength: after 24 h in a medium of µ = 0.011, only 50% IBP was released, whereas the 
total drug load was released in a medium of µ = 0.055 or higher. Above an ionic strength of 
0.11 no differences in drug release profiles were observed, which was also reported by 
Talukdar and Kinget [34], since under these conditions XG formed a helical structure and 
further addition of salts had no influence on its rheological properties [57].  
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Figure 11: Dissolution profiles (mean ± S.D., n = 6) of mini-matrices containing 60% IBP, 
20% EC and 20% XG75 at different ionic strengths: (●) µ = 0.011, (■) µ = 0.022, (▲) µ = 
0.055, (○) µ = 0.11, (□) µ = 0.15, (△) µ = 0.2. 
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A similar drug release dependency on the ionic strength was noticed for the 10 and 
30% XG75 mini-matrices (data not shown). Visual inspection of the XG matrices (Figure 12) 
after 24 h of dissolution testing showed enhanced swelling of the mini-matrices in a 
dissolution medium of high ionic strength, which correlated with a higher IBP release. This 
behaviour might be attributed to the conformation of XG molecules which depended on the 
salt concentration. In aqueous solutions, a transition of XG occurs from a random coil at low 
ionic strength to an ordered elongated double helix with increasing salt concentrations. The 
ordered elongated conformation is able to form a gel, unlike the random coil [34]. Hence, at 
the lower ionic strengths, the disordered XG molecules resulted in less gel formation, a 
reduced swelling of the mini-matrices and a slower drug release rate. Based on these 
findings it is likely that within the physical range of gastric and intestinal ionic strengths (µ = 
0.01-0.166 according to Johnson et al. [58]) the drug release of XG containing formulations 
would be affected. The higher drug release in media of increasing salt concentrations is 
consistent with data reported by other investigators [12, 13, 34, 49, 59-62]. 
 
 
(a)    (b) 
Figure 12: Mini-matrices containing 60% IBP, 20% EC and 20% XG75 after 24 h immersion 
in the dissolution medium at different ionic strengths: (a) µ = 0.011, (b) µ = 0.2. 
 
 
3.6. Friability and hardness 
 
The physical properties of the mini-matrices extruded with different XG concentrations 
and particle sizes are summarized in Table 5. Increasing the XG concentration resulted in an 
increase of friability, which was correlated with a decrease of crushing strength. This can be 
due to the weaker binding forces between EC and XG in comparison with EC-EC bonds. The 
influence of XG particle size was negligible. The low friability (0.01-0.32%) of the mini-
matrices gives an indication of the resistance to abrasion, and the results were conform to 
the requirements set forth in section 2.2.3.4.  
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Table 5: Friability (%, n = 1) and hardness (N, mean ± S.D., n = 10) of the hot-melt extruded 
mini-matrices. 
  Friability (%) Hardness (N) 
XG75 10% 0.01 39.1 ± 8.3 
 20% 0.03 32.5 ± 5.5 
 30% 0.19 28.6 ± 3.5 
XG180 10% 0.01 41.0 ± 7.4 
 20% 0.07 32.0 ± 4.7 
 30% 0.23 25.9 ± 3.9 
XG11K 10% 0.03 40.6 ± 3.2 
 20% 0.13 29.5 ± 3.1 
 30% 0.32 24.5 ± 3.8  
 
 
3.7. Stability study 
 
Due to the incorporation of the hydrophilic polymer, these formulations might be 
susceptible to storage conditions. Therefore, the stability of these mini-matrices was 
evaluated under specific conditions of relative humidity and temperature.  
The release profiles indicated that all experimental mini-matrices were stable for at 
least 12 months during storage at 25°C/60% RH. Storage at 40°C/75% RH did not affect 
ibuprofen release from 10% XG mini-matrices. However, the drug release from the 20 and 
30% XG formulations was increased: after 12 months, the amount of drug released after 4 h 
increased from 30 and 42% for the 20 and 30% XG mini-matrices, respectively, to 51 and 
75%, respectively. 
Immediately after production of the mini-matrices, the water content was similar (0.04, 
0.08 and 0.09% for the 10, 20 and 30% XG formulation, respectively) (Figure 13). Storage during 
12 months at both conditions resulted in an increase of the water uptake which depended on XG 
concentration and storage conditions: 3.6 and 4.6% for the 20 and 30% XG formulations, 
respectively, when stored at 25°C/60% RH; 4.3 and 6.8%, respectively, when stored at 40°C/75% 
RH. No difference was seen in water uptake of the 10% XG formulations between both storage 
conditions (2.3 and 2.0% for 25°C/60% RH and 40°C/75% RH, respectively).  
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Figure 13: Water content (%, mean ± S.D., n = 3) of mini-matrices in function of xanthan gum 
concentration, and storage time and conditions. 
 
 
Although the mini-matrices had the same water content after the extrusion process, they 
were softer with increasing XG concentration using the indentation test (116, 95 and 73 N for the 
10, 20 and 30% XG mini-matrices, respectively) (Figure 14).  
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Figure 14: Hardness (N, mean ± S.D., n = 10) of mini-matrices in function of xanthan gum 
concentration, and storage time and conditions. 
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From the results of the texture analysis it is clear that the mini-matrices became softer 
during 12 months storage: at 25°C/60% RH 103 and 80 N for the 10 and 20% XG mini-matrices, 
respectively, and at 40°C/75% RH 83 and 71 N for the 10 and 20% XG mini-matrices, 
respectively. No difference in tablet hardness was observed for the 30% XG mini-matrices when 
stored at the different conditions (51 and 52 N at 25°C/60% RH and 40°C/75% RH, respectively).  
The stability data revealed that drug release, water uptake and hardness of the XG 
formulations changed when stored for 12 months at 25°C/60% RH and 40°C/75% RH, and 
therefore these mini-matrices should be appropriately packaged.  
 
 
3.8. In vivo evaluation 
 
3.8.1. Method validation 
 
3.8.1.1. Specificity 
 
Chromatograms after extraction of blank plasma, plasma spiked with indomethacin 
(internal standard) and plasma spiked with ibuprofen and indomethacin are shown in Figure 
15. The chromatograms indicate that there was no interference of drug and internal standard 
with endogenous compounds, and separation between ibuprofen and indomethacin was 
complete. As shown in Figure 15, a retention time of ± 12 min and ± 32 min was obtained for 
ibuprofen and indomethacin, respectively. It was concluded that the method was selective to 
determine ibuprofen in dog plasma. 
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Figure 15: Chromatograms showing ibuprofen and indomethacin after extraction of (top) 
blank dog plasma, (middle) plasma spiked with indomethacin and (bottom) plasma spiked 
with ibuprofen and indomethacin. 
Absorption 
Time (min)
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3.8.1.2. Linearity 
 
Linearity was expressed by the mean linear regression equation (slope and intercept) 
and its coefficient of determination (n = 10).  
The mean calibration curve (Y = 0.2527 (± 0.0436) X – 0.0101 (± 0.0235)) was linear 
between 0 and 20 µg/ml ibuprofen, with a coefficient of determination of 0.9997 ± 0.0003.  
 
 
3.8.1.3. Precision 
 
The coefficients of variation (C.V.) (%) of the repeatability (intra-assay precision) and 
the intermediate precision (within-laboratory precision) are shown in Table 6. 
 
Table 6: Coefficients of variation (%) of the repeatability (n = 4) and the intermediate 
precision (n = 5). 
Coefficient of variation (%) 
Concentration (µg/ml)  
Repeatability Intermediate precision 
0.25  8.0 12.5 
0.50  6.3 7.9 
1.00  4.3 7.1 
2.50  3.8 4.9 
5.00  5.8 4.8 
7.50  2.9 6.2 
15.00  3.9 4.4 
20.00  3.7 7.6 
 
For the repeatability as well as the intermediate precision, the coefficients of variation 
at all concentrations were lower than 15%. 
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3.8.1.4. Accuracy 
 
The accuracy was determined for all ibuprofen concentrations and the mean results 
are presented in Table 7. 
 
Table 7: Accuracy (%, mean ± S.D., n = 10). 
Concentration (µg/ml) Calculated concentration (µg/ml) Accuracy (%) C.V. (%) 
0.25 0.22 ± 0.03 86.8 ± 12.3 14.1 
0.50 0.47 ± 0.04 94.3 ± 8.3 8.8 
1.00 0.95 ± 0.03 95.4 ± 3.2 3.3 
2.50 2.54 ± 0.11 101.4 ± 4.3 4.2 
5.00 4.97 ± 0.13 99.4 ± 2.5 2.5 
7.50 7.50 ± 0.29 100.0 ± 3.9 3.9 
15.00 15.51 ± 0.28 103.4 ± 1.8 1.8 
20.00 19.63 ± 0.15 98.1 ± 0.7 0.7 
 
The proposed method can be considered as accurate as an accuracy of at least 
86.8% was obtained and the highest coefficient of variation was 14.1%.  
 
 
3.8.1.5. Recovery 
 
The recovery of ibuprofen and indomethacin from plasma are shown in Table 8. 
 
Table 8: Recovery (%, mean ± S.D., n = 10) of ibuprofen and indomethacin from plasma. 
Concentration (µg/ml)  Ibuprofen Indomethacin 
0.25  83.3 ± 10.9 - 
2.50  84.4 ± 5.6 73.5 ± 14.7 
7.50  82.4 ± 5.1 - 
20.00  88.9 ± 9.1 - 
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3.8.1.6. Limit of detection and limit of quantification 
 
Based on the mean linear regression equation of ibuprofen the limit of detection and 
the limit of quantification for ibuprofen are 0.31 and 0.93 µg/ml, respectively. Both 
parameters were higher than the lowest concentration of the calibration curve but as 
accuracy and precision for the concentration of 0.25 µg/ml were within accepted limits [43], 
the concentration of 0.25 µg/ml was considered as limit of quantification.  
 
 
3.8.2. In vivo performance 
 
In the previous paragraphs of this chapter, the in vitro behaviour of the mini-matrices 
formulated with ethylcellulose and xanthan gum was described. It showed that the drug release 
from these mini-tables could be modified by appropriate selection of the type and concentration of 
the hydrophilic component (xanthan gum). To investigate the biopharmaceutical properties of 
these sustained-release formulations an in vivo study using dogs was performed to determine the 
bioavailability of ibuprofen from a sustained-release hot-melt extruded mini-tablet formulation. The 
bioavailability of the experimental formulations was compared to the in vivo behaviour of a 
commercial sustained- and immediate-release dosage form.  
 
An in vitro burst release was observed at 30% XG when using the coarsest particle size 
XG11K (Figure 7). Therefore, to prevent the burst release in vivo, the formulations containing 
XG75 (finest XG particle size) were selected for in vivo analysis. 
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Figure 16 shows the mean plasma concentration-time profiles after oral administration of 
300 mg ibuprofen to 6 dogs as Junifen®, Ibu-Slow® 600 mg (½ tablet) and the experimental mini-
matrices. The pharmacokinetic parameters are reported in Table 9. 
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Figure 16: Mean plasma concentration-time profiles (± S.D., n = 6) after oral administration of 
300 mg ibuprofen to dogs: (●) 10% XG75 mini-matrices, (▲) 20% XG75 mini-matrices, (■) 
30% XG75 mini-matrices, (○) Ibu-Slow® 600 (½ tablet), (△) Junifen® (15 ml).  
 
With regard to the extent of absorption, the mean AUC0-36h of the formulations F-1, F-
2, F-3 and Ibu-Slow® 600 mg (½ tablet), were 34.8, 129.7, 134.9 and 186.2 µg.h/ml, 
respectively; yielding relative bioavailabilities of the mini-matrices versus Ibu-Slow® 600 mg 
(½ tablet) of 19.3, 70.6 and 73.8%, respectively. The similar in vivo behaviour of the 20 and 
30% XG formulations was not reflected in their in vitro dissolution profiles (Figure 7) since a 
significant difference in drug release was noticed for these formulations. Therefore, it was 
investigated if the drug release properties were altered when a larger sample size (500 mg) 
of mini-matrices was filled into a capsule (similar to the dosage form that was administered to 
the dogs).  
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Table 9: Mean pharmacokinetic parameters (± S.D., n = 6) after oral administration of 300 
mg ibuprofen to dogs as 10% XG75 mini-matrices, 20% XG75 mini-matrices, 30% XG75 
mini-matrices, Ibu-Slow® 600 (½ tablet) and Junifen® (15 ml). 
 
Cmax 
(µg/ml) 
Tmax 
(h) 
AUC0-36h 
(µg.h/ml) 
HVDt50%Cmax
(h) 
Frel* 
(%) 
RD 
 
10% XG75 3.0 ± 0.5a      5.7 ± 3.9a,b 34.8 ± 8.8a 10.6 ± 3.8a,b 19.3 ± 5.5a 3.6 ± 1.4a
20% XG75 9.8 ± 2.3b      
      
     
    
6.3 ± 2.9a,b 129.7 ± 40.0b 9.5 ± 4.0a,b 70.6 ± 22.9b 3.1 ± 1.2a
30% XG75 15.8 ± 4.6b,c 3.7 ± 0.8b 134.9 ± 32.6b 6.9 ± 2.1b 73.8 ± 19.5b 2.2 ± 0.6a
Ibu-Slow® 
600 
(½ tablet) 
® 
18.4 ± 5.7c 4.3 ± 2.0a,b 186.2 ± 39.8b 8.5 ± 1.8b - 2.8 ± 0.7a
Junifen
(15 ml) 32.1 ± 3.7
d 1.0 ± 0.0a 175.4 ± 46.9b 3.1 ± 0.4a - - 
 
-: not applicable 
*: using Ibu-Slow® 600 (½ tablet) as reference 
a, b, c, d: means in the same column with different superscript are different at the 0.05 level of 
significance  
 
Similar dissolution profiles (Figure 17) and swelling (Figure 18) were obtained for the 
10% XG75 formulation, irrespective of the amount of mini-matrices. However, the release 
rate for the mini-matrices containing 20 and 30% XG was reduced (Figure 17) by increasing 
the sample size in the dissolution basket, although sink conditions were maintained (solubility 
of ibuprofen: 4.48 ± 0.08 mg/ml at 37°C [8]). Due to the rapid swelling of XG at 20 and 30% 
after hydration by the dissolution medium, the mini-matrices stick together with increasing 
sample size (Figure 18): the increased diffusion path length reduced the drug release rate 
and similar drug release profiles were obtained at both XG concentrations. The formulations 
F-2 and F-3 had a pronounced sustained-release profile with RD values of 3.1 and 2.2, 
respectively. In comparison with the 30% XG mini-tablets, the 20% XG formulation is 
characterized by a higher Tmax (3.7 and 6.3 h, respectively) and a lower Cmax (15.8 and 9.8 
µg/ml, respectively), which is typical for sustained-release formulations and which is reflected 
in its higher HVDt50%Cmax and RD. It was interesting to observe that during the initial phase of 
the plasma concentration-time profiles a slower absorption was seen for the mini-matrices 
containing 20% XG. This delayed onset of action can be seen as an advantage since it could 
favourably affect the clinical effect of an ibuprofen dose administered in the evening by 
preventing the morning stiffness typically associated with rheumatoid arthritis. Examining the 
plasma concentration-time profiles revealed a constant drug absorption pattern over 36 h for 
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the 20% XG mini-matrices compared with the 30% XG mini-matrices and the reference 
formulation. From the data in Table 9, it can be concluded that Cmax and Tmax are similar for 
the 30% XG mini-tablets and Ibu-Slow® 600 mg (½ tablet). The similar pharmacokinetic 
parameters of both formulations supported the hypothesis that the 30% XG mini-matrices 
behaved in vivo as a single-unit dosage form instead of multiparticulates due to the 
immediate swelling of the 30% XG mini-matrices upon contact with the gastro-intestinal fluids 
and the formation of a plug. Although swelling was also noticed for the 20% XG mini-tablets, 
they performed in vivo as a multiparticulate dosage form since they differ in Cmax and Tmax 
values from Ibu-Slow® 600 mg (½ tablet). This bioavailability study demonstrated that the 
matrix mini-tablets formulated with EC and XG can be used to prepare sustained-release 
dosage forms. 
 
0
20
40
60
80
100
120
0 4 8 12 16 20 2
Time (h)
IB
P 
re
le
as
ed
 (%
)
4
 
Figure 17: Influence of xanthan gum concentration and sample size introduced in the 
dissolution medium on the drug release profiles (mean ± S.D., n = 6) of mini-matrices 
containing 60% IBP, EC and XG: (●) 10% XG75 60 mg, (○) 10% XG75 500 mg, (▲) 20% 
XG75 60 mg, (△) 20% XG75 500 mg, (■) 30% XG75 60 mg, (□) 30% XG75 500 mg. 
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(a)    (b)    (c) 
   
(d)    (e)    (f) 
Figure 18: Mini-matrices containing 60% IBP, EC and XG after 6 h immersion in the 
dissolution medium: (a) 10% XG75 60 mg, (b) 20% XG75 60 mg, (c) 30% XG75 60 mg, (d) 
10% XG75 500 mg, (e) 20% XG75 500 mg, (f) 30% XG75 500 mg.  
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4. CONCLUSIONS 
 
The present work was conducted in order to assess the influence of xanthan gum 
(concentration and particle size) on the in vitro release of ibuprofen from ethylcellulose mini-
matrices manufactured by hot-stage extrusion. Since the drug release was modified by 
changing the xanthan gum concentration as well as the xanthan gum particle size, the mini-
matrices based on a combination of ethylcellulose and this hydrophilic additive offered a 
flexible system to tailor the drug release to the required specifications. Increasing xanthan 
gum concentrations yielded a faster drug release, higher liquid uptake, swelling and erosion 
rate. The low susceptibility to the agitation speed suggested that diffusion is the predominant 
mechanism of drug release. However, diffusion was not the only mechanism controlling drug 
release from these systems as the rate and extent of drug release was also dependent on 
the swelling (relaxation) of the hydrated polymer mass. 
From the validation, it could be concluded that a specific, linear, precise and accurate 
HPLC method was obtained. In vivo data showed that oral administration of a xanthan 
gum/ethylcellulose formulation was able to sustain plasma levels in dogs.  
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ABSTRACT  
 
 Mini-matrices (multiple-unit dosage form) with release-sustaining properties were 
developed by hot-melt extrusion (cylindrical die: 3 mm) using metoprolol tartrate as model 
drug and ethylcellulose as sustained-release agent. A burst release of metoprolol tartrate 
was seen from mini-matrices formulated with triethyl citrate or triacetin (hydrophilic 
plasticizers), whereas drug release from matrices plasticized with dibutyl sebacate or diethyl 
phthalate (hydrophobic) was slow and followed zero-order kinetics. Despite the different 
hydrophilic character of the plasticizers, all had the same plasticizing effect during 
processing. Dibutyl sebacate was selected as plasticizer for further development and its 
concentration was optimized to 50% (w/w) of the ethylcellulose concentration. Xanthan gum, 
a hydrophilic polymer, was added to the formulation to increase drug release. Changing the 
xanthan gum concentration modified the in vitro drug release: increasing xanthan gum 
concentrations (1, 2.5, 5, 10 and 20%, w/w) yielded a faster drug release. Zero-order drug 
release was obtained at 5% (w/w) xanthan gum. The production of the extrudates was 
reproducible, and after an equilibration time of 5 min extrudates with a constant quality were 
produced. Incorporation of kneading paddles in the screw configuration allowed to 
manufacture smooth extrudates when processing the formulation at 60°C. The mixing 
efficacy and drug release were not affected by the number of mixing zones or their position 
along the extruder barrel. Using a screw configuration only consisting of transport zones 
resulted at 60°C in extrudates with an irregular surface structure and powder spots (identified 
as metoprolol tartrate via Raman spectroscopy) were seen on the extrudates surface. Using 
a higher processing temperature (70°C) improved the surface structure but metoprolol 
tartrate spots were still visible on the surface. Raman analysis revealed that metoprolol 
tartrate was homogeneously distributed in the mini-matrices, independent of screw design 
and processing conditions. Simultaneously changing the powder feed rate (6-50 g/min) and 
screw speed (30-200 rpm) did not alter extrudate quality or dissolution properties.  
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1. INTRODUCTION 
 
Hot-melt extrusion is a technology used in the pharmaceutical industry to produce 
matrix formulations into which a drug is homogeneously embedded. Its major advantage over 
conventional techniques (e.g. direct compression) for manufacturing sustained-release 
matrices is the continuity of the production process as the different steps (mixing, melting, 
homogenizing and shaping) are carried out on a single machine [1-3].  
The excellent feasibility of ethylcellulose, a polymer with thermoplastic properties, for 
hot-stage extrusion has been established in a variety of applications [4-7]. Previous work has 
shown that hot-melt extrusion is an appropriate technique to develop mini-matrices using 
ethylcellulose to sustain the release of ibuprofen: the combination of ethylcellulose and a 
hydrophilic component (hydroxypropylmethylcellulose [8-10], xanthan gum [8-11]) offered a 
flexible system to tailor the in vitro as well as in vivo drug release. This technique to 
manufacture sustained-release mini-matrices using a combination of ethylcellulose, xanthan 
gum and ibuprofen is discussed in detail in Chapter 1.  
Due to the specific drug-matrix interaction, the low-melting ibuprofen (melting point 
76°C) was identified as a plasticizer for ethylcellulose [12]. Consequently, the characteristics 
of ethylcellulose/hydrophilic polymer mini-matrices containing ibuprofen are not predictive of 
the extrusion and dissolution properties of ethylcellulose mini-matrices containing non-
plasticizing drugs. Therefore, ibuprofen was substituted by a drug with a higher melting point 
(metoprolol tartrate, 123°C) and a conventional plasticizer was added to the formulation.  
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In the present study sustained-release mini-matrices were developed by hot-melt 
extrusion of a metoprolol tartrate/ethylcellulose mixture with the addition of xanthan gum to 
tailor drug release. The aim was to examine the effect of different plasticizers on the 
extrusion behaviour and extrudate quality. After optimization of the formulation (type and 
concentration of plasticizer, xanthan gum concentration) to obtain zero-order drug release, 
the effect of extrusion process parameters (screw design, powder feed rate and screw 
speed) on the quality and drug release properties of the mini-matrices was evaluated. 
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2. MATERIALS AND METHODS 
 
2.1. Materials  
 
The matrix consisted of ethylcellulose (EC) (Ethocel® Std 10 FP Premium; particle 
size: 3-15 µm; ethoxyl content: 48-49.5% (w/w); viscosity: 9-11 mPa.s (5% solution in 
toluene/EtOH 80/20, 25°C)), kindly donated by Dow Chemical Company (Midland, USA), and 
a hydrophilic component: xanthan gum (XG) (Xantural® 75, mean particle size of 75 µm) 
supplied by CP Kelco (Liverpool, UK). 
 
 
2.1.1. Metoprolol tartrate 
 
Metoprolol tartrate (MPT) (average diameter: 10 µm) was received from Esteve 
Quimica (Barcelona, Spain) and selected as model drug (Figure 1). 
 
 
 
Figure 1: Chemical structure of metoprolol tartrate. 
 
Metoprolol tartrate is a β1-selective adrenergic blocking agent and widely used as a 
drug of choice in the management of hypertension, angina pectoris, arrhythmias and heart 
failure [13]. It is a drug with high solubility and permeability, is well-absorbed over a large part 
of the gastro-intestinal tract and a well-defined relationship between the beta-blocking effect 
and plasma drug concentration is known. Its relatively short half life (3-4 h) makes it a 
suitable candidate for an extended-release formulation [14-19]. Metoprolol tartrate is a 
racemic drug, and the S-enantiomer is pharmacologically active. The influence of 
stereoselective pharmacokinetics and first pass metabolism on the development of an in 
vitro/in vivo correlation for its enantiomers has been described [20, 21]. Metoprolol tartrate is 
characterized by rapid systemic clearance (hepatic first pass metabolism) and thus 
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necessitates repeated daily dosing. Therefore, the enhanced therapeutic efficacy of this drug 
through the provision of constant drug input and maintenance of steady-state blood levels is 
well-documented. Although it is challenging to deliver highly water soluble drugs via 
sustained-release formulations – due to their susceptibility to dose-dumping – several 
approaches have been used to formulate different types of controlled-release metoprolol 
tartrate formulations (matrix tablets [22-26], multi-layer matrix tablets [27-29], pulsatile drug 
delivery capsules [30], multiple-unit dosage forms [31-36], solid dispersions [37]) in order to 
improve the clinical efficacy of metoprolol tartrate.  
 
 
2.1.2. Plasticizers 
 
Different plasticizers (dibutyl sebacate (DBS), diethyl phthalate (DEP), triethyl citrate 
(TEC) and triacetin (TA) (Figure 2)) were tested as potential plasticizers for ethylcellulose, 
and were obtained from Sigma-Aldrich (Steinheim, Germany). 
 
Plasticizers are typically low molecular weight compounds capable of softening 
polymers by weakening the intermolecular forces that hold the polymer chains together and, 
in doing so, improve the movement of polymer chains with respect to each other. These 
agents are able to decrease the glass transition temperature (Tg) and the melt viscosity of 
the polymer by increasing the free volume between polymer chains. With the addition of a 
plasticizer, a hot-melt extrusion process can be conducted at a lower temperature and with 
less torque (shear forces), thereby improving the processing stability of both the polymer and 
drug. Plasticizers may also improve the physico-mechanical properties of hot-melt extruded 
dosage forms: there is a decrease in both the tensile strength and Young’s modulus, while 
the polymer flexibility is increased, resulting in elongation of the final product when dealing 
with extruded films [38-45]. Conventional plasticizers are used in a concentration range of 5-
10% by weight of the extrudable mass [46, 47], and the efficiency of a plasticizer is related to 
its chemical structure and the interaction between its functional groups with those of the 
polymer(s) [48]; because polyethylene glycol (PEG) and polyethylene oxide (PEO) are 
composed of the same structural repeating unit, PEG and PEO low molecular weight can be 
used as processing aid for PEO high molecular weight to reduce the melt viscosity, friction 
and chain entanglements between the PEO molecules [49-51].  
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(a)       (b) 
   
(c)       (d) 
 
Figure 2: Chemical structure of (a) dibutyl sebacate, (b) dietyl phthalate, (c) triethyl citrate 
and (d) triacetin. 
 
Whereas the behaviour and properties of traditional plasticizers such as phthalates 
have been well-documented, some drugs were found to have a plasticizing effect. It is 
reported that ibuprofen acted as a plasticizer for ethylcellulose [12, 41, 52] and Eudragit® RS 
PO [53], whereas the Tg of the latter could also be lowered by chlorpheniramine maleate and 
indomethacin [44], and methylparaben [54]. Eudragit® E 100 was plasticized by lidocaine HCl 
[39], whereas Eudragit® RS 30 D was plasticized by methylparaben, chlorpheniramine 
maleate and ibuprofen [41]. Hydrocortisone and chlorpheniramine maleate softened the 
matrix structure of hydroxypropylcellulose films [40], whereas vitamin E TPGS could be used 
as processing aid when extruding hydroxylpropylcellulose/polyethylene oxide films by 
decreasing the barrel pressure and torque of the extruder equipment [43].  
The utility of various surfactants as plasticizers for hot-melt extrusion was also 
investigated [55]. 
 
 
All other chemicals were at least of analytical grade (VWR, Leuven, Belgium). 
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2.2. Methods  
 
2.2.1. Preparation of co-evaporates and hot-melt extruded samples 
 
The glass transition temperature (Tg) of EC in EC/plasticizer co-evaporates (containing 0, 
10, 20 and 30% (w/w) DBS, DEP, TEC or TA), in hot-melt extruded EC/DBS mixtures (ratio: 95/5, 
80/20 and 66/33 (w/w)) and in hot-melt extruded MPT/EC/plasticizer (30/50/20, w/w/w) mixtures 
was determined via differential scanning calorimetry (DSC).  
 
 
2.2.1.1. Co-evaporates 
 
Co-evaporates were prepared by dissolving the plasticizer and EC in ethanol. The 
polymer solution (total solid content: 0.5 g in 150 ml) was transferred into a Teflon flask and a 
rotavapor (Büchi Rotavapor R-200, Flawil, Switzerland) was used to remove the solvent under 
reduced pressure at 70°C. The films were peeled from the perfluoroalkoxy surface of the flask and 
stored in an oven at 70°C for 2 days to ensure complete removal of ethanol. Subsequently the 
films were pulverized in a mortar using liquid nitrogen, further dried and stored at 40°C before 
subjecting the samples to thermal analysis. 
 
 
2.2.1.2. Hot-melt extruded samples 
 
Hot-melt extruded EC/DBS samples were prepared at a powder feed rate of 6 g/min and a 
screw speed of 30 rpm, using the standard screw configuration and different extrusion 
temperatures (range: 50-200°C with 25°C intervals). Hot-melt extruded MPT/EC/plasticizer 
mixtures were processed at 65°C.  
 
Additionally, the influence of MPT on the Tg of EC is measured in an extruded sample 
having an EC/MPT ratio of 33.3/30 (w/w) (i.e. the lowest EC/MPT ratio in the formulations tested 
thus offering the highest probability for interaction). 
 
The thermal profile (via modulated temperature differential scanning calorimetry) of MPT 
before and after processing (extrusion of MPT powder as well as the production of mini-matrices, 
both at a processing temperature of 65°C) was compared to obtain information about the thermal 
stability during processing. 
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2.2.2. Optimization of plasticizer 
 
To select a suitable plasticizer EC was combined with different plasticizers (DBS, 
DEP, TEC, TA) in a ratio of 2.5/1 (w/w). The MPT content of these formulations was 30% 
(w/w). The components were blended in a planetary mixer (15 min, 90 rpm) (Kenwood Major 
Classic, Hampshire, UK) and incubated overnight at room temperature to achieve sufficient 
interaction between EC and plasticizer. The mixture was passed through the screws of the 
powder feeder of the extruder and recycled into the powder reservoir to grind the 
MPT/EC/plasticizer mixture prior to hot-melt extrusion. Hot-melt extrusion was performed 
using a laboratory-scale intermeshing co-rotating twin-screw extruder (MP19TC-25, APV 
Baker, Newcastle-under-Lyme, UK) having a length-to-diameter ratio of 25/1. The machine 
was equipped with a Brabender twin-screw powder feeder and an extrusion screw having 
two mixing sections and a densification zone (this screw configuration is further referred to as 
the standard screw profile). The die block (2.6 cm thickness) was fixed to the extruder barrel, 
and additionally, an axially mounted die plate (1.9 cm thickness) was attached to the die 
block, with a cylindrical hole of 3 mm diameter for shaping the extrudates. The following 
extrusion conditions were used: a screw speed of 30 rpm, a powder feed rate of 6 g/min and 
a temperature of 65°C for the five heating zones along the barrel. After cooling down to room 
temperature, the extruded rods (∅ = 3 mm) were manually cut, using surgical blades, into 
mini-matrices of 2 mm length. The influence of the plasticizer type on drug release was 
evaluated via in vitro dissolution testing. 
 
To optimize the extrudate quality and mini-matrix properties, formulations with variable 
DBS concentrations were processed (EC/DBS ratio: 5/1, 3/1, 2/1 and 1.4/1, w/w). The MPT and 
XG content were 30 and 10% (w/w), respectively. The mini-matrices were manufactured using the 
same process as described above, except for the temperature: the initial extrusion temperature 
was set at 80°C and was lowered in steps of 10°C until shark skinning of the extrudate occurred. 
The surface properties of the extrudates were visually inspected for any defects and evaluated for 
their suitability to be cut into mini-matrices (deformation due to cutting, smoothness of the cutting 
surfaces and edges) using a digital camera (C3030 Olympus) linked to an image analysis system 
(analySIS®, Soft Imaging system, Münster, Germany) (magnification 9.5x).  
 
 
2.2.3. Influence of xanthan gum 
 
To modify the drug release and obtain zero-order release kinetics from the EC mini-
matrices, XG was added to the formulation in concentrations of 0, 1, 2.5, 5, 10 and 20% 
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(w/w). The MPT content was 30% (w/w), the EC/DBS ratio 2/1 (w/w). The formulations were 
processed via hot-melt extrusion: screw speed of 30 rpm, powder feed rate of 6 g/min, 
extrusion temperature of 60°C, using the standard screw profile described above. In vitro 
dissolution testing and swelling properties of the mini-matrices were evaluated via 
microscopic analysis (digital camera (C3030 Olympus) linked to an image analysis system 
(analySIS®, Soft Imaging system, Münster, Germany) (magnification 9.5x)) after 4 h 
immersion in the dissolution medium. 
 
 
2.2.4. Influence of the extrusion process parameters 
 
The influence of process parameters (screw design, powder feed rate and screw speed) 
on the extrusion process, extrudate quality and drug release properties of an optimized 
formulation (MPT/XG/EC/DBS ratio: 30/5/43.3/21.7, w/w/w/w) was evaluated. 
 
The standard configuration (Figure 3a) of the screw (length: 47.5 cm, diameter: 1.9 
cm) consisted of transport elements (forwarding elements who serve as drivers to transport 
the material through the extruder), 2 kneading blocks and a discharge element (densification 
zone). The conveying sections are built from transport elements having a double helix and a 
pitch of 9.5 mm. The kneading blocks consist of disks (4.75 mm thickness, mixing elements) 
which ensure blending of the powder mixture. The first kneading block (at 26.6 cm from the 
discharge end) consists of 10 disks with increasing staggering angle (4 disks at 30°, 4 disks 
at 60° and 2 disks at 90°). The second kneading block (at 15.2 cm from the discharge end) 
has 6 disks with a staggering angle of 60°. The discharge element is placed at the end of the 
screw and has a length of 2.8 cm and a pitch of 5.0 mm. Next to the standard screw design, 
experiments were also performed with a screw having only one kneading block (the first or 
second mixing zone, the kneading paddles of the other mixing zone were replaced by 
transport elements) and without kneading block (the screw consisted of only transport 
elements and the discharge zone) (Figure 3b). The extrusion was carried out at a powder 
feed rate of 6 g/min, screw speed of 30 rpm and a processing temperature of 60°C.  
 
The effect of production rate (depending on powder feed rate and screw speed) was 
determined by manufacturing mini-matrices at the following conditions: standard screw 
configuration, processing temperature of 60°C and variable powder feed rate and screw 
speed: 6 g/min in combination with 30 rpm, 25 g/min with 100 rpm, and 50 g/min with 200 
rpm. 
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(a) 
(b) 
 
Figure 3: Configuration of the intermeshing co-rotating screws. (a) Standard screw 
configuration with 2 kneading blocks: (1) transport zone, (2) mixing zone, (3) transport zone, 
(4) mixing zone, (5) transport zone, (6) densification zone. (b) Screw configuration without 
kneading paddle elements: (7) transport zone, (8) densification zone.  
 
Extrudate quality and mini-matrix properties in function of process parameters (screw 
design and production rate) were visually evaluated (microscopic analysis, using a digital 
camera (C3030 Olympus) linked to an image analysis system (analySIS®, Soft Imaging 
system, Münster, Germany) (magnification 9.5x)) and via in vitro dissolution testing. 
 
Using the standard extrusion settings (standard screw configuration, processing 
temperature of 60°C, powder feed rate of 6 g/min and screw speed of 30 rpm), the 
reproducibility of the extrusion process was evaluated by processing 3 batches on 3 
consecutive days, and the equilibration time of the production process was determined by 
collecting extrudate samples at several time points (5, 10, 15, 20 and 25 min after start-up). 
In vitro dissolution testing was used as evaluation method to differentiate between samples 
collected at different days and at different sampling points. 
 
MPT distribution in the mini-matrices prepared via different extrusion processes 
(using 0, 1 or 2 kneading blocks) was evaluated by Raman spectroscopic mapping. Three 
1 2 3 4 5 6
7 8
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areas (2150 x 1150 µm2) (two at the edges and one in the middle of the mini-matrix) of each 
mini-matrix (n = 3) were scanned using a 10x long working distance objective lens (laser spot 
size: 50 µm) in point-by-point mapping mode with a step size of 100 µm in both the x and y 
directions. The resulting map provides an overview of the MPT distribution in the mapped 
area. The mapping system used for this study was a RamanRxn 1 Analyzer and Microprobe 
(Kaiser Optical Systems, Ann Arbor, USA), equipped with an air cooled CCD detector (back-
illuminated deep depletion design). The laser wavelength during the experiments was the 
785 nm line from a 785 nm Invictus NIR diode laser. All spectra were recorded at a resolution 
of 4 cm-1 using a laser power of 400 mW and a laser light exposure time of 20 s per collected 
spectrum. Before data analysis, spectra were baseline corrected. Data collection and data 
analysis was done using the HoloGRAMSTM data collection software package, the 
HoloMAPTM data analysis software and Matlab® software package (version 6.5.). 
 
 
2.2.5. Thermal analysis 
 
The thermal behaviour of powders, co-evaporates and hot-melt extruded samples 
was evaluated using a 2920 Modulated DSC (TA Instruments, Leatherhead, UK) equipped 
with a refrigerated cooling system (RCS). Dry helium at a flow rate of 40 ml/min was used as 
the purge gas through the DSC cell and 150 ml/min of nitrogen through the RCS unit. 
Samples (± 10 mg) were run in closed aluminium pans supplied by TA Instruments; the mass 
of each empty sample pan was matched with the mass of the empty reference pan to ± 0.10 
mg. The experimental method consisted of an initial 5 min isothermal equilibration period at 
0°C. During the subsequent heating run the following experimental parameters were used: 
an underlying heating rate of 2°C/min from 0 to 200°C, a modulation amplitude of 0.212°C 
and a period of 40 s. Temperature and enthalpic calibration was performed with an indium 
standard, whereas calibration of the heat capacity was performed with a sapphire standard. 
The results were analyzed using the TA Instruments Universal Analysis Software. 
Measurements were performed in duplicate and the Tg values (midpoint half height) are 
reported.  
 
 
2.2.6. In vitro drug release 
 
The mini-matrices (approximately 60 mg) were introduced in a basket (USP 27, 
dissolution apparatus 1 [56]). The dissolution was performed in a VK 7010 dissolution system 
combined with a VK 8000 automatic sampling station (VanKel, New Jersey, USA). Demineralized 
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water was used as the dissolution medium. The temperature of the medium (900 ml) was kept at 
37 ± 0.5°C, while the rotational speed of the baskets was set at 100 rpm. Samples of 5 ml were 
withdrawn at 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 h and spectrophotometrically analyzed for MPT at 
222 nm by means of a Perkin-Elmer Lambda 12 UV-VIS double beam spectrophotometer 
(Zaventem, Belgium).  
 
Due to interference of DEP in the absorption spectrum of MPT, dissolution samples of 
mini-matrices containing DEP were analyzed using a validated HPLC-UV method. All chemicals 
were of analytical or HPLC grade. The HPLC equipment (Merck-Hitachi, Darmstadt, Germany) 
consisted of a solvent pump (L-7100) set at a constant flow rate of 1.0 ml/min, a variable 
wavelength UV-detector (L-7400) set at 222 nm, a reversed-phase column and precolumn 
(LiChroCART® 250-4 and 4-4, LiChrospher® 100 RP-18 5 µm), an auto-sampler injection system 
(L-7200) with a 100 µl loop (Valco Instruments Corporation, Houston, Texas, USA) equipped with 
an automatic integration system (software D-7000 Multi-Manager). The mobile phase consisted of 
0.01 M KH2PO4/acetonitrile/methanol (55/22.5/22.5, v/v/v).  
 
For both spectrophotometric methods, the MPT concentrations were calculated from a 
calibration curve between 0 and 50 µg/ml. The dissolution was simultaneously performed in 6 
dissolution vessels, each vessel containing 4 mini-matrices.  
 
 
2.2.6.1. Method validation 
 
For the general considerations about method validation of an analytical procedure, we 
refer to Chapter 1 and the guidelines of the International Conference on Harmonisation (ICH) [57]. 
The following parameters were evaluated: specificity, linearity, precision, accuracy and the limit of 
detection as well as of quantification. 
 
 
2.2.6.1.1. Specificity 
 
Specificity of the HPLC method was assessed at 222 nm by comparing the 
chromatograms of dissolution medium spiked with MPT, dissolution medium spiked with DEP 
and a dissolution sample (containing MPT and DEP).  
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2.2.6.1.2. Linearity 
 
Different calibration curves (n = 10) were prepared. For each calibration curve, 
different metoprolol tartrate concentrations were investigated (2.5, 5, 10, 20, 30, 40 and 50 
µg/ml in water) to cover the range of the unknown samples. 
 
 
2.2.6.1.3. Precision 
 
The within-day repeatability was determined using the variation of the peak area of 
samples injected at different times (n = 5) during the same day. The analyses performed over 
five different days can be considered as the intermediate precision or within-laboratory 
precision (between-day repeatability). The precision was calculated for different metoprolol 
tartrate concentrations (2.5, 5, 10, 20, 30, 40 and 50 µg/ml). 
 
 
2.2.6.1.4. Accuracy 
 
Accuracy was determined for different metoprolol tartrate concentrations (2.5, 5, 10, 
20, 30, 40 and 50 µg/ml) (n = 10). 
 
 
2.2.6.1.5. Limit of detection and limit of quantification 
 
 The limit of detection (LOD) and limit of quantification (LOQ) were calculated based on the 
standard deviation of the intercept and slope of the mean calibration curve. 
 
 
2.2.7. X-ray diffraction 
 
To investigate the crystallinity of the components in the mini-matrices, X-ray 
diffraction was performed (on pulverized mini-matrices). The X-ray patterns of MPT, EC, XG 
and mini-matrices were determined using a D5000 Cu Kα Diffractor (λ = 0.154 nm) 
(Siemens, Karlsruhe, Germany) with a voltage of 40 mA in the angular range of 10° < 2θ < 
60° using a step scan mode (step width = 0.02°, counting time = 1 s/step). 
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3. RESULTS AND DISCUSSION 
 
3.1. Optimization of plasticizer 
 
Previous work [12] identified ibuprofen (melting point 76°C) as a plasticizer for EC, 
and therefore the characteristics of ibuprofen/EC mini-matrices are not predictive of the 
extrusion and dissolution properties of EC mini-matrices containing non-plasticizing drugs. 
The aim of this work was to substitute ibuprofen by MPT: due to its higher melting point 
(123°C), a specific drug-matrix interaction (due to melting of the drug) is unlikely in case 
extrusion is performed at a temperature below the drug melting point. Therefore, the effect of 
MPT on the polymer Tg was examined. Analyzing the thermal behaviour of an EC/MPT 
(33.3/30, w/w) hot-melt extruded sample (extrusion temperature: 65°C) only revealed the 
melting endotherm of MPT (Tm 122.6 ± 0.4°C), whereas no Tg of EC was detected. Since the 
Tg of EC powder was determined 127.9 ± 0.2°C, one can assume that the Tg of EC in the 
melt-extruded samples is masked by the melting endotherm of MPT (peak ranging from 
108.5 to 126.0°C). Although a slight decrease in Tg of EC could be overwhelmed by the 
melting signal of MPT, any interaction occurring during extrusion between MPT and EC is 
limited (since no Tg of EC was detected at a temperature below the melting endotherm of 
MPT) and the incorporation of a conventional plasticizer is required to lower the extrusion 
temperature in order to reduce thermal degradation and improve extrudate quality. 
 
The Tm of MPT prior to extrusion and when processed at 65°C (as powder as well as 
in the MPT/EC/plasticizer mixtures) was similar, proving its thermal stability during 
production. Previous work at the Laboratory of Pharmaceutical Technology confirmed the 
chemical stability of ethylcellulose and xanthan gum after hot-melt extrusion at this 
processing temperature using similar shearing forces [58]. The thermochemical stability and 
volatility of the plasticizer during processing must also be taken into consideration. Since 
other researchers found that plasticizer concentration only decreased when processed in 
films at 180°C [59], the amount of plasticizer in our formulations will remain constant since 
extrusion was performed at 60°C. 
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3.1.1. Plasticizer type 
 
3.1.1.1. Co-evaporates 
 
The effect of plasticizer type and concentration is shown in Figure 4 (n = 3). Tg of EC 
decreased at higher plasticizer concentrations, although an increase from 20 to 30% (w/w) 
did not induce a further drop of Tg. Despite the different polarity of the plasticizers 
(hydrophilic: TEC, TA / lipophilic: DBS, DEP) the efficiency of all plasticizers was similar.  
 
0
20
40
60
80
100
120
140
0 10 20 3
Concentration plasticizer (%)
Tg
 E
C
 (°
C
)
0
 
Figure 4: Influence of plasticizer concentration and type on the Tg of EC (mean ± S.D., n = 3) 
processed as co-evaporates: (□) DBS, (△) DEP, (○) TEC, (x) TA. 
 
 
3.1.1.2. Hot-melt extruded samples 
 
Using co-evaporates it was not possible to select a specific plasticizer. However, co-
evaporates could overestimate the plasticizing efficacy since ideal solid dispersions were 
manufactured, maximizing plasticizer/polymer interactions. Therefore, hot-melt extruded 
samples (MPT/EC/plasticizer in a ratio of 30/50/20 (w/w/w)) were processed to select the 
optimal plasticizer. Neither the extrusion process nor the extrudate quality was influenced by 
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the plasticizer type since the pressure (4, 3, 8 and 3 bar for DBS, DEP, TEC and TA 
formulations, respectively) and torque (37, 37, 37 and 34% for DBS, DEP, TEC and TA 
formulations, respectively) were similar when extruding with the different plasticizers 
(extrusion temperature: 65°C). For all hot-melt extruded samples, the Tg of EC was detected 
in the temperature range of 55-60°C. Comparing these results with the Tg shifts of the co-
evaporates showed that the plasticizing efficiency of the 4 plasticizer types was similar in 
both methods, indicating that intense intermolecular mixing also occurred during the hot-melt 
extrusion process, ensuring complete miscibility of plasticizers and EC. In contrast, Aitken-
Nichol and co-workers [39] suggested that intermolecular mixing was better in a solution-cast 
film compared to a highly viscous melt: lidocaine HCl being a more effective plasticizer in 
solution cast films than in the extruded films. 
 
 
3.1.1.3. Method validation 
 
3.1.1.3.1. Specificity 
 
The chromatograms (Figure 5) showed that MPT and DEP were completely 
separated, and therefore the method was selective to determine MPT in dissolution samples: 
a retention time of ± 7 min and ± 15 min was obtained for MPT and DEP, respectively. 
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Figure 5: Chromatograms showing metoprolol tartrate and diethyl phthalate in (top) water 
spiked with MPT, (middle) water spiked with DEP and (bottom) dissolution sample. 
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3.1.1.3.2. Linearity 
 
The mean calibration curve (Y = 82741 (± 1564) X - 30938 (± 8556)) was linear 
between 0 and 50 µg/ml metoprolol tartrate, with a coefficient of determination of 0.9999 (± 
0.0001). 
 
 
3.1.1.3.3. Precision 
 
The coefficients of variation (C.V.) (%) of the repeatability (intra-assay precision) and 
the intermediate precision (within-laboratory precision) are shown in Table 1. 
 
Table 1: Coefficients of variation (%) of the repeatability (n = 5) and the intermediate 
precision (n = 5). 
Coefficient of variation (%) 
Concentration (µg/ml)  
Repeatability Intermediate precision 
2.5  1.9 7.9 
5.0  0.7 3.4 
10.0  0.7 2.7 
20.0  0.8 2.0 
30.0  0.4 2.9 
40.0  0.8 1.4 
50.0  0.6 1.7 
 
 For the repeatability as well as the intermediate precision, the coefficients of variation 
at all concentrations were lower than 15%. 
 
 
3.1.1.3.4. Accuracy 
 
 The accuracy was determined for all metoprolol tartrate concentrations and the mean 
results are presented in Table 2. 
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Table 2: Accuracy (%, mean ± S.D., n = 10). 
Concentration (µg/ml) Calculated concentration (µg/ml) Accuracy (%) C.V. (%) 
2.5 2.84 ± 0.40 113.5 ± 16.0 14.1 
5.0 5.63 ± 0.63 112.6 ± 12.5 11.1 
10.0 9.59 ± 0.14 95.9 ± 1.4 1.4 
20.0 18.98 ± 0.13 94.9 ± 0.6 0.7 
30.0 31.30 ± 1.22 104.3 ± 4.1 3.9 
40.0 40.10 ± 0.29 100.2 ± 0.7 0.7 
50.0 48.29 ± 0.69 96.6 ± 1.4 1.4 
 
 The proposed method can be considered as accurate as an accuracy of at least 
94.9% was obtained and the highest coefficient of variation was 14.1%. 
 
 
3.1.1.3.5. Limit of detection and limit of quantification 
 
Based on the mean linear regression equation of metoprolol tartrate the limit of 
detection and the limit of quantification for metoprolol tartrate are 0.34 and 1.03 µg/ml, 
respectively.  
 
 
3.1.1.4. Influence of plasticizer type on drug release 
 
Drug release in function of plasticizer type is shown in Figure 6: the release rate was 
affected, indicating that the chemical nature of the plasticizer plays a major role for the 
underlying drug release mechanism. DBS and DEP provided a linear release of MPT, 
however, not all drug was released within 24 h. On the other hand, complete release was 
noticed for TEC- and TA-containing mini-matrices, but the burst effect was significant 
probably due to the hydrophilicity of these plasticizers. Other investigators [60-63] already 
described a similar effect of water solubility of the plasticizer on the drug release mechanism. 
Lecomte and co-workers [64] compared a lipophilic (dibutyl sebacate) and hydrophilic 
(triethyl citrate) plasticizer and reported that triethyl citrate rapidly leached from a polymer 
coat affecting film permeability and drug diffusion. In contrast dibutyl sebacate remained in 
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the polymer layer, reducing the drug release rate. Furthermore, the plasticizer concentration 
can also affect the drug release profile, as reported by other investigators [58, 63, 65, 66]. 
Due to the burst effect of the hydrophilic plasticizers, DBS was selected for MPT/EC 
formulations, since this combination seemed able to provide zero-order drug release from the 
mini-matrices.  
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Figure 6: Influence of plasticizer type on the dissolution profiles (mean ± S.D., n = 6) of mini-
matrices containing 30% (w/w) MPT and EC/plasticizer (2.5/1, w/w): (■) DBS, (□) DEP, (▲) 
TEC, (△) TA. 
 
 
3.1.2. Plasticizer concentration 
 
Depending on the DBS concentration in the formulation and the processing 
temperature, the pressure and torque during production varied (Table 3): both parameters 
increased with decreasing processing temperatures (irrespective of the DBS content) due to 
the higher viscosity of the material at these production conditions. Processing was also 
easier at higher DBS levels as Tg of EC was lowered to about 100.1, 43.8 and 38.8°C after 
extrusion (at 125°C) of binary EC/DBS mixtures containing 5, 20 and 33% (w/w) DBS, 
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respectively (Table 4). The minimum extrusion temperature allowing processing also 
confirmed the efficiency of DBS during extrusion of EC: a 66/33 (w/w) and 80/20 (w/w) 
EC/DBS mixture could be processed at 50 and 75°C, respectively, whereas a 95/5 (w/w) 
mixture already blocked the extruder at an extrusion temperature of 100°C.  
 
Table 3: Pressure (bar) and torque (%) during production of mini-matrices using different 
EC/DBS ratios (w/w) at different processing temperatures. The MPT and XG content were 30 
and 10% (w/w), respectively. 
EC/DBS ratio 
(w/w) 
 
Processing 
temperature (°C) 
 
Pressure 
(bar) 
 
Torque 
(%) 
 
Extrudate 
 
Mini-matrices 
 
5/1 80 0 8 sticky - 
 70 4 12 smooth cracks 
 60 66 93 shark skinning twisted - 
3/1 80 0 16 sticky - 
 70 1 20 smooth cracks 
 60 6 31 smooth cracks 
 50 26 43 shark skinning - 
2/1 80 0 18 sticky - 
 70 1 26 smooth smooth 
 60 4 35 smooth smooth 
 50 10 45 rough - 
 40 39 78 shark skinning - 
1.4/1 80 0 19 sticky - 
 70 0 22 smooth smooth 
 60 2 29 smooth smooth 
 50 4 38 smooth smooth 
 40 9 59 rough - 
 
-: not applicable 
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For all formulations, the extrudates were sticky and had droplets (mainly DBS) on 
their surface when extruded at 80°C (Table 3). At higher DBS concentration it was possible 
to process the extrudates at lower temperature before surface defects were observed: at 
40°C the extrudate with an EC/DBS ratio of 2/1 (w/w) showed shark skinning (Figure 7a), 
whereas at the same processing temperature the extrudate showed only a rough surface 
(Figure 7b) when an EC/DBS ratio of 1.4/1 (w/w) was used. Since mini-matrices with cracks 
(Figure 7c) are excluded from further optimization and evaluation (drug release from these 
mini-matrices would be difficult to control), an EC/DBS ratio of at least 2/1 (w/w) is required 
to produce mini-matrices with good quality (without cracks) (Figure 7d). As it is preferential to 
use the lowest plasticizer concentration possible, an EC/DBS ratio of 2/1 (w/w) is selected for 
further experiments.  
 
(a)      (b) 
(c)      (d) 
Figure 7: Extrudates and mini-matrices in function of EC/DBS ratio and processing 
temperature: (a) MPT/XG/EC/DBS (30/10/40/20, w/w/w/w) produced at 40°C showing shark 
skinning, (b) MPT/XG/EC/DBS (30/10/35/25, w/w/w/w) produced at 40°C showing rough 
surface, (c) MPT/XG/EC/DBS (30/10/50/10, w/w/w/w) produced at 70°C showing mini-
matrices with cracks, (d) MPT/XG/EC/DBS (30/10/40/20, w/w/w/w) produced at 60°C. 
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Shark skinning can be described as a regular ridged surface distortion, with the ridges 
running perpendicular to the extrusion direction. Shark skinning is thought to be formed in the 
die channel or at the exit. The melt, as it proceeds along the die channel, has a velocity 
profile, with maximum velocity at the centre and zero velocity at the wall. The material at the 
wall has to accelerate to the velocity at which the extrudate is leaving the die, generating 
tensile stress. If the stress exceeds the tensile strength, the surface ruptures causing the 
surface roughness. The shark skinning problem can generally be reduced by increasing the 
die temperature, reducing the screw speed or the addition of a lubricant [67, 68].  
 
MPT/XG/EC/DBS (30/10/50/10, w/w/w/w) extrudates processed at 60°C also showed 
a twisting distortion: a polymer can remember its history of turning along the spiral screw, 
even after it has been passed through the die. This phenomenon is called turning memory. 
During passage down the screw, the melt receives a prolonged mechanical treatment during 
which alignment of the polymer chains can occur. Since passage through the die is relatively 
short, there is no time to replace the spiralled configuration by a new one. The turning 
memory of the melt can be removed by installing a breaker plate-screen pack assembly in 
the die zone [67]. 
 
As can be seen from Table 4, the Tg of EC decreased with increasing DBS content: 
110, 80 and 45°C for an EC/DBS ratio of 95/5, 80/20 and 66/33 (w/w), respectively (before 
hot-melt extrusion). After processing the Tg was decreased, irrespective of the processing 
temperature: about 100, 50 and 40°C for an EC/DBS ratio of 95/5, 80/20 and 66/33 (w/w), 
respectively. Due to the mixing efficiency of the kneading elements of the extrusion screw the 
better plasticizer-polymer interaction during hot-melt extrusion explains the lower Tg after 
hot-melt extrusion. 
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Table 4: Glass transition temperature (Tg, °C) of EC for different EC/DBS ratios (w/w) at 
different processing temperatures (mean ± S.D., n = 3). 
EC/DBS ratio (w/w)  Processing temperature (°C) Tg (°C) 
95/5  before extrusion 111.3 
  200 101.5 
  175 107.5 
  150 104.2 
  125 100.1 
80/20  before extrusion 79.4 
  200 46.6 
  175 43.0 
  150 45.5 
  125 43.8 
  100 48.5 
  75 54.7 
66/33  before extrusion 45.7 
  200 38.9 
  175 38.6 
  150 42.8 
  125 38.8 
  100 41.4 
  75 38.5 
  50 37.2 
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3.2. Influence of xanthan gum 
 
The drug release rate from hot-melt extruded dosage forms is highly dependent upon 
the characteristics of the carrier material. Most of the materials used in hot-melt extruded 
dosage forms are water insoluble [5, 6, 69, 70] or have slow hydration or gelation rates [40, 
49]. To improve or modulate drug release from these systems, various excipients with 
different physicochemical properties can be added. In this study XG was incorporated in the 
formulation to increase the drug release rate by increasing the hydrophilicity and porosity of 
the dosage form during dissolution [11]: drug release from MPT/EC/DBS (30/50/20, w/w/w) 
mini-matrices was limited to 45% in 24 h. 
The different formulations were easily processed, independent of XG concentration: 
the pressure and torque varied between 1 and 5 bar, and 30 and 35%, respectively. All 
formulations were produced at 60°C except for the 20% (w/w) XG formulation when a barrel 
temperature of 65°C was required to produce smooth extrudates. Increasing XG 
concentrations yielded a faster drug release and a zero-order drug release was only obtained 
at ≤ 5% (w/w) XG (Figure 8).  
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Figure 8: Influence of xanthan gum concentration on the dissolution profiles (mean ± S.D., n 
= 6) of mini-matrices containing 30% (w/w) MPT, XG, EC and DBS (EC/DBS 2/1, w/w). XG 
concentration (w/w): (■) 0%, (▲) 1%, (●) 2.5%, (□) 5%, (△) 10%, (○) 20%. 
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The 5% XG formulation was selected as reference, since incomplete drug release 
and burst effect were seen at lower and higher XG concentrations, respectively. Similar to 
EC/XG matrices containing ibuprofen [11], swelling of the mini-matrices containing 10 and 
20% (w/w) XG was responsible for their faster MPT release (Figure 9).  
 
  
(a)      (b) 
  
(c)    (d) 
Figure 9: Mini-matrices containing 30% (w/w) MPT, XG, EC and DBS (EC/DBS 2/1, w/w) after 4 h 
immersion in the dissolution medium. XG concentration (w/w): (a) 0%, (b) 5%, (c) 10%, (d) 20%.  
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Figure 10 shows the X-ray diffraction spectra of MPT, EC, XG and mini-tablets containing 
5, 10 and 20% XG. As can be seen from the figure, the drug was crystalline, while EC and XG 
were amorphous. The drug remained crystalline in the hot-melt extruded mini-tablets as sharp 
peaks of MPT could be observed in the diffraction pattern of the mixtures. Furthermore, no 
difference in drug crystallinity could be seen in mini-matrices with different XG content, since the 
diffraction spectra of the different hot-melt extruded mixtures (varying in XG concentration) were 
overlapping. However, the diffraction peaks were smaller in comparison with the pure material, 
illustrating the presence of smaller crystals. 
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Figure 10: X-ray diffraction pattern of (red) XG, (purple) MPT, (green) EC, (blue) 5% XG 
mini-matrices, (pink) 10% XG mini-matrices, (yellow) 20% XG mini-matrices. 
 
 
3.3. Reproducibility and equilibration of the production process 
 
 The extrusion process did not vary between the production of 3 batches on 
consecutive days: the pressure and torque varied between 3 and 5 bar, and 30 and 32%, 
respectively. The production of the 5% (w/w) XG extrudates was reproducible since the drug 
release profiles coincided, revealing the robustness of the production method. After an 
equilibration time of 5 minutes extrudates of constant quality were obtained since no 
influence on the extrudate quality and release characteristics was seen for different extrusion 
times. 
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3.4. Influence of the extrusion process parameters 
 
Modifications of the screw configuration allow to alter the production method as the 
different screw elements (feed, mixing, discharge) can be optimized to suit a particular application 
[3, 71]. Literature reports described a significant influence of the screw design on the efficiency of 
a hot-melt extrusion process [4], extrudate quality and the physico-chemical properties 
(crystallinity and dissolution properties) of extruded material [72, 73].  
 
In our study, the pressure and torque were neither influenced by the number nor the 
position of the mixing zones: 3, 7 and 3 bar, and 30, 36 and 33% when using both mixing zones, 
only the first mixing zone and only the second mixing zone, respectively.  
 
Using a screw design with two mixing sections, smooth extrudates were obtained, yielding 
mini-matrices of good quality (Figure 11a). In case of extrusion (at 60°C) without kneading 
paddles (pressure: 2 bar, torque: 14%) the extrudates had a rough surface with powder spots 
(which Raman identified as MPT) (Figure 11b) confirming that kneading paddle elements are 
required for intensive mixing which was also reported by others [72, 73]. Using this screw 
configuration, smooth extrudates could be obtained when the barrel temperature was increased 
with 10°C (pressure: 0 bar, torque: 10%). However, powder spots were still detected (Figure 11c) 
since the kneading elements have an effect on the residence time and mixing intensity in the 
extruder and facilitate dispersion of the drug in the polymer. Mini-matrices from extruded rods 
produced with only transport elements did not have good quality (cracks) (Figure 11b and 11c) 
and were therefore not submitted to dissolution testing. 
 
   
(a)    (b)    (c) 
Figure 11: Extrudates and mini-matrices consisting of MPT/XG/EC/DBS (30/5/43.3/21.7, w/w/w/w) 
produced at (a) 60°C with 2 kneading blocks, (b) 60°C without kneading blocks, (c) 70°C without 
kneading blocks. 
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Although it was reported that a screw configuration with less kneading paddles induced 
less shear and decreased the residence time of material in the extruder [72-74], in our study the 
mixing efficacy was not influenced if the number of mixing zones was reduced, provided that at 
least one mixing zone was present. Drug release was also not influenced by the number or the 
position of the mixing zones (Figure 12), what was also noticed by other investigators [75].  
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Figure 12: Influence of screw design on the drug release profiles (mean ± S.D., n = 6) of 
mini-matrices containing MPT/XG/EC/DBS (30/5/43.3/21.7, w/w/w/w): (■) kneading block 1 
and 2, (▲) kneading block 1, (●) kneading block 2. 
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The distribution of MPT in the mini-matrices was monitored via Raman using the 627-653 
cm-1 spectral band as no overlap with other ingredients occurred at these wavenumbers (Figure 
13). 
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Figure 13: Raman spectra from the compounds in the mini-matrices. 
 
Figure 14a is a picture from a mini-matrix tablet produced via extrusion at 60°C with 2 
kneading blocks. The blue dots in the picture indicate the spots on the mini-matrix surface where 
Raman spectra were collected. Based on the intensity of the Raman signal across the scanned 
sections of the mini-matrices it was confirmed that MPT is homogeneously distributed in the mini-
matrix, since the same MPT intensities were measured in the centre and at the edges of the mini-
matrices (Figure 14b, red indicating an area with high MPT concentration at the tablet surface, 
blue an area without MPT). 
 
 
 
 
 
 
 
 
 
(a)      (b) 
Figure 14: (a) Mapped area of mini-matrix (border) – extruded at 60°C with 2 kneading blocks, (b) 
interpolated map from a mapped mini-matrix (border) – extruded at 60°C with 2 kneading blocks, 
representing uniform MPT distribution. 
 
 
125
CHAPTER 2 
 
 
 
ata\thomas\microprobe\ellen verhoeven\dringende stalen\60 graden\spots op extrudaat\0
0 500 1000 1500 2000 2500 3000
0
1
2
3
4
5
6
x 104
Raman Shift (1/cm)
C
ou
nt
s
                       
pure MPT
a b
c d Ra an shift (cm
-1)
C
ou
nt
s 
(A
U
)
C
ou
nt
s
C
ou
nt
s
C
ou
nt
s 
(A
U
)
Similar results were obtained for all mapped areas of the analyzed mini-matrices, 
irrespective of the production process, provided that kneading paddles were present in the screw. 
In case of tablets prepared at 70°C without kneading blocks MPT distribution on the tablet surface 
was not homogeneous (Figure 15b). This area of high MPT intensity in the Raman map 
corresponded to a white particle that visually could be seen (Figure 15a and 15c at a 
magnification of 10 and 100, respectively). The Raman spectrum (Figure 15d) identified this 
particle as an API cluster as only the spectrum of MPT was detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Mini-matrices extruded at 70°C without kneading elements have local high MPT 
amounts: (a) mapped area of mini-matrix (border), (b) interpolated map from a mapped mini-
matrix (border) representing inhomogeneous drug distribution, (c) white particle on the tablet 
surface, (d) Raman spectrum of white particle on the tablet surface.  
 
To evaluate the effect of production rate on the extrusion process and extrudate quality, 
the powder feed rate and screw speed were simultaneously adjusted to ensure a constant fill level 
of the extrusion chamber. By increasing both process parameters, the residence time in the 
extruder was influenced [76]. Smooth extrudates were obtained at all processing conditions. A 
pressure of 3, 2 and 2 bar, and a torque of 30, 46 and 42% were recorded at a powder feed rate 
and screw speed of 6 g/min and 30 rpm, 25 g/min and 100 rpm, 50 g/min and 200 rpm, 
respectively. Using a high powder feed rate (25 and 50 g/min) in combination with a high screw 
speed (100 and 200 rpm), a lower barrel temperature was set (50°C) to compensate for the heat 
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generated due to the friction [4, 71]. The extrudate quality was independent of the powder feed 
rate and screw speed, whereas Henrist et al. observed an increase in radius and porosity and a 
decrease in mechanical strength of the extrudate when processed at a higher screw speed and 
powder feed rate [77]. The production rate did not alter the drug release characteristics of the 
mini-matrices (Figure 16), although other investigators reported a lower drug release when 
increasing the powder feed rate and screw speed [77]. Nakamichi and co-workers reported that 
the extrudate quality and properties were not influenced by the screw speed, in case kneading 
elements were used [72].  
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Figure 16: Influence of powder feed rate and screw speed on the drug release profiles (mean ± 
S.D., n = 6) of mini-matrices containing MPT/XG/EC/DBS (30/5/43.3/21.7, w/w/w/w): (■) 6 g/min - 
30 rpm, (▲) 25 g/min - 100 rpm, (●) 50 g/min - 200 rpm. 
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4. CONCLUSIONS 
 
This chapter showed that hot-melt extrusion can be used to produce 
ethylcellulose/xanthan gum mini-matrices with controlled drug delivery. Dibutyl sebacate was 
found to be a suitable plasticizer to obtain smooth extrudates and mini-matrices. Using 
xanthan gum, zero-order release kinetics with almost complete drug release could be 
obtained. Modifications of process parameters (screw design, powder feed rate and screw 
speed) had no influence on the extrusion process or on the extrudate quality, drug 
homogeneity and release characteristics, confirming the robustness of the process. 
However, a drawback of this robustness is the fact that it offers limited flexibility for 
optimization of drug release.  
Therefore, further experiments (discussed in the next chapter) were performed using 
polyethylene oxides as an alternative for xanthan gum. 
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ABSTRACT  
 
 Mini-matrices with release-sustaining properties were developed by hot-melt 
extrusion (diameter 3 mm, height 2 mm) using metoprolol tartrate as model drug (30%, w/w) 
and ethylcellulose as sustained-release agent. Polyethylene glycol or polyethylene oxide was 
added to the formulation to increase drug release. Changing the hydrophilic polymer 
concentration (0, 1, 2.5, 5, 10, 20 and 70%, w/w) and molecular weight (6000, 100.000, 
1.000.000 and 7.000.000) modified the in vitro drug release: increasing concentrations 
yielded faster drug release (irrespective of molecular weight), whereas the influence of 
molecular weight depended on concentration. Smooth extrudates were obtained when 
processed at 40 and 70°C for polyethylene glycol and polyethylene oxide formulations, 
respectively. Raman analysis revealed that metoprolol tartrate was homogeneously 
distributed in the mini-matrices, independent of hydrophilic polymer concentration and 
molecular weight. Also drug and polymer crystallinity were independent of both parameters. 
An oral dose of 200 mg metoprolol tartrate was administered to dogs either as immediate-
release preparation (Lopresor® 100), as sustained-release formulation (Slow-Lopresor® 200 
Divitabs®), or as experimental mini-matrices (varying in hydrophilic polymer concentration). 
The sustained-release effect of the experimental formulations was limited and relative 
bioavailabilities (using Slow-Lopresor® 200 Divitabs® as reference) of 66.2 and 148.2% were 
obtained for 5 and 20% PEO 1.000.000 mini-matrices, respectively. 
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CHAPTER 3 
POLYETHYLENE OXIDE TO TAILOR  
METOPROLOL TARTRATE RELEASE:  
IN VITRO AND IN VIVO EVALUATION  
 
 
 
1. INTRODUCTION 
 
Hot-melt extrusion is a technology used in the pharmaceutical industry to produce 
matrix formulations where a drug is homogeneously embedded in a release-controlling 
polymer matrix. Since the different steps (mixing, melting, homogenizing and shaping) are 
continuously performed as a one-step process on a single machine, it has advantages over 
direct compression and granulation as conventional technique to manufacture controlled-
release matrices [1-3].  
Ethylcellulose, a polymer with thermoplastic properties, has been intensively 
investigated as drug carrier in hot-stage extrusion [4-7]. Mini-matrices could be developed by 
hot-melt extrusion using ethylcellulose to sustain the release of ibuprofen: the combination of 
ethylcellulose and a hydrophilic component (hydroxypropylmethylcellulose [8-10], xanthan 
gum [8-11]) offered a flexible system to tailor the in vitro as well as in vivo drug release.  
Due to the specific drug-matrix interaction, the low-melting ibuprofen (melting point 
76°C) was identified as a plasticizer for ethylcellulose [12]. As a consequence, the 
characteristics of ethylcellulose/hydrophilic polymer mini-matrices containing ibuprofen were 
not predictive of the extrusion and dissolution properties of ethylcellulose mini-matrices 
containing non-plasticizing drugs. Therefore, ibuprofen was substituted by a drug with a 
higher melting point (metoprolol tartrate, 123°C) and a conventional plasticizer was added to 
the formulation [13].  
In the present study sustained-release mini-matrices were developed by hot-melt 
extrusion of a metoprolol tartrate/ethylcellulose/dibutyl sebacate mixture with the addition of 
polyethylene glycol or polyethylene oxide as hydrophilic polymer to tailor drug release. The aim 
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was to examine the effect of different concentrations (0-70%, w/w) and molecular weights 
(polyethylene glycol 6000 and polyethylene oxide 100.000-7.000.000) of these hydrophilic 
polymers on drug and polyethylene glycol/polyethylene oxide release, drug homogeneity and drug 
and polymer crystallinity. The influence of polyethylene oxide concentration on bioavailability in 
dogs was also evaluated and compared with xanthan gum mini-matrices [13] and an equivalent 
dose of a sustained-release metoprolol tartrate matrix tablet (Slow-Lopresor® 200 Divitabs®). 
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2. MATERIALS AND METHODS 
 
2.1. Materials  
 
Metoprolol tartrate (MPT) (10 µm) (Esteve Quimica, Barcelona, Spain) was selected 
as model drug. The matrix consisted of ethylcellulose (EC) (Ethocel® Std 10 FP Premium; 
particle size: 3-15 µm; ethoxyl content: 48-49.5% (w/w); viscosity: 9-11 mPa.s (5% solution in 
toluene/EtOH 80/20, 25°C)), kindly donated by Dow Chemical Company (Midland, USA), and 
a hydrophilic component: xanthan gum (XG) (Xantural® 75, mean particle size: 75 µm) (CP 
Kelco, Liverpool, UK) or polyethylene glycol or polyethylene oxide. Dibutyl sebacate (DBS) 
(Sigma-Aldrich, Steinheim, Germany) was used as plasticizer for ethylcellulose.  
 
 
2.1.1. Polyethylene glycol, polyethylene oxide 
 
Polyethylene glycol (PEG) having a molecular weight (MW) of 6000 was purchased 
from Fagron (Waregem, Belgium). Different types of polyethylene oxide (PEO, SentryTM 
PolyoxTM WSR N10, N12K and 303 having a MW of 100.000, 1.000.000 and 7.000.000, 
respectively) were supplied from Dow Chemical Company (Midland, USA). 
 
Polyethylene glycol (Figure 1c) and polyethylene oxide (Figure 1d) are non-ionic, 
water soluble, linear, semi-crystalline, high molecular weight homo-polymers manufactured 
by polymerization of ethylene glycol (Figure 1a) and ethylene oxide (Figure 1b), respectively. 
The polymer backbone of both is identical, but the major difference between the two 
materials is the terminal end-groups: PEG has hydroxyl groups at both ends of the chain, 
whereas PEO has one hydroxyl end-group. They are available in a broad range of molecular 
weights, i.e. PEG up to 20.000 g/mol (daltons, Da), PEO from 100.000 up to 8.000.000 Da 
[14-16]. Polyethylene oxides can be used as tablet binder in direct compression [14, 17-27], 
in hot-melt produced dosage forms (e.g. tablets, films, beads, solid dispersions, solid 
solutions) [16, 28-41] or in other drug delivery systems (e.g. nanoparticles, hydrogels) [42-
46]. High molecular weight PEOs have been successfully applied in controlled-release 
dosage forms, because the rate of swelling, mucoadhesive properties and erosion of the 
polymer allow to sustain the release of active ingredients. As the swelling properties (thus 
matrix forming capacity) depend on the molecular weight, modification of the release kinetics 
is possible by choosing the appropriate type of PEO grade. 
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(a)       (b)    
 
     
 
(c)       (d) 
 
Figure 1: Chemical structure of (a) ethylene glycol, (b) ethylene oxide, (c) polyethylene 
glycol, (d) polyethylene oxide. 
 
 
 All other chemicals were at least of analytical grade (VWR, Leuven, Belgium). 
 
 
2.2. Methods  
 
2.2.1. Hot-melt extrusion 
 
2.2.1.1. Production of mini-matrices 
 
The MPT content was kept constant at 30% (w/w). The concentration of hydrophilic 
polymer varied between 0 and 70% (w/w) for all PEG/PEO types under investigation. The 
remaining part of the formulation consisted of EC/DBS, in a ratio of 2/1 (w/w) [13]. The 
concentrations of PEG, PEO and EC/DBS were varied according to Table 1.  
 
Table 1: Composition (%, w/w) of the mini-matrices. 
MPT 30 30 30 30 30 30 30 
PEG/PEO - 1 2.5 5 10 20 70 
EC 46.7 46 45 43.3 40 33.3 - 
DBS 23.3 23 22.5 21.7 20 16.7 - 
 
 
 
144
 POLYETHYLENE OXIDE TO TAILOR METOPROLOL TARTRATE RELEASE: IN VITRO AND IN VIVO EVALUATION  
 
The components were blended in a planetary mixer (15 min, 90 rpm) (Kenwood Major 
Classic, Hampshire, UK) and incubated overnight at room temperature to achieve sufficient 
interaction between EC and plasticizer. The mixture was passed through the screws of the 
powder feeder of the extruder and recycled into the powder reservoir to homogeneously distribute 
DBS in the powder prior to hot-melt extrusion. Hot-melt extrusion was performed using a 
laboratory-scale intermeshing co-rotating twin-screw extruder (MP19TC-25, APV Baker, 
Newcastle-under-Lyme, UK) having a length-to-diameter ratio of 25/1. The machine was 
equipped with a Brabender twin-screw powder feeder and an extrusion screw having two mixing 
sections and a densification zone. The die block (2.6 cm thickness) was fixed to the extruder 
barrel and the axially mounted die plate (1.9 cm thickness, with a cylindrical hole of 3 mm 
diameter for shaping the extrudates) was attached to the die block. The following extrusion 
conditions were used: a screw speed of 30 rpm, a powder feed rate of 6 g/min and a temperature 
of 40 and 70°C for the five heating zones along the barrel for extrusion of PEG and PEO 
formulations, respectively. After cooling down to room temperature, the extruded rods (∅ = 3 mm) 
were manually cut, using surgical blades, into mini-matrices of 2 mm length.  
 
The surface properties of the extrudates were visually inspected for defects (shark 
skinning) and evaluated for their suitability to be cut into mini-matrices (deformation due to cutting, 
smoothness of the cutting surfaces and edges) using a digital camera (C3030 Olympus) linked to 
an image analysis system (analySIS®, Soft Imaging system, Münster, Germany) (magnification 
9.5x). Drug and PEG/PEO release was evaluated by dissolution testing. Drug (and polymer) 
crystallinity and homogeneity was evaluated by X-ray diffraction and Raman analysis, 
respectively. 
 
 
2.2.1.2. Hot-melt extruded samples 
 
To investigate the thermal stability of the polymers (EC, PEG and PEO) during the 
hot-melt extrusion process, the polymers were extruded at 100 and 200°C, using the process 
parameters described above. The samples (powder before extrusion, extruded samples at 
100 and 200°C) were analyzed by means of gel filtration chromatography with the 
appropriate polymer standards.  
 
Binary mixtures (EC/DBS, EC/PEG(PEO), EC/MPT, DBS/PEG(PEO) and 
MPT/PEG(PEO)) were extruded under the same processing conditions as described above, 
and evaluated for changes in glass transition temperature, melting point, crystallinity and 
possible interactions by modulated temperature differential scanning calorimetry (MTDSC) 
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(by comparing the results with the thermograms of the powder blends prior to extrusion). All 
types of PEG/PEO were investigated. The ratios of both components in these blends were 
identical to their ratio in the mini-matrices (containing 2.5, 10, 20 and 70% (w/w) hydrophilic 
polymer).  
 
 
2.2.2. In vitro drug and PEG/PEO release 
 
Drug release from the mini-matrices (approximately 60 mg) was determined using 
USP apparatus 1 (baskets) [47], in a VK 7010 dissolution system combined with a VK 8000 
automatic sampling station (VanKel, New Jersey, USA). Demineralized water was used as 
dissolution medium. The temperature of the medium (900 ml) was kept at 37 ± 0.5°C, while 
the rotational speed of the baskets was set at 100 rpm. Samples of 5 ml were withdrawn at 
0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 h and spectrophotometrically analyzed for MPT at 222 nm 
by means of a Perkin Elmer Lambda 12 UV-VIS double beam spectrophotometer (Zaventem, 
Belgium). The dissolution was performed in 6 dissolution vessels, each vessel containing 4 
mini-matrices.  
 
PEG/PEO release from the mini-matrices was determined using the USP paddle 
method under the same conditions as described above. PEG/PEO concentrations in the 
samples were measured by gel filtration chromatography (GFC) (detection via refractive 
index). Due to the sensitivity of the GFC analysis, the sample size for dissolution testing was 
increased (36, 9, 5 and 2 g mini-matrices for the 2.5, 10, 20 and 70% PEG/PEO 
formulations, respectively) and the paddle method was used. The PEG/PEO release was 
performed in twofold. The stability of PEG/PEO following hot-melt extrusion was also 
determined via GFC. For PEG 6000 and PEO 100.000 analysis, a Waters 600 
Controller/Waters 610 Fluid Unit pump (flow rate: 1.0 ml/min) with a Waters 410 Differential 
Refractometer was used. 20 µl sample (using a 100 µl Hamilton syringe) was injected on the 
column (TSK-gel® G 4000 PW (TosoHaas; 7.5 mm ID x 30 cm – particle size 17 µm) and 
TSK-gel® G 3000 PW (7.5 mm ID x 30 cm – particle size 10 µm) coupled in series). PEO 
1.000.000 and 7.000.000 samples were analyzed using a Waters 515 HPLC pump (flow: 1.0 
ml/min) combined with a Waters Differential Refractometer R401. 20 µl sample was injected 
on the column (TSK-gel® G 6000 PW (7.5 mm ID x 30 cm – particle size 17 µm) and TSK-
gel® G 5000 PW (7.5 mm ID x 30 cm – particle size 10 µm) coupled in series). The 
chromatograms were integrated using the Millenium 2010 Chromatography Manager 
(Version 2.15.01). The mobile phase consisted of water (Milli-Q® Water Purification System), 
filtered using Durapore® membrane filters (0.45 µm – HVLP type) and degassed with helium. 
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The PEG/PEO concentrations were calculated from a calibration curve between 0.10 and 
5.00 mg/ml, using polymer standards (analytical or HPLC grade).  
 
To determine the in vitro release properties of the formulations used during the in vivo 
experiments, a dissolution experiment was performed with hard-gelatin capsules (n° 000) 
containing 667 mg mini-matrices. Their swelling behaviour (after 4 and 24 h immersion in the 
dissolution medium) was also evaluated by microscopic analysis using a digital camera 
(C3030 Olympus) linked to an image analysis system (analySIS®, Soft Imaging system, 
Münster, Germany) (magnification 9.5x). 
 
 
2.2.3. Raman analysis 
 
MPT distribution in the mini-matrices containing different concentrations and types of 
PEG/PEO was evaluated by Raman spectroscopic mapping. Three areas (2150 x 1150 µm2) 
(two at the edges and one in the middle of the mini-matrix) of each mini-matrix (n = 3) were 
scanned using a 10x long working distance objective lens (laser spot size: 50 µm) in point-
by-point mapping mode with a step size of 100 µm in both the x and y directions. The 
resulting map provides an overview of the MPT distribution in the mapped area. The 
mapping system used for this study was a RamanRxn 1 Analyzer and Microprobe (Kaiser 
Optical Systems, Ann Arbor, USA), equipped with an air cooled CCD detector (back-
illuminated deep depletion design). The laser wavelength during the experiments was the 
785 nm line from a 785 nm Invictus NIR diode laser. All spectra were recorded at a resolution 
of 4 cm-1 using a laser power of 400 mW and a laser light exposure time of 20 s per collected 
spectrum. Before data analysis, spectra were baseline corrected. Data collection and data 
analysis was done using the HoloGRAMSTM data collection software package, the 
HoloMAPTM data analysis software and Matlab® software package (version 6.5.). 
 
 
2.2.4. Thermal analysis 
 
The glass transition temperature (Tg) and/or melting point (Tm) of the pure components 
(EC, MPT, DBS, PEG and PEO) and in binary mixtures of these materials (powder blends prior to 
extrusion and hot-melt extruded samples) were determined via modulated temperature differential 
scanning calorimetry (MTDSC).  
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The thermal behaviour of powders and hot-melt extruded samples was evaluated 
using a 2920 Modulated DSC (TA Instruments, Leatherhead, UK) equipped with a 
refrigerated cooling system (RCS). Dry helium at a flow rate of 40 ml/min was used as purge 
gas through the DSC cell and 150 ml/min nitrogen through the RCS unit. Samples (± 10 mg) 
were run in closed aluminium pans supplied by TA Instruments; the mass of each empty 
sample pan was matched with the mass of the empty reference pan to ± 0.10 mg. The 
experimental method consisted of an initial 5 min isothermal equilibration period at 0°C. 
During the subsequent heating run the following experimental parameters were used: an 
underlying heating rate of 2°C/min from -70 to 200°C, a modulation amplitude of 0.212°C and 
a period of 40 s. Temperature and enthalpic calibration were performed with an indium 
standard, whereas calibration of the heat capacity was performed with a sapphire standard. 
The results were analyzed using the TA Instruments Universal Analysis Software. 
Measurements were performed in duplicate and the Tg values (midpoint half height) are 
reported.  
 
 
2.2.5. X-ray diffraction 
 
To investigate the crystallinity of the components in the mini-matrices, X-ray 
diffraction was performed (on pulverized mini-matrices). The X-ray patterns of MPT, EC, 
PEG, PEO and mini-matrices were determined using a D5000 Cu Kα Diffractor (λ = 0.154 
nm) (Siemens, Karlsruhe, Germany) with a voltage of 40 mA in the angular range of 10° < 2θ 
< 60° using a step scan mode (step width = 0.02°, counting time = 1 s/step). 
 
 
2.2.6. In vivo evaluation 
 
All procedures were performed in accordance with the guidelines and approval of the 
local Institutional Animal Experimentation Ethics Committee. 
 
 
2.2.6.1. Subjects and study design 
 
A group of 6 male mixed-breed dogs (weight 22.0-38.0 kg) was used in this study. To 
investigate the influence of the concentration of the hydrophilic component (PEO or XG) on 
the bioavailability of metoprolol tartrate, the following drug formulations were administered: 
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F-1:  hot-melt extruded mini-matrices, consisting of 30% MPT, 5% XG, 43.3% EC and 
21.7% DBS (5% XG) 
F-2:  hot-melt extruded mini-matrices, consisting of 30% MPT, 10% XG, 40% EC and 20% 
DBS (10% XG) 
F-3:  hot-melt extruded mini-matrices, consisting of 30% MPT, 20% XG, 33.3% EC and 
16.7% DBS (20% XG) 
F-4:  hot-melt extruded mini-matrices, consisting of 30% MPT, 5% PEO 1.000.000, 43.3% 
EC and 21.7% DBS (5% PEO) 
F-5:  hot-melt extruded mini-matrices, consisting of 30% MPT, 20% PEO 1.000.000, 33.3% 
EC and 16.7% DBS (20% PEO) 
F-6:  Lopresor® 100 (commercially available immediate-release tablets containing 100 mg 
metoprolol tartrate (Sankyo Pharma, Louvain-la-Neuve, Belgium))  
F-7:  Slow-Lopresor® 200 Divitabs® (commercially available hydrophilic matrix tablets 
containing 200 mg metoprolol tartrate (Sankyo Pharma, Louvain-la-Neuve, Belgium)) 
 
 The mini-matrices of the experimental formulations were filled in hard-gelatin 
capsules n° 000, each capsule containing 200 mg metoprolol tartrate. Lopresor® 100 (2 
tablets) and Slow-Lopresor® 200 Divitabs® (1 tablet) were used as immediate- and sustained-
release reference formulations, respectively. The formulations were administered in 
randomized order with a wash-out period of at least 8 days between different sessions. On 
the experimental days the dogs were fasted for 12 h prior to the study period, although water 
was available ad libitum. Before administration of the formulations, an intravenous cannula 
was placed in the lateral saphenous and a blank blood sample was obtained. The 
formulations were orally administered with 10 ml water. The blood samples (2 ml at each 
sampling) were collected in dry heparinized tubes 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 36 h after 
intake of the formulations. No food was administered to the dogs during the initial 24 h of the 
test, afterwards they resumed their usual diet. Water could be taken freely. Within 1 h after 
collection, blood was centrifuged for 10 min at 1450g and the plasma was immediately 
assayed for metoprolol tartrate. 
 
 
2.2.6.2. Metoprolol tartrate assay 
 
The metoprolol tartrate plasma concentrations were determined by a validated HPLC-
fluorescence method. All chemicals were of analytical or HPLC grade. 
 
 
 
149
CHAPTER 3 
 
A solid phase extraction (SPE) procedure was used to extract metoprolol tartrate. The 
SPE equipment consisted of Oasis® HLB (1 cc 30 mg) cartridges (Waters, Brussels, 
Belgium) and a 16-port vacuum manifold (Alltech Europe, Laarne, Belgium). Extraction 
cartridges were first conditioned by rinsing consecutively with methanol (1 ml), water (1 ml) 
and phosphate-buffered saline (PBS) (1 ml). Plasma samples (300 µl) were mixed with 20 µl 
alprenolol (5.625 µg/ml alprenolol in water, as internal standard) and 680 µl PBS, 
homogenized by 30 s vortexing, and then loaded on the column. The columns were washed 
with water (1 ml) and the analytes were then eluted with methanol (1 ml). The eluates were 
evaporated to dryness under N2, reconstituted in 150 µl water (30 s of vortexing) and 20 µl 
solution was injected in the HPLC system. The metoprolol tartrate plasma concentrations 
were determined via a calibration curve. For the standard curves, spiked samples were 
prepared by mixing 280 µl plasma with 20 µl of a solution containing different concentrations 
of metoprolol tartrate in water (0.375, 0.5625, 0.75, 2.25, 5.625, 7.5, 15.0 and 22.5 µg/ml). To 
these spiked samples 20 µl alprenolol (internal standard solution) and 680 µl PBS was 
added. These mixtures were extracted as described above. 
 
The HPLC equipment (Merck-Hitachi, Darmstadt, Germany) consisted of a solvent 
pump (L-7110) set at a constant flow rate of 0.8 ml/min, a variable wavelength fluorescence 
detector (L-7480) set at an excitation and emission wavelength of 275 and 300 nm, 
respectively, a LiChrospher® 100 CN 5 µm column (250 mm x 4 mm) and precolumn (4 mm x 
4 mm), an auto-sampler (Gilson 234 autoinjector, Middleton, Wisconsin, USA) with a 50 µl 
loop (Valco Instruments, Houston, Texas, USA) and an automatic integration system 
(software D-7000 Multi-Manager) to collect and process the signals. The mobile phase 
consisted of acetonitrile/sodium dihydrogen orthophosphate buffer (2 M)/water (5/0.5/94.5, 
v/v/v). The mixture was adjusted to pH 3.0 with phosphoric acid.  
 
 
2.2.6.3. Method validation 
 
For the general considerations about method validation of an analytical procedure, we 
refer to Chapter 1 and the guidelines of the International Conference on Harmonisation (ICH) [48]. 
 
 
2.2.6.3.1. Specificity 
 
In our experiment, specificity was determined at an excitation and emission wavelength of 
275 and 300 nm, respectively, by comparing the chromatograms after extraction of blank plasma, 
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plasma spiked with internal standard alprenolol, and plasma spiked with metoprolol tartrate and 
alprenolol. 
 
 
2.2.6.3.2. Linearity 
 
Different calibration curves (n = 10) were prepared. For each calibration curve, blank 
plasma of dogs was spiked with different metoprolol tartrate solutions to obtain plasma 
concentrations from 0 to 3 µg/ml, and internal standard (alprenolol, 0.75 µg/ml) to cover the 
concentration range of the unknown samples. 
 
 
2.2.6.3.3. Precision 
 
The within-day repeatability was determined using the variation of the peak area of 
samples injected at different times (n = 3) during the same day. The analyses performed over 
five different days can be considered as the intermediate precision or within-laboratory 
precision (between-day repeatability). The precision was calculated for different metoprolol 
tartrate concentrations (0.05, 0.075, 0.1, 0.3, 0.75, 1, 2 and 3 µg/ml). 
 
 
2.2.6.3.4. Accuracy 
 
Accuracy was determined for different metoprolol tartrate concentrations (0.05, 0.075, 
0.1, 0.3, 0.75, 1, 2 and 3 µg/ml) (n = 10). 
 
 
2.2.6.3.5. Recovery 
 
 The recovery experiments (extracted samples: n = 10, non-extracted samples: n = 3) 
were performed at metoprolol tartrate and alprenolol concentrations of 0.05, 0.3, 1 and 3 
µg/ml, and 0.75 µg/ml, respectively. 
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2.2.6.3.6. Limit of detection and limit of quantification 
 
 The limit of detection (LOD) and limit of quantification (LOQ) were calculated based on the 
standard deviation of the intercept and slope of the mean calibration curve. 
 
 
2.2.6.4. Data analysis 
 
The peak plasma concentration (Cmax), the time to reach Cmax (Tmax) and the extent of 
absorption (area under the curve, AUC0-36h) were calculated using the MW-Pharm Program 
version 3.0 (Mediware 1987-1991, Utrecht, The Netherlands). The AUC0-36h was calculated 
using logarithmic and linear trapezoidal rules. The relative bioavailability (Frel, expressed in 
%) was calculated as the ratio of AUC0-36h between a test formulation and the sustained-
release reference formulation (Slow-Lopresor® 200 Divitabs®). The sustained-release 
characteristics of a formulation were evaluated by the time span during which the plasma 
concentrations were at least 50% of the Cmax value (HVDt50%Cmax, the width of the plasma 
concentration profile at 50% of Cmax) [49, 50]. The HVDt50%Cmax values were determined from 
the individual plasma concentration-time profiles. The ratio between the HVDt50%Cmax values 
of a test formulation and the immediate-release reference formulation (Lopresor® 100) 
(expressed as RD) is indicative of the sustained-release effect: a ratio of 1.5, 2 and > 3 
indicating a low, intermediate and strong sustained-release effect, respectively [49]. 
 
 
2.2.6.5. Statistical analysis 
 
The effect of metoprolol tartrate formulation on the bioavailability was assessed by 
repeated-measures ANOVA (univariate analysis). To further compare the effects of the 
different treatments, a multiple comparison among pairs of means was performed using a 
Bonferroni post-hoc test with P < 0.05 as significance level. The normality of the residuals 
was tested with a Kolmogorov-Smirnov test. SPSS version 16.0 was used to perform the 
statistical analysis. 
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3. RESULTS AND DISCUSSION 
 
3.1. In vitro evaluation 
 
The drug release rate from hot-melt extruded dosage forms is mainly determined by 
the ratio of hydrophilic and hydrophobic polymers included in the matrix formulations [5, 6, 
16, 51-53]. Based on this principle polymeric hot-melt extruded mini-matrices consisting of 
EC (hydrophobic matrix former) and XG (hydrophilic additive to modify drug release) yielded 
zero-order release kinetics of freely water soluble drugs. Drug release depended on XG 
concentration and grade [11, 13] as these factors determined the swelling behaviour and 
water uptake of the mini-matrices. As an alternative to XG, PEG and PEO could be used as 
these polymers have already been used for hot-melt extrusion. Since it is known that the 
swelling properties of PEO depend on their molecular weight [16-24, 28], variable 
concentrations and grades of PEG/PEO were processed in combination with EC to modify 
drug release from these matrices. 
 
The different formulations (Table 1) were easily processed at an extrusion 
temperature of 40 and 70°C for PEG and PEO formulations, respectively, independent of 
PEG/PEO concentration and MW: no surface defects were detected and the extrudates 
having a smooth surface could be cut into high quality mini-tablets (without cracks or other 
irregularities at the cutting edges). 
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Whereas previous work by the authors [13] already confirmed that MPT is stable at 
these processing temperatures, the thermal stability of EC, PEG and PEO after hot-melt 
extrusion at 100 and 200°C was analyzed using GFC since polymers are subjected to 
mechanical, thermal and oxidative degradation during hot-melt extrusion. For all polymers, 
the MW profile of the samples prior to and after extrusion overlapped. As an example, the 
GFC chromatograms of PEO 1.000.000 are shown (Figure 2). The retention time of PEG 
6000, PEO 100.000, 1.000.000 and 7.000.000 during GFC analysis were 15, 11, 13 and 10 
min, respectively. Other investigators reported that PEO stability in matrix tablets prepared 
by hot-melt extrusion depended on storage and processing temperature, screw speed and 
the MW of the polymer [16, 29]. 
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Figure 2: Gelfiltration chromatograms of PEG 6000: (□) prior to extrusion, hot-melt extruded 
sample at (△) 100°C and (○) 200°C. 
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An increase of PEG/PEO content significantly increased the drug release rate, 
irrespective of their MW due to the higher hydrophilicity of the matrix. Figure 3 shows 
exemplarily the results obtained for PEO 100.000-containing mini-matrices. For all mini-
matrices, the release from a formulation containing 1 and 2.5% PEG/PEO was similar, 
whereas the data of the 5% PEG/PEO mini-matrices coincided with the 10% PEG/PEO 
formulations. Interestingly the mini-matrices retained their cylindrical shape during dissolution 
testing and did not significantly swell, except for the 70% PEG/PEO formulations which had 
dissolved after approximately 1 h. Although the swelling of purely hydrophilic PEG/PEO 
matrices and films has been reported during dissolution [16-24, 28], the cohesive nature of 
the EC matrix structure probably restricted swelling of the mini-matrices upon wetting. 
Formulations with 0, 1, 2.5, 5 and 10% showed zero-order, but incomplete release kinetics. 
Complete drug release was observed at PEG/PEO concentrations of 20% and above, 
however the burst release from these formulations was significant: 43.6 and 81.6% released 
after 30 min (PEO 100.000).  
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Figure 3: Influence of PEO 100.000 concentration on the dissolution profiles (mean ± S.D., n 
= 6) of mini-matrices containing 30% (w/w) MPT, EC/plasticizer (2/1, w/w) and PEO 100.000: 
(■) 0%, (▲) 2.5%, (●) 10%, (□) 20% and (△) 70%. 
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At low PEG/PEO concentration (1-2.5%) no effect of PEG/PEO MW on drug release 
was observed. Although a slower drug release is described from hydrophilic matrices 
containing higher MW PEO due to the increasing viscosity of the polymer [16-24, 28, 30] (a 
higher MW increases gel strength, which tends to decrease the diffusion of the drug), drug 
release from matrices containing 5 and 10% PEG 6000 and PEO 100.000 was significantly 
slower in comparison to the PEO 1.000.000 and 7.000.000 mini-matrices (Figure 4). This 
might be due to the faster release of low MW PEG/PEO from the matrix (in comparison with 
the release of high MW PEO), resulting in molecular rearrangement of EC, thus modifying 
the porous network inside the matrix and hindering drug release. The dissolution conditions 
provided sufficient mobility for the EC polymer chains as MTDSC analysis showed that Tg of 
EC in combination with DBS (EC/DBS ratio: 2/1) was 40°C.  
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Figure 4: Influence of PEG/PEO MW on the dissolution profiles (mean ± S.D., n = 6) of mini-
matrices containing 30% (w/w) MPT, EC/plasticizer (2/1, w/w) and 10% (w/w) hydrophilic 
polymer: (■) PEG 6000, (▲) PEO 100.000, (●) PEO 1.000.000, (□) PEO 7.000.000. 
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At 20 and 70% PEG/PEO the drug release rate was slower using high MW PEO 
(Figure 5), which is consistent with data reported by other investigators [16-24, 28, 30], due 
to the increasing viscosity at higher MW since the properties of PEG/PEO became more 
predominant for drug release.  
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Figure 5: Influence of PEG/PEO MW on the dissolution profiles (mean ± S.D., n = 6) of mini-
matrices containing 30% (w/w) MPT and 70% (w/w) hydrophilic polymer: (■) PEG 6000, (▲) 
PEO 100.000, (●) PEO 1.000.000, (□) PEO 7.000.000. 
 
PEG/PEO release increased at higher PEG/PEO concentration (irrespective of MW) 
as less matrix forming polymer was present and the mini-matrices became less hydrophobic. 
In addition, PEG/PEO release from mini-matrices depended on the MW of the hydrophilic 
polymer as the viscous nature of high MW PEO reduced its mobility and consequently 
release kinetics. MPT release was not in all cases correlated with PEG/PEO leaching, 
especially in relation to the effect of PEG/PEO MW: although a slower PEG/PEO release 
was observed for all formulations formulated with high MW PEO, drug release was not 
affected by PEO MW in case of mini-matrices containing low PEG/PEO concentrations (1-
2.5%) and drug release from mini-matrices containing 5-10% PEG/PEO increased when 
using higher MW PEG/PEO.  
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 The MPT distribution in the mini-matrices was monitored off-line via Raman using the 
627-653 cm-1 spectral band as no overlap with other ingredients occurred at these 
wavenumbers (Figure 6). No difference was seen between the different PEG/PEO types. 
Based on the intensity of the Raman signal across the scanned sections of the mini-matrices 
it was confirmed that MPT is homogeneously distributed in the mini-matrix irrespective of the 
PEG/PEO concentration and MW. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Raman spectra from the compounds in the mini-matrices. 
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Figure 7 shows the X-ray diffraction spectra of MPT, EC, PEO 1.000.000 and 20% 
PEO 1.000.000 mini-tablet. The drug and hydrophilic polymer were crystalline, while EC was 
amorphous. The X-ray pattern of the hot-melt extruded 20% PEO 1.000.000 mini-tablet 
showed only diffraction peaks corresponding to MPT and PEO 1.000.000, indicating that 
these products remained crystalline during extrusion. However, the diffraction peaks were 
smaller in comparison with the pure materials, illustrating the presence of smaller crystals. 
Other investigators also noticed a reduction of PEO peak intensity (decrease of crystallinity) 
following thermal processing in combination with peak broadening (due to a wider 
distribution of crystal size) [31-34]. 
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Figure 7: X-ray diffraction pattern of (red) PEO 1.000.000, (purple) MPT, (green) EC and 
(blue) 20% PEO 1.000.000 mini-matrix. 
 
To check for changes in the thermal behaviour of the components or to identify 
interactions between components, MTDSC analysis was performed: the values of Tg of EC 
and Tm of MPT were 127.9 ± 0.2°C and 122.6 ± 0.4°C, respectively. The Tm of PEG 6000, 
PEO 100.000, PEO 1.000.000 and PEO 7.000.000 is 60.3 ± 0.0°C, 65.4 ± 0.4°C, 67.7 ± 
0.1°C and 69.5 ± 0.3°C, respectively. After extrusion of PEG and PEO samples at 40 and 
70°C, respectively, (blends without PEG or PEO were processed at both temperatures) no 
shifts in Tg and Tm were detected in case of binary mixtures and the individual thermal 
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signals were detected, indicating that no interactions between components occurred during 
extrusion under the processing conditions described above. However, others reported 
changes in drug and polymer thermal transitions when drug and PEOs were co-processed, 
associated with their (partially) miscibility and formation of solid dispersions and solid 
solutions [24, 28-36]. All binary blends of EC/DBS, EC/PEG(PEO), EC/MPT and 
MPT/PEG(PEO) could be processed via extrusion and were subsequently analyzed via 
MTDSC. In contrast, only a binary mixture of PEG(PEO)/DBS in a ratio of 20/16.7 
(corresponding to a formulation with 20% hydrophilic polymer) could be processed via 
extrusion for PEO 1.000.000 and 7.000.000 as the other PEG(PEO)/DBS ratios (Table 1) 
and PEG/PEO grades resulted in phase separation (due to the high liquid fraction). 
 
 
3.2. In vivo evaluation 
 
3.2.1. Method validation 
 
3.2.1.1. Specificity 
 
 Chromatograms after extraction of blank plasma, plasma spiked with alprenolol 
(internal standard) and plasma spiked with metoprolol tartrate and alprenolol are shown in 
Figure 8. The chromatograms indicate that there was no interference of drug and internal 
standard with endogenous compounds, and separation between metoprolol tartrate and 
alprenolol was complete. As shown in Figure 8, a retention time of ± 19 min and ± 56 min 
was obtained for metoprolol tartrate and alprenolol, respectively. It was concluded that the 
method was selective to determine metoprolol tartrate in dog plasma. 
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Absorption 
Time (min)
Figure 8: Chromatograms showing metoprolol tartrate and alprenolol after extraction of (top) 
blank dog plasma, (middle) plasma spiked with alprenolol and (bottom) plasma spiked with 
metoprolol tartrate and alprenolol. 
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3.2.1.2. Linearity 
 
 The mean calibration curve (Y = 2.6975 (± 0.3274) X + 0.0435 (± 0.0258), n = 10) 
was linear between 0 and 3 µg/ml metoprolol tartrate, with a coefficient of determination of 
0.9976 ± 0.0015. 
 
 
3.2.1.3. Precision 
 
 The coefficients of variation (C.V.) (%) of the repeatability (intra-assay precision) and 
the intermediate precision (within-laboratory precision) are shown in Table 2. 
 
Table 2: Coefficients of variation (%) of the repeatability (n = 3) and the intermediate 
precision (n = 5). 
Coefficient of variation (%) 
Concentration (µg/ml)  
Repeatability Intermediate precision 
0.05  6.3 10.5 
0.075  9.5 7.8 
0.1  6.1 11.4 
0.3  8.6 1.7 
0.75  7.9 11.6 
1.0  6.8 6.1 
2.0  10.5 5.5 
3.0  3.7 4.1 
 
 For the repeatability as well as the intermediate precision, the coefficients of variation 
at all concentrations were lower than 15%. 
 
 
3.2.1.4. Accuracy 
 
 The accuracy was determined for all metoprolol tartrate concentrations and the mean 
results are presented in Table 3. 
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Table 3: Accuracy (%, mean ± S.D., n = 10). 
Concentration (µg/ml) Calculated concentration (µg/ml) Accuracy (%) C.V. (%) 
0.05 0.06 ± 0.01 125.7 ± 14.8 11.8 
0.075 0.08 ± 0.01 109.8 ± 9.5 8.7 
0.1 0.11 ± 0.01 107.9 ± 9.0 8.3 
0.3 0.31 ± 0.03 102.8 ± 11.2 10.9 
0.75 0.69 ± 0.07 91.7 ± 8.8 9.6 
1.0 1.02 ± 0.11 101.9 ± 10.9 10.7 
2.0 1.96 ± 0.18 98.1 ± 8.9 9.1 
3.0 3.08 ± 0.13 102.6 ± 4.4 4.3 
 
The proposed method can be considered as accurate as an accuracy of at least 
91.7% was obtained and the highest coefficient of variation was 11.8%.  
 
 
3.2.1.5. Recovery 
 
The recovery of metoprolol tartrate and alprenolol from plasma are shown in Table 4. 
 
Table 4: Recovery (%, mean ± S.D., n = 10) of metoprolol tartrate and alprenolol from 
plasma. 
Concentration (µg/ml)  Metoprolol tartrate Alprenolol 
0.05  79.3 ± 13.4 - 
0.3  85.0 ± 14.1 - 
0.75  - 85.1 ± 5.3 
1.0  83.7 ± 9.9 - 
3.0  80.4 ± 5.4 - 
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3.2.1.6. Limit of detection and limit of quantification 
 
Based on the mean linear regression equation of metoprolol tartrate the limit of 
detection and the limit of quantification for metoprolol tartrate are 0.03 and 0.10 µg/ml, 
respectively. The limit of quantification was higher than the lowest concentration of the 
calibration curve but as accuracy and precision for the concentration of 0.05 µg/ml were 
within accepted limits [54], the concentration of 0.05 µg/ml was considered as limit of 
quantification.  
 
 
3.2.2. In vivo performance 
 
MPT, a drug with high solubility and permeability is well-absorbed over a large part of 
the gastro-intestinal tract. Its relatively short half life (3-4 h) makes MPT a suitable candidate 
for an extended-release formulation [55-60]. The enhanced therapeutic efficacy of this drug 
through the provision of constant drug input and maintenance of steady-state blood levels is 
well-documented and different types of controlled-release formulations improved the clinical 
efficacy of MPT. Its administration in dogs is considered to be safe [61, 62].  
 
Prior to the investigation of the influence of PEG/PEO concentrations on MPT 
release, the authors investigated in Chapter 2 the effect of XG concentration on in vitro drug 
release [13]. Based on the different swelling behaviour of the mini-matrices formulated with 
both hydrophilic polymers upon contact with the dissolution medium (swelling in case of XG 
versus no swelling for PEG/PEO mini-matrices), it is of interest to compare the bioavailability 
of both types of mini-tablets. Drug release from formulations without hydrophilic polymer and 
with low concentrations (1 and 2.5%, w/w) of XG [13] and PEG/PEO (Figure 3) was not 
complete after 24 h, and these mini-matrices were therefore not selected for in vivo analysis. 
The MPT release kinetics from 5, 10 and 20% XG mini-matrices (all resulting in complete 
drug release after 24 h) were significantly different [13], and these formulations were 
selected for the in vivo study. Only formulations with 5 and 20% PEO were administered to 
the dogs as 10% PEO mini-tablets yielded similar dissolution profiles as 5% PEO mini-
matrices. Mini-matrices with 70% PEG/PEO gave a burst release (Figure 3) and were 
consequently not of interest as sustained-release dosage form. PEO 1.000.000 (intermediate 
MW) was selected as hydrophilic polymer for the in vivo analysis. 
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Figure 9 shows the mean plasma concentration-time profiles after oral administration 
of 200 mg MPT to 6 dogs as Lopresor® 100 (2 tablets), Slow-Lopresor® 200 Divitabs® (1 
tablet) and the experimental mini-matrices. The pharmacokinetic parameters are reported in 
Table 5. 
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Figure 9: Mean plasma concentration-time profiles (± S.D., n = 6) after oral administration of 
200 mg metoprolol tartrate to dogs: (■) Lopresor® 100 (2 tablets), (□) Slow-Lopresor® 200 
Divitabs® (1 tablet), (●) 5% XG mini-matrices, (○) 10% XG mini-matrices, (x) 20% XG mini-
matrices, (▲) 5% PEO 1.000.000 mini-matrices and (△) 20% PEO 1.000.000 mini-matrices. 
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Table 5: Mean pharmacokinetic parameters (± S.D., n = 6) after oral administration of 200 
mg metoprolol tartrate to dogs as 5% XG mini-matrices, 10% XG mini-matrices, 20% XG 
mini-matrices, 5% PEO 1.000.000 mini-matrices, 20% PEO 1.000.000 mini-matrices, 
Lopresor® 100 (2 tablets) and Slow-Lopresor® 200 Divitabs® (1 tablet). 
 
Cmax 
(µg/ml) 
Tmax 
(h) 
AUC0-36h 
(µg.h/ml) 
HVDt50%Cmax 
(h) 
Frel* 
(%) 
RD 
 
5% XG 3.9 ± 0.7 3.3 ± 1.4 39.2 ± 16.2 4.6 ± 1.8 51.5 ± 27.8 1.6 ± 0.4 
10% XG 6.6 ± 2.3 3.5 ± 1.4 72.1 ± 22.5 5.7 ± 2.3 94.4 ± 43.2 2.2 ± 1.1 
20% XG 13.9 ± 3.5 2.7 ± 0.8 100.6 ± 39.9 4.0 ± 1.6 131.5 ± 70.0 1.4 ± 0.2 
5% PEO 1.000.000 5.9 ± 2.1 2.2 ± 0.4 51.5 ± 22.6 4.3 ± 1.2 66.2 ± 31.0 1.6 ± 0.5 
20% PEO 1.000.000 21.3 ± 7.9 2.7 ± 0.5 113.5 ± 54.9 3.7 ± 1.0 148.2 ± 87.7 1.4 ± 0.6 
Lopresor® 100 
(2 tablets) 31.8 ± 4.6 1.3 ± 0.5 151.3 ± 51.4 2.9 ± 1.2 - - 
Slow-Lopresor® 200 
Divitabs® (1 tablet) 13.3 ± 2.8 3.2 ± 1.0 87.8 ± 35.8 4.9 ± 1.2 - 2.0 ± 1.0 
 
-: not applicable 
*: using Slow-Lopresor® 200 Divitabs® (1 tablet) as reference 
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The in vivo behaviour of the experimental mini-matrices was reflected in their in vitro 
dissolution profiles (Figure 10). 
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Figure 10: Influence of XG and PEO 100.000 concentration on the dissolution profiles (mean 
± S.D., n = 6) of mini-matrices containing 30% (w/w) MPT, EC/plasticizer (2/1, w/w) and 
hydrophilic polymer: (●) 5% XG, (○) 10% XG, (x) 20% XG, (▲) 5% PEO 1.000.000 and (△) 
20% PEO 1.000.000. 
 
An increasing XG concentration of 5 to 20% enhanced drug release, which was 
reflected in the higher AUC0-36h and Frel. The same observation was valid for the PEO mini-
matrices as the AUC0-36h values correlated with the in vitro release profiles. Concerning the 
AUC values, no hot-melt extruded formulation was significantly different when compared with 
the sustained-release reference formulation Slow-Lopresor® 200 Divitabs® (P > 0.05), 
although the AUC values tended to increase at higher hydrophilic polymer concentration. 
None of the formulations showed a strong sustained-release effect since RD values ranged 
from 1.4 to 1.6, except for the 10% XG mini-matrices which showed an intermediate 
sustained-release effect (RD 2.2). In comparison with the 20% XG mini-tablets, the 10% XG 
formulation is characterized by a higher Tmax (2.7 and 3.5 h, respectively) and lower Cmax 
(13.9 and 6.6 µg/ml, respectively), which is typical for sustained-release formulations and 
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which is reflected in its higher HVDt50%Cmax (4.0 and 5.7 h, respectively) and RD (1.4 and 2.2, 
respectively). Only the Cmax values of 5% XG (mean difference: 9.4 (95% C.I.: 1.9-16.8; P = 
0.018)) and 5% PEO (mean difference: 7.4 (95% C.I.: 0.4-14.4; P = 0.039)) formulations 
were significantly different from Slow-Lopresor® 200 Divitabs® at the 0.05 level of 
significance. For all experimental formulations, Tmax and HVDt50%Cmax values showed no 
significant difference in comparison with the sustained-release reference formulation (P > 
0.05). Frel of the 5 and 10% XG formulations were significantly different (mean difference: 
42.9 (95% C.I.: 3.6-82.3; P = 0.035)), whereas no significant difference between the PEO 
formulations was seen (P > 0.05). Concerning the sustained-release effect, the RD values of 
the experimental formulations were not significantly different from Slow-Lopresor® 200 
Divitabs®. Based on the pharmacokinetic data (Table 5) Cmax and Tmax of 20% XG mini-
tablets (multiparticulate dosage form) and Slow-Lopresor® 200 Divitabs® (single-unit dosage 
form) were similar which supported the hypothesis that 20% XG mini-matrices behaved in 
vivo as a single-unit dosage form instead of multiparticulates. This was confirmed by the 
swelling behaviour of the 20% XG mini-matrices during dissolution (using a larger sample 
size of mini-matrices filled into a capsule, similar to the dosage form administered to the 
dogs): due to the rapid swelling of XG, the mini-matrices stick together and the increased 
diffusion path length from this plug reduced drug release, AUC0-36h and Frel [11] (Figure 11a 
and 11b). In contrast, PEO mini-matrices did not swell during dissolution testing (Figure 11c 
and 11d). Previous work [11] has also shown that ibuprofen mini-matrices with 20 and 30% 
XG behaved similar in vivo, caused by their similar swelling behaviour upon immersion with 
the dissolution medium. However, in this study a significant difference in pharmacokinetic 
parameters and plasma concentration-time profiles between 10 and 20% XG formulations 
was observed. This can be due to the fact that in this study a drug with a high water solubility 
was used (in comparison with ibuprofen, which is a BSC class II drug) which is less affected 
by the rapid swelling of XG.  
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(a)      (b) 
  
(c)      (d) 
Figure 11: Swelling behaviour of mini-matrices after immersion in the dissolution medium: (a) 
20% XG – 4 h, (b) 20% XG – 24 h, (c) 20% PEO 1.000.000 – 4 h, (d) 20% PEO 1.000.000 – 
24 h. 
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4. CONCLUSIONS 
 
This chapter showed that hot-melt extrusion can be used to produce mini-matrices 
with controlled drug delivery: the presented ethylcellulose-polyethylene glycol/polyethylene 
oxide mini-matrices allow to manufacture sustained-release dosage forms with a wide range 
of drug release patterns. Importantly, not only the slope, but also the shape of the resulting 
release curves can be adjusted by varying the polyethylene glycol/polyethylene oxide content 
and molecular weight. All components remained stable under the processing conditions. 
Neither drug and polymer crystallinity, nor drug homogeneity were influenced by the 
concentration and type of hydrophilic polymer.  
From the validation, it could be concluded that a specific, linear, precise and accurate 
HPLC method was obtained. In vivo data showed that oral administration of ethylcellulose-
xanthan gum matrices was able to sustain metoprolol tartrate plasma levels in dogs. Xanthan 
gum and polyethylene oxide behaved differently upon contact with the swelling medium. 
In the next chapter, further work was conducted in order to determine the underlying 
mass transport mechanism of drug and hydrophilic polymer during dissolution, and 
experiments were performed to predict the effects of the mini-matrix geometry on the 
resulting drug release kinetics and to evaluate the validity of these theoretical predictions. 
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CHAPTER 4 
MATHEMATICAL MODELLING  
OF DRUG AND POLYMER RELEASE  
FROM HOT-MELT EXTRUDED MINI-MATRICES 
 
 
 
1. INTRODUCTION 
 
Incorporation of a drug in a polymeric matrix is often used to sustain drug release. To 
produce these sustained-release matrices, hot-melt extrusion is becoming a widely used 
technology in the pharmaceutical industry using several thermoplastic polymers to control 
drug release [1-7]. Cylindrical-shaped mini-matrices manufactured via hot-melt extrusion 
provided zero-order release kinetics of freely water soluble drugs using ethylcellulose as 
matrix former and hydroxypropylmethylcellulose [8-10], xanthan gum [8-13, Chapter 1, 
Chapter 2] or polyethylene glycol/polyethylene oxide [13, Chapter 3] as hydrophilic polymers 
to modify the release rate. Increasing xanthan gum concentrations caused swelling of the 
mini-matrices (creating pores in the matrix through which the drug was released), resulting in 
accelerated drug release [11, 12]. In the previous chapter, it has been shown that a wide 
range of metoprolol tartrate release patterns can be obtained by adding different amounts 
and types (molecular weight) of polyethylene glycol/polyethylene oxide to the formulation 
[13].  
The present study evaluates the release mechanism of a model drug (metoprolol 
tartrate) and the hydrophilic polymer (polyethylene glycol/polyethylene oxide) from hot-melt 
extruded mini-matrices (3 mm diameter, 2 mm height) formulated with polyethylene 
glycol/polyethylene oxide and ethylcellulose. The drug release kinetics from these diffusion-
controlled mini-matrices was quantitatively predicted in function of the polyethylene 
glycol/polyethylene oxide concentration (0-70%, w/w) and grade (polyethylene glycol 6000 
and polyethylene oxide 100.000-7.000.000) and in function of the device geometry (diameter 
varied between 1 and 12 mm for constant height, height varied between 1 and 32 mm for 
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constant diameter). The validity of these theoretical predictions was evaluated by 
independent experiments. In addition, a comprehensive mathematical theory was developed 
allowing a quantitative description of drug and polyethylene glycol/polyethylene oxide 
transport in ethylcellulose-based mini-matrices considering time-dependent diffusivities.  
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2. MATERIALS AND METHODS 
 
2.1. Materials  
 
Metoprolol tartrate (MPT) (10 µm) (Esteve Quimica, Barcelona, Spain) was selected 
as model drug. The matrix consisted of ethylcellulose (EC) (Ethocel® Std 10 FP Premium; 
particle size: 3-15 µm; ethoxyl content: 48-49.5% (w/w); viscosity: 9-11 mPa.s (5% solution in 
toluene/EtOH 80/20, 25°C)), kindly donated by Dow Chemical Company (Midland, USA), and 
a hydrophilic component: polyethylene glycol (PEG) (PEG 6000, Fagron, Waregem, 
Belgium) or polyethylene oxide (PEO) (SentryTM PolyoxTM WSR N10, N12K and 303, 
molecular weight (MW): 100.000, 1.000.000 and 7.000.000, respectively) (Dow Chemical 
Company, Midland, USA). Dibutyl sebacate (DBS) (Sigma-Aldrich, Steinheim, Germany) was 
used as plasticizer for ethylcellulose. All other chemicals were of analytical grade (VWR, 
Leuven, Belgium). 
 
 
2.2. Methods 
 
2.2.1. Preparation of mini-matrices via hot-melt extrusion 
 
The composition of the investigated mini-matrices is shown in Table 1. For all 
formulations the MPT content was kept constant at 30% (w/w), while the concentration of 
hydrophilic polymer (PEG or PEO) was varied between 0 and 70% (w/w). The remaining part 
of the formulation consisted of EC/DBS, blended at a ratio of 2/1 (w/w) [12]. 
 
Table 1: Composition (%, w/w) of the hot-melt extruded mini-matrices. 
MPT 30 30 30 30 30 30 30 
PEG/PEO - 1 2.5 5 10 20 70 
EC 46.7 46 45 43.3 40 33.3 - 
DBS 23.3 23 22.5 21.7 20 16.7 - 
 
The components were blended in a planetary mixer (15 min, 90 rpm) (Kenwood Major 
Classic, Hampshire, UK) and incubated overnight at room temperature to achieve sufficient 
interaction between ethylcellulose and the plasticizer. The mixture was passed through the screws 
of the powder feeder of the extruder at room temperature and recycled into the powder reservoir 
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in order to homogeneously distribute DBS in the powder prior to hot-melt extrusion. Hot-melt 
extrusion was performed using a laboratory-scale intermeshing co-rotating twin-screw extruder 
(MP19TC-25, APV Baker, Newcastle-under-Lyme, UK) with a length-to-diameter ratio of 25/1. 
The machine was equipped with a Brabender twin-screw powder feeder, a screw with two mixing 
sections and a densification zone [11-13]. The die block (2.6 cm thickness) was fixed to the 
extruder barrel and the axially mounted die plate (1.9 cm thickness, with a cylindrical hole of 3 mm 
diameter for shaping the extrudates) was attached to the die block. The following extrusion 
conditions were used: a screw speed of 30 rpm, a powder feed rate of 6 g/min and a temperature 
of 40 and 70°C for the five heating zones along the barrel for extrusion of PEG and PEO 
formulations, respectively. After cooling down to room temperature, the extruded rods were 
manually cut, using surgical blades, into mini-matrices of the desired length. Dies with different 
dimensions (varying diameters between 1 and 12 mm) were used in order to produce extrudates 
with different diameters. 
 
 
2.2.2. In vitro drug and PEG/PEO release 
 
Drug release from the mini-matrices (approximately 60 mg) was determined using the 
USP apparatus 1 (rotating baskets, 100 rpm, 4 mini-matrices per vessel) (VK 7010, 
combined with a VK 8000 automatic sampling station, VanKel, New Jersey, USA). 
Demineralized water (900 ml, 37 ± 0.5°C) was used as release medium. At predetermined 
time points, 5 ml samples were withdrawn and analyzed for the drug content by UV 
spectroscopy (λ = 222 nm, Lambda 12 UV-VIS double beam spectrophotometer, Perkin 
Elmer, Zaventem, Belgium). Each experiment was conducted 6 times. 
 
PEG/PEO release from the mini-matrices was determined using the USP paddle 
method under the same conditions as described above. PEG/PEO concentrations in the 
samples were measured by gel filtration chromatography (GFC) (detection via the refractive 
index) [13, Chapter 3]. Due to the sensitivity of the GFC analysis, the sample size was 
increased (36, 9, 5 and 2 g mini-matrices for the 2.5, 10, 20 and 70% PEG/PEO 
formulations, respectively) and the paddle method was used. All experiments were 
conducted twice.  
 
In case drug or PEG/PEO release levelled off below 100%, the experimentally 
determined plateau value was considered as the 100% reference value for the modelling of 
drug and PEG/PEO release (= amount of mobile species). 
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2.2.3. Porosity of the mini-matrices 
 
To determine the changes in the porosity of the mini-matrices upon exposure to the 
release medium, 40 mini-matrices were subjected to the same conditions as described 
above for the in vitro release studies. At predetermined time points, the mini-matrices were 
removed, frozen using liquid nitrogen and freeze-dried (Amsco-Finn Aqua GT4 freeze-dryer, 
Amsco, Darmstadt, Germany) during 25 h (freezing to -45°C within 175 min at 1000 mbar, 
primary drying was performed at -25°C and at a pressure varying between 0.8 and 1 mbar 
during 13 h, followed by secondary drying at elevated temperature (10°C) and reduced 
pressure (0.1-0.2 mbar) for 7 h). The samples were only introduced in the freeze-drier when 
the shelf temperature was below -40°C. After freeze-drying, the mini-matrices were stored 
over silica until true volume measurements with a helium pycnometer (AccuPyc 1330, 
Micromeritics, Norcross, USA). The porosity of the mini-matrices was calculated based on 
these values and on the mini-matrices’ apparent volume, which was determined using a 
digital calliper (Bodson, Luik, Belgium). 
 
 
2.2.4. X-ray tomography 
 
The mini-matrices (before exposure to the release medium, and after 24 h exposure to the 
release medium) were scanned with the in-house developed high resolution micro-CT scanner of 
the Ghent University Centre for X-ray Tomography (www.UGCT.ugent.be). The system is 
composed of a Feinfocus X-ray tube with transmission target and beryllium exit window, a Micos 
high precision air-bearing rotation stage and a Varian Paxscan 2520 a-Si flat panel detector. The 
tube was operated at 60 kV tube voltage in micro-focus mode at 2.8 W which results in a 3 µm 
spot size. During the scans the sample was rotated over 360° in 0.45° steps where four shadow 
images were recorded in every step. The detector consists of a CsI screen with 2000 x 1600 
pixels of 127 µm and it was operated in non-binning mode with an exposure time of 2 s. The 
source-to-object distance was 20 mm and the source-to-detector distance was 860 mm in order to 
have a factor 42 magnification with 3 µm resolution. 
 The 800 shadow images were processed and reconstructed to 1500 cross-sectional 
images of 1100 x 1100 pixels with 3 µm pixel size with Octopus software. From each mini-matrix a 
central region of 300 slices was used for statistical analysis. 
 To process the images two selections were made: one with the material of the mini-matrix 
and another one with the pores. This was achieved by segmentation based on the greyscale, and 
subsequent some filtering to remove the noise (these results should be sceptically analyzed as 
limiting factors such as noise and resolution make the obtaining of these results slightly operator 
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dependent). The voids were subsequently separated and classified for equivalent diameters. 
Separating the pores makes it possible to have a better analysis of the porosity but it removes the 
pore interconnectivity, however the pores are mostly connected through ducts with a diameter of 
about 1 µm and in order to analyze this the resolution of the scan is too low. Equivalent diameters 
means that for each pore the volume was calculated in µm3 and that volume is then considered as 
a perfect sphere, the diameter of that sphere is the equivalent diameter.  
 The set of 300 cross-sections that were statistically analyzed were subsequently loaded in 
a 3D rendering software (VGstudio). In this way, it is made possible to represent the porosity and 
the size distribution of the pores. 
 
 
2.2.5. Raman spectroscopy 
 
MPT distribution in the mini-matrices, before exposure to the dissolution medium and 
24 h after exposure to the release medium, was evaluated by Raman spectroscopic 
mapping. Prior to Raman analysis, the tablets obtained after 24 h of dissolution were frozen 
using liquid nitrogen and freeze-dried over 25 h, as described above to determine the 
porosity. After freeze-drying the samples were cut along their radial (Figure 1a) and axial axis 
(Figure 1b). At the exterior surface as well as at the radial cutting surface three areas (1000 x 
600 µm2, Figure 1a) (n = 3) were scanned using a 10x long working distance objective lens 
(laser spot size: 50 µm) in point-by-point mapping mode with a step size of 50 µm in both the 
x and y directions. In addition, 24 h after exposure to the release medium, 6 areas (1000 x 
600 µm2, Figure 1b) (n = 3) of the axial cutting surface were mapped via Raman 
spectroscopy. 
The resulting map provides an overview of the MPT distribution in the mapped area. 
The mapping system used for this study was a RamanRxn 1 Analyzer and Microprobe 
(Kaiser Optical Systems, Ann Arbor, USA), equipped with an air cooled CCD detector (back-
illuminated deep depletion design). The laser wavelength during the experiments was the 
785 nm line from a 785 nm Invictus NIR diode laser. All spectra were recorded at a resolution 
of 4 cm-1 using a laser power of 400 mW and a laser light exposure time of 30 s per collected 
spectrum. Before data analysis, spectra were baseline corrected. Data collection and data 
analysis was done using the HoloGRAMSTM data collection software package, the 
HoloMAPTM data analysis software and Matlab® software package (version 6.5.). 
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Figure 1: Schematic drawing of the areas (presented as blue rectangles) mapped with 
Raman spectroscopy: (a) surface and half height (radial cutting surface) are mapped along 
the diameter of the mini-matrix, (b) 6 areas of the axial cutting surface are mapped. 
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3. RESULTS AND DISCUSSION 
 
Previous investigation in Chapter 3 showed that the release rates of MPT (used as 
model drug) and PEG/PEO from hot-melt extruded mini-matrices strongly depended on the 
concentration as well as on the type of PEG/PEO incorporated in the EC-based cylinders 
[13]. The aim of this study was to better understand these phenomena and to be able to 
quantitatively predict the effects of the device design and changes in the composition on the 
resulting drug release kinetics. 
 
 
3.1. “Simple” mathematical theory 
 
As diffusion is likely to play a major role in the underlying drug and PEG/PEO release 
mechanisms, Fick’s second law was used as a basis for the mathematical analysis. As the 
investigated mini-matrices are cylindrical in shape, it is important to consider drug and 
PEG/PEO transport in radial as well as in axial direction [14]: 
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Where, ck and Dk are the concentration and diffusion coefficient of the diffusing species (k = 
1: drug; k = 2: PEG/PEO), respectively; t represents time; and r, z and θ denote the radial, 
axial and angular coordinate, respectively. This partial differential equation was solved 
considering the following initial and boundary conditions: 
• drug and PEG/PEO are initially homogeneously distributed throughout the mini-
matrices (before exposure to the release medium) 
• perfect sink conditions are maintained through the experiments for all diffusing 
species 
• the cylinders do not significantly swell or shrink during drug release 
• the diffusion coefficients of MPT and PEG/PEO are constant during the entire drug 
release period 
leading to: 
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Where Mk,t and Mk,∞ are the amounts of drug or PEG/PEO released at time t, and at infinite 
time (k = 1: drug; k = 2: PEG/PEO); qn are the roots of the Bessel function of the first kind of 
order zero [J0(qn) = 0]; R and H represent the radius and length of the cylinder; Dk denotes 
the time-independent diffusion coefficient of the drug or PEG/PEO. 
Equation 2 was fitted to the various experimentally measured drug and PEG/PEO 
release profiles from EC-based mini-matrices containing 0-70% (w/w) PEG/PEO of different 
molecular weight: 6000-7.000.000 Da. Examples for such fittings are shown in Figure 2.  
 
 
189
CHAPTER 4 
 
(a) 
0
25
50
75
100
0 6 12 18 24
Time (h)
M
PT
 re
le
as
ed
 (%
)
experiment
theory
 
(b) 
0
25
50
75
100
0 6 12 18 24
Time (h)
PE
O
 re
le
as
ed
 (%
)
experiment
theory
 
 
Figure 2: Experiment (symbols) and theory (curves, simple model with constant diffusion 
coefficients, equation 2): (a) MPT release from mini-matrices containing 20% PEO 
1.000.000, (b) PEO release from mini-matrices containing 10% PEO 100.000. 
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As it can be seen, good agreement between theory and experiment was obtained in 
the case of MPT and PEO release from cylinders initially containing 20% PEO 1.000.000 and 
10% PEO 100.000, respectively. This indicates that the mass transport of both species is 
likely to be dominated by diffusion with constant diffusion coefficients. Based on these 
fittings, the apparent diffusivities of MPT and PEO could be determined to be equal to 1.56 . 
10-7 (± 0.80) cm²/s and 6.74 . 10-8 (± 0.74) cm²/s, respectively. The higher diffusivity of the 
drug compared to the PEO can be explained by the much smaller molecular weight. 
However, also significant deviations were observed between the theoretically calculated MPT 
or PEG/PEO release profile and the experimentally measured values. Figure 3 shows two 
examples: drug and PEO release from mini-matrices initially free of PEG/PEO (i.e. containing 
only 30% MPT and 70% EC) and containing 10% PEO 7.000.000, respectively. Thus, in 
these cases the underlying mass transport mechanisms are more complex.  
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Figure 3: Experiment (symbols) and theory (curves, simple model with constant diffusion 
coefficients, equation 2): (a) MPT release from mini-matrices free of PEG/PEO, (b) PEO 
release from mini-matrices containing 10% PEO 7.000.000. 
192
MATHEMATICAL MODELLING OF DRUG AND POLYMER RELEASE FROM HOT-MELT EXTRUDED MINI-MATRICES  
 
Table 2 gives an overview on the various systems which were studied and whether or 
not the “simple” mathematical model considering constant diffusion coefficients (equation 2) 
was applicable or not (either D values are indicated, or “non-constant” marked). Importantly, 
there is a clear tendency: drug and PEG/PEO release follows pure diffusion control with 
constant diffusion coefficients: (i) at high initial PEG/PEO loadings (≥ 20%), irrespective of 
the molecular weight of PEG/PEO, and (ii) at low/intermediate PEG/PEO loadings (1-10%) in 
the case of low/intermediate molecular weight PEG/PEOs (MW ≤ 100.000 Da). In the first 
case, the mini-matrices become highly porous upon PEG/PEO leaching. In the second case 
the PEG/PEO molecules are rather small, thus, time-dependent changes of the matrix 
porosity during drug release can be expected to be only of minor importance for drug and 
PEG/PEO mobility. In contrast, at low initial PEG/PEO loadings the mobility of large 
molecules, such as high molecular weight PEG/PEOs is likely to be affected by changes in 
the matrix porosity: with increasing pore size the mobility of these species significantly 
increases. This hypothesis is in good agreement with the type of systematic deviations 
between the fitted theory (“simple” model) and the experimentally determined amounts of 
released MPT and PEG/PEO (Figure 3): at early time points diffusional mass transport is 
theoretically overestimated, whereas at late time points it is underestimated (higher mobility 
in reality). 
An increase in the PEG/PEO content (irrespective of the PEG/PEO molecular weight) 
resulted in increased drug and polymer diffusion coefficients, which is in good agreement 
with the experimentally determined increasing drug and PEG/PEO release rates (Chapter 3). 
This can be explained by the increased porosity of the cylinders upon drug and PEG/PEO 
leaching (resulting in increased drug and polymer mobility) and to an increased hydrophilicity 
of the systems (resulting in faster water penetration rates during dissolution). Furthermore, 
the apparent diffusion coefficients of the drug and PEG/PEO generally increase with 
decreasing PEG/PEO molecular weight in the systems (irrespective of the PEG/PEO 
content), which can be described using equation 2 (Table 2). With decreasing molecular 
weight, the mobility of PEG/PEO increases (due to the reduced size of the molecules and 
lower viscosity of the solution), resulting in facilitated leaching into the bulk fluid and, thus, 
increased system porosity and increased drug mobility. 
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Table 2: Effects of the initial PEG/PEO concentrations and molecular weights (MW) on the 
apparent diffusion coefficient of metoprolol tartrate (Ddrug) and PEG/PEO (DPEG/PEO) in the 
investigated mini-matrices (mean ± S.D., n = 6). 
 
PEG/PEO concentration  
(%, w/w) 
 
MW PEG/PEO 
(Da) 
 
Ddrug 
(cm2/s) 
 
DPEG/PEO 
(cm2/s) 
0 - non-constant - 
1 6000 - - 
 100.000 - - 
 1.000.000 - - 
 7.000.000 non-constant - 
2.5 6000 - 4.21 . 10-8 ± 0.37 
 100.000 1.92 . 10-8 ± 0.01 non-constant 
 1.000.000 - non-constant 
 7.000.000 non-constant non-constant 
5 6000 2.29 . 10-8 ± 0.27 - 
 100.000 2.22 . 10-8 ± 0.17 - 
 1.000.000 non-constant - 
 7.000.000 non-constant - 
10 6000 2.60 . 10-8 ± 0.19 1.21 . 10-7 ± 0.02 
 100.000 2.50 . 10-8 ± 0.19 6.74 . 10-8 ± 0.74 
 1.000.000 non-constant 6.16 . 10-8 ± 1.51 
 7.000.000 non-constant non-constant 
20 100.000 4.47 . 10-7 ± 0.86 1.36 . 10-7 ± 0.15 
 1.000.000 1.56 . 10-7 ± 0.80 7.12 . 10-8 ± 1.30 
 7.000.000 2.02 . 10-7 ± 0.15 7.32 . 10-8 ± 0.10 
70 6000 1.13 . 10-5 ± 0.38 2.68 . 10-6 ± 0.62 
 100.000 1.38 . 10-6 ± 0.55 1.45 . 10-6 ± 0.60 
 1.000.000 2.98 . 10-7 ± 0.34 1.11 . 10-7 ± 0.15 
 7.000.000 2.36 . 10-7 ± 0.40 9.72 . 10-8 ± 0.99 
 
-: not determined 
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In addition to this deeper insight into the underlying mass transport mechanisms, the 
mathematical modelling of the mini-matrices, which can be described by equation 2 (“simple” 
theory) also offers an interesting practical benefit: the effects of the initial radius and height of 
the cylinders on the resulting drug and PEG/PEO release kinetics can be predicted in a 
quantitative way. Figure 4 shows some examples for such predictions. Knowing the diffusion 
coefficients of MPT and PEG/PEO from the fittings of the “simple” model to the release 
kinetics determined with mini-matrices initially containing 10% PEO 100.000 or 20% PEO 
1.000.000 and with a height of 2 mm and a radius of 1.5 mm, drug and PEG/PEO leaching 
into the release medium was predicted from cylinders with the same height, but varying 
thickness: 0.5, 1.0, 3.0 and 6.0 mm, respectively (curves in Figure 4a and 4b). As it can be 
seen, a significant decrease in the mass transport rates was predicted with increasing radius 
of the cylinders. This is due to the decrease in the relative surface area available for diffusion 
(decreasing “surface area/volume” ratio). Importantly, these theoretical predictions could be 
confirmed by independent experimental MPT and PEG/PEO leaching measurements 
(symbols in Figure 4a and 4b). For extrudates with a radius of 0.5 mm, there was an 
important deviation between the experimental data and theoretical predictions. However, if 
predictions were made taking die swelling [15, 16] of these matrices into account (the actual 
radius of these mini-matrices was 0.7 mm) the correlation between theory and experiment 
was good. Die swelling was less pronounced using other die geometries and die swelling 
was not taken into account for predicting drug release. This clearly indicates that drug and 
PEG/PEO release from these hot-melt extruded mini-matrices is predominantly controlled by 
pure diffusion with constant diffusion coefficients. The theoretically predicted effects of the 
height of mini-matrices initially containing 10% PEO 100.000 or 20% PEO 1.000.000 on the 
resulting drug release kinetics from cylinders with a constant radius of 1.5 mm are illustrated 
in Figure 4c and 4d. Clearly, also the variation of the cylinder height from 1 to 32 mm strongly 
affects the resulting drug release patterns. Again, an increase in the relative surface area 
available for diffusion (due to a decreasing matrix height) led to increased MPT release rates. 
Compared to the effects of the cylinder radius, the consequences of the relative changes in 
the matrix height are less pronounced. This can be attributed to the fact that the surface area 
of a cylinder depends on the radius to the power of two and to the height to the power of one 
only. Importantly, also in these cases, independent MPT and PEG/PEO release 
measurements confirmed the theoretical predictions (symbols in Figure 4c and 4d). The 
observed impact of the device geometry on the resulting drug release kinetics is in good 
agreement with reports in the literature, including swellable tablets [17-20]. 
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Figure 4: Theoretical predictions and independent experimental verification (except for the 
reference formulations) of the effects of the cylinders’ radii and heights (indicated in the 
figures) on the resulting MPT release kinetics from mini-matrices containing (a) 10% PEO 
100.000 (constant height = 2 mm), (b) 20% PEO 1.000.000 (constant height = 2 mm), (c) 
10% PEO 100.000 (constant radius = 1.5 mm), (d) 20% PEO 1.000.000 (constant radius = 
1.5 mm). 
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3.2. “Complex” mathematical theory 
 
To better understand the observed significant deviations between the “simple” 
mathematical theory and the experimentally determined drug and PEG/PEO release kinetics 
from mini-matrices with low/intermediate initial PEG/PEO loadings (1-10%) and high 
molecular weight PEG/PEOs (MW ≥ 1.000.000 Da), the porosity of the mini-matrices was 
determined before and upon exposure to the release medium using X-ray tomography as 
well as helium pycnometry. As it can be seen in Figure 5a and 5b, the matrices showed 
already an initial porosity, which was higher at the edges (Figure 5b: significant number of 
smaller pores at the edges, whereas a few larger pores are located at the centre). 
Importantly, this porosity significantly increased upon exposure to the release medium, at 
least partially due to drug and PEG/PEO leaching into the bulk fluid (Figure 5c). After 24 h 
exposure, a highly porous matrix was observed, which partially also showed crack formation 
(Figure 5d and 5e). 
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Figure 5: Porosity of mini-matrices containing 10% PEO 7.000.000 before and after exposure 
to the release medium: (a) cross-section at t = 0 h (before exposure), (b) visualization of the 
pore distribution and sizes at t = 0 h (before exposure), (c) experimentally determined, time-
dependent increase in porosity, (d) cross-section after 24 h exposure, (e) visualization of the 
pore distribution and sizes after 24 h exposure. 
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This significant increase in the matrix porosity is not taken into account by the “simple” 
mathematical theory. Importantly, the time-dependent change in system porosity is likely to 
result in significant changes in the mobility of the drug and PEG/PEO, especially at 
low/intermediate PEG/PEO loadings. The following, more complex mathematical theory 
takes such effects into account. It is also based on Fick’s law of diffusion for cylindrical 
geometry (equation 1) and considers radial and axial mass transfer. The underlying model 
assumptions are as follows: 
• drug and PEG/PEO are initially homogeneously distributed throughout the mini-
matrices (before exposure to the release medium) 
• perfect sink conditions are maintained through the experiments for all diffusing 
species 
• the cylinders do not significantly swell or shrink during drug release 
As time-dependent drug and PEG/PEO diffusion coefficients are taken into account, there is 
no analytical solution for this initial value problem. Thus, a numerical method, based on finite 
differences was applied. The major principles of this theory are briefly described in the 
following, the reader is referred to the literature for more details [21, 22]. As there is no 
concentration gradient of any component with respect to the angle θ (Figure 6), equation 1 
can be transformed into: 
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To minimize the computation time, also the symmetry plane at z = 0 (Figure 6) is taken into 
account. Thus, it is sufficient to describe the changes in the MPT and PEG/PEO 
concentrations within the 2-dimensional rectangle highlighted in Figure 6 to be able to 
calculate the mass transport phenomena in the entire cylinder: upon rotation around the z-
axis the upper half of the mini-matrix is described, and due to the symmetry at the z = 0 
plane, the whole cylinder can be considered. 
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Figure 6: Schematic presentation of a cylinder mini-matrix for the mathematical analysis. Two 
symmetry planes are illustrated: for r = 0 and z = 0 as well as the rotational symmetry of the 
system with respect to the angle θ. Furthermore, the locations of the two cross-sections 
referred to in Figure 9 are illustrated. 
 
The initial condition of this theory takes into account the fact that MPT as well as PEG/PEO 
are uniformly distributed throughout the mini-matrices before exposure to the release 
medium (at t = 0). Thus, the drug and PEG/PEO concentrations at any position are equal to 
the respective initial concentrations (c1 initial, c2 initial): 
 
t = 0  c1 = c1 initial  0 ≤  r ≤ R 0 ≤  z ≤  Z  (4) 
t = 0  c2 = c2 initial  0 ≤  r ≤  R 0 ≤  z ≤  Z  (5) 
 
where R denotes the radius and Z the half height of the mini-matrix. As perfect sink 
conditions are provided for all diffusing species throughout the experiments, the MPT and 
r 
Z z=0 
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PEG/PEO concentrations at the surface of the cylinders are always equal to zero upon 
exposure to the release medium: 
 
t > 0 c1 = 0  0 ≤  r ≤  R z = Z       (6) 
t > 0 c1 = 0  0 ≤  z ≤  Z r = R       (7) 
t > 0 c2 = 0  0 ≤  r ≤  R z = Z       (8) 
t > 0  c2 = 0   0 ≤  z ≤  Z  r = R        (9) 
 
Due to the symmetries at z = 0 and r = 0 (Figure 6), there are no concentration gradients at z = 0 
for 0  r ≤  R and at r = 0 for 0 ≤  z ≤  Z for any of the diffusing components: ≤
 
t > 0 0
z
c1 =∂
∂
 0 ≤  r ≤  R z = 0    (10) 
t > 0 0
r
c1 =∂
∂
 0 ≤  z ≤  Z r = 0    (11) 
t > 0 0
z
c2 =∂
∂
 0 ≤  r ≤  R z = 0    (12) 
t > 0 0
r
c2 =∂
∂
 0 ≤  z ≤  Z  r = 0    (13) 
 
Furthermore, the time-dependent porosity of the matrices is taken into account (Figure 5). 
The increase in MPT and PEG/PEO mobility within the mini-matrices is considered as follows 
as a function of the system porosity: 
 
100
)t(εD
)t(D critkk
⋅=      (14) 
 
where Dk crit represents a critical diffusion coefficient (as diffusion takes place in confined 
regions, this value is not necessarily equal to the diffusivity in pure release medium), being 
characteristic for the diffusing species, and ε denotes the porosity of the cylinder in percent. 
Thus, the consequences of the dynamic changes in the structure of the mini-matrices during 
drug release on the conditions for the multi-component diffusion are quantitatively taken into 
account. 
As the matrix porosity increases upon MPT and PEG/PEO leaching, there is no 
analytical solution for the described set of partial differential equations (equation 3-14). To be 
able to calculate the changes in the MPT and PEG/PEO concentrations within the 2-
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dimensional rectangle highlighted in Figure 6, the radius of the mini-matrix, R, and half 
height, Z, are divided into I and J space intervals, ∆r and ∆z, respectively (Figure 7).  
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Figure 7: Schematic presentation of the basis principle of the applied numerical analysis for 
the complex mathematical model considering time-dependent diffusion coefficients. 
 
This generates a grid of (I+1)x(J+1) grid points. The time is divided into g time intervals ∆t 
(for most of the simulations I = J = 50 and g = 500.000 were chosen). At t = 0 (before 
exposure to the release medium), the drug and PEG/PEO concentrations are known from the 
initial conditions (equation 4, 5). Importantly, using equation 3 and 6-14, the concentration 
profiles of the diffusing species at a new time step (t = t0+∆t) can be calculated, when the 
concentration profiles are known at the previous time step (t = t0): the concentration of a 
particular species at a certain inner grid point (ix∆r, jx∆z) at the new time step (t = t0+∆t) is 
calculated from its concentrations at the same grid point (ix∆r, jx∆z) and the four direct 
neighbours [(i-1)x∆r, jx∆z; ix∆r, (j-1)x∆z; ix∆r, (j+1)x∆z; (i+1)x∆r, jx∆z] at the previous time 
step (t = t0). The respective concentrations at the outer grid points (i = 0 v i = I v j = 0 v j = J) 
at a new time step (t = t0+∆t) are calculated using the boundary conditions (equation 6-13). 
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As all initial concentrations are known, the concentration profiles at t = 0+∆t, t = 0+2∆t, t = 
0+3∆t,..., t = 0+g∆t can be calculated sequentially. Furthermore, the total amounts of MPT 
and PEG/PEO within the cylinders are calculated at each time step (by integrating the 
respective concentrations with respect to r, z and θ). Based on experimentally determined 
porosity of the mini-matrices, the drug and PEG/PEO diffusivities can be calculated at any 
time point using equation 14. For the implementation of the mathematical model the 
programming language C++ was used (Borland C++ Builder V.6.0). 
 
 As it can be seen in Figure 8, much better agreement between the complex theory 
and the experimentally measured MPT and PEG/PEO release kinetics from the mini-
matrices was obtained in the case of drug release from mini-matrices initially containing 10% 
PEO 7.000.000 as well as in the case of PEO release from mini-matrices initially containing 
10% PEO 7.000.000 or 2.5% PEO 100.000 than with the simple mathematical model. This is 
due to the more realistic description of the diffusional mass transport: due to the increase in 
device porosity, drug and PEG/PEO release are facilitated. Importantly, in the case of MPT 
release from mini-matrices initially containing 2.5% PEO 100.000 the agreements between 
the complex and the simple mathematical model with the experimentally measured drug 
release kinetics were similar. This confirms the above described hypothesis that in these 
cases, the changes in the conditions for drug and PEG/PEO release are not of significance 
and that time-independent diffusion coefficients can be considered. Figure 8 only shows 
some examples, the before mentioned is true for all the investigated mini-matrices. 
 
 It has to be pointed out that the agreement between theory and experiment is not yet 
perfect, even in the case of the complex mathematical theory. For example, in Figure 8a and 
8c still some systematic (but less important) deviations can be seen. This might at least 
partially be attributed to the fact that crack formation sets on in these systems after a certain 
lag-time, as it can be seen in Figure 5d. This leads to increased surface areas available for 
diffusion at late time points and, thus, increased drug and PEG/PEO release rates. The 
proposed mathematical theories do not take this dynamic process of crack formation into 
account. Thus, the models (slightly) underestimate drug release at late time points. The 
observed overestimation of drug release at early time points is a consequence of the fitting 
procedure. It was beyond the scope of this study to include the onset and degree of crack 
formation in the mathematical theories. This would require the knowledge of additional, 
system-specific parameters, which are difficult to determine. 
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Figure 8: Experiment (symbols) and theory (dashed curves: simple model with constant 
diffusion coefficients, solid curves: complex model with time-dependent diffusion 
coefficients): (a) MPT release from mini-matrices containing 10% PEO 7.000.000, (b) MPT 
release from mini-matrices containing 2.5% PEO 100.000, (c) PEO release from mini-
matrices containing 10% PEO 7.000.000, (d) PEO release from mini-matrices containing 
2.5% PEO 100.000.  
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The distribution of MPT in the mini-matrices was monitored via Raman using the 627-
653 cm-1 spectral band as no overlap with Raman signals from the other tablet ingredients 
occurred at this spectral range (see Chapter 3, Figure 6). Based on the intensity of the 
Raman signal across the scanned sections of the mini-matrices it was confirmed that MPT is 
homogeneously distributed in the mini-matrix before exposure to the release medium, since 
the MPT intensities were similar in the centre and at the edges of the mini-matrices, for z = Z 
(exterior surface) and z = 0 (half height). After exposure to the release medium (24 h), 
surprisingly a lower drug concentration was only detected at the tablet edges, whereas even 
at the exterior surface the centre still contained high MPT concentrations (Figure 9a). 
However, mapping of the axial cutting surface (Figure 9b) showed that MPT preferentially 
diffused in axial direction during dissolution. This can be explained by the fact that during hot-
melt extrusion the polymers are orientated parallel to the extrusion flow, resulting in a 
preferential diffusion route for drug release. This observation is in agreement with the 
anisotropic swelling due to axial relaxation of the polymers (Chapter 1). In addition, a drug 
particle will select the shortest diffusion path length to the release medium: since the height 
of our tablets is 2 mm in comparison with a diameter of 3 mm, the axial route is followed 
(especially of great importance for particles at the centre of the tablet).  
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Figure 9: Schematic drawing of the experimentally determined MPT concentration with 
Raman spectroscopy in mini-matrices containing 2.5% PEO 100.00): (a) after 24 h exposure 
to the release medium – exterior surface and radial cutting surface (see also Figure 1a), (b) 
after 24 h exposure to the release medium – axial cutting surface (see also Figure 1b). The 
MPT distribution in the mini-matrices is schematically presented via a binary colour code 
(blue indicating an area with low MPT concentration, red indicating an area with high MPT 
concentration). A more detailed presentation of the MPT concentration was not possible as 
the Raman signal could not be normalized over the different scanned areas. 
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4. CONCLUSIONS 
 
The presented novel mathematical theories offer two major advantages: (i) deeper 
insight into the underlying mass transport processes governing drug and excipient release 
from mini-matrices can be gained, and (ii) the optimization of existing devices and 
development of novel devices can be facilitated, because the effects of formulation 
parameters, such as the tablet height and radius on the resulting drug release kinetics can 
be predicted in a quantitative way. 
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Hot-melt extrusion is a well-established technique in the plastics industry. In the 
pharmaceutical field it is investigated as an application to develop pharmaceutical dosage forms: 
granules, sustained-release pellets and matrix tablets, transdermal drug delivery systems and 
drug/polymer solid dispersions or solid solutions. A detailed description of the extrusion process, 
the different types of equipment, and an overview of drugs and polymers processed with hot-melt 
extrusion are given in the INTRODUCTION. This chapter also describes the advantages of 
multiparticulate systems compared with conventional dosage forms and some of the production 
methods used to manufacture multiple-unit drug delivery systems. Matrix systems are commonly 
used as oral sustained-release dosage forms, however their drug release profile is generally 
characterized by a burst release effect. Since constant rate delivery is the primary goal of 
sustained-release systems, considerable efforts have been made in the development of new drug 
delivery concepts in order to avoid the burst effect and to obtain zero-order drug release. Different 
strategies proposed to limit burst release from matrix systems are presented in the introduction. 
 
The OBJECTIVE of this doctoral thesis was to develop a polymeric multiparticulate dosage 
form by means of a simple, flexible and economically feasible manufacturing method. Therefore, 
the properties of mini-matrices consisting of lipophilic as well as hydrophilic polymers to tailor drug 
release and processed using hot-melt extrusion were evaluated. 
 
CHAPTER 1 describes the formulation study of mini-matrices with release-sustaining 
properties, developed by means of hot-melt extrusion, using ibuprofen as model drug and 
ethylcellulose as sustained-release agent. Xanthan gum, a hydrophilic polymer, was added 
to the formulation to increase drug release since ibuprofen release from the 
ibuprofen/ethylcellulose matrices (60/40, w/w) was too slow (20% in 24 h). In the first part of 
chapter 1, it was revealed that changing the xanthan gum concentration as well as its particle 
size modified the in vitro drug release. Increasing xanthan gum concentrations yielded a 
faster drug release due to a higher liquid uptake, swelling and erosion rate. Regarding the 
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effect of the xanthan gum particle size, no difference was observed for formulations 
containing 10 and 20% xanthan gum. However, using 30% xanthan gum, drug release was 
influenced by the particle size of the hydrophilic polymer due to the susceptibility of the 
coarser xanthan gum particles to erosion. The mean porosity data of the mini-matrices 
indicated that the initial porosity (≤ 5.5%) is independent of the composition (xanthan gum 
concentration, xanthan gum particle size) of the mini-matrices and therefore not responsible 
for any difference in drug release. Drug release from the mini-matrices was mainly diffusion-
controlled, but swelling played an important role to obtain complete drug release within 24 h, 
and ibuprofen release was unaffected by the hydrodynamic conditions of the in vitro 
dissolution test. Drug release was influenced by the ionic strength of the medium as the 
conformation of xanthan gum molecules is determined by the salt concentration. Increasing 
the xanthan gum concentration resulted in a higher friability (≤ 0.32%), which was correlated 
with a decrease of crushing strength; the influence of xanthan gum particle size was 
negligible. The stability data revealed that drug release, water uptake and hardness of the 
xanthan gum formulations changed when stored for 12 months at 25°C/60% relative humidity 
and 40°C/75% relative humidity, and therefore these mini-matrices should be appropriately 
packaged. In the second part of this chapter, an oral dose of 300 mg ibuprofen was 
administered to 6 dogs either as an immediate-release preparation (Junifen®), as a 
sustained-release formulation (Ibu-Slow® 600 mg (½ tablet)) or as the experimental mini-
matrices (varying in xanthan gum concentration). An HPLC-UV method, validated according 
to the ICH-guidelines, was used for determination of drug levels in dog plasma. No 
interference with endogenous compounds was detected. Calibration curves were linear in the 
whole concentration range (R2 = 0.9997 ± 0.0003; n = 10). The recovery of ibuprofen (0.25-
20 µg/ml range) after extraction varied between 82.4 and 88.9%, while 73.5% of internal 
standard (indomethacin) was recovered. The method was precise for the same concentration 
range, since the coefficients of variation for repeatability and intermediate precision ranged 
between 2.9 and 8.0% and between 4.4 and 12.5%, respectively. Ibuprofen could be 
determined accurately as an accuracy between 86.8 and 103.4% was obtained. The limits of 
detection and quantification were both set at 0.25 µg/ml. Administration of the experimental 
formulations sustained the ibuprofen release. Although a significant difference in dissolution 
rate of the 20 and 30% xanthan gum mini-matrices was detected in vitro, the difference in 
relative bioavailability (using Ibu-Slow® 600 mg as reference) was limited (70.6 and 73.8%, 
respectively).  
 
 In CHAPTER 2, mini-matrices (multiple-unit dosage form) with release-sustaining 
properties were developed by hot-melt extrusion (cylindrical die: 3 mm) using ethylcellulose 
as sustained-release agent and metoprolol tartrate as a model drug which has no plasticizing 
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effect on the polymer. A burst release of metoprolol tartrate was seen from mini-matrices 
formulated with triethyl citrate or triacetin (hydrophilic plasticizers), whereas drug release 
from matrices plasticized with dibutyl sebacate or diethyl phthalate (hydrophobic) was slow 
and followed zero-order kinetics. Despite the different hydrophilic character of the 
plasticizers, all had the same plasticizing effect during processing. Dibutyl sebacate was 
selected as plasticizer for further development and its concentration was optimized to 50% 
(w/w) of the ethylcellulose concentration. Xanthan gum, a hydrophilic polymer, was added to 
the formulation to increase drug release. Changing the xanthan gum concentration modified 
the in vitro drug release: increasing xanthan gum concentrations (1, 2.5, 5, 10 and 20%, w/w) 
yielded a faster drug release. Zero-order drug release was obtained at 5% (w/w) xanthan 
gum. Based on X-ray diffraction analysis, it was revealed that metoprolol tartrate remained 
crystalline in the hot-melt extruded mini-tablets, independent of the xanthan gum 
concentration. The production of the extrudates was reproducible, and after an equilibration 
time of 5 min extrudates with a constant quality were produced. Incorporation of kneading 
paddles in the screw configuration allowed to manufacture smooth extrudates when 
processing the formulation at 60°C. The mixing efficacy and drug release were not affected 
by the number of mixing zones or their position along the extruder barrel. Using a screw 
configuration only consisting of transport zones resulted at 60°C in extrudates with an 
irregular surface structure, and powder spots (identified as metoprolol tartrate via Raman 
spectroscopy) were seen on the extrudates surface. Using a higher processing temperature 
(70°C) improved the surface structure but metoprolol tartrate spots were still visible on the 
surface. Raman analysis revealed that metoprolol tartrate was homogeneously distributed in 
the mini-matrices, independent of screw design and processing conditions. Simultaneously 
changing the powder feed rate (6-50 g/min) and screw speed (30-200 rpm) did not alter 
extrudate quality or dissolution properties.  
 
 In CHAPTER 3, it was proposed to substitute xanthan gum for polyethylene glycol or 
polyethylene oxides, because it is known that the swelling properties of these polymers 
depend on their molecular weight. Mini-matrices with release-sustaining properties were 
developed by hot-melt extrusion (diameter 3 mm, height 2 mm) using metoprolol tartrate as 
model drug (30%, w/w) and ethylcellulose as sustained-release agent. Polyethylene glycol or 
polyethylene oxide was added to the formulation to increase drug release. Changing the 
hydrophilic polymer concentration (0, 1, 2.5, 5, 10, 20 and 70%, w/w) and molecular weight 
(6000, 100.000, 1.000.000 and 7.000.000) modified the in vitro drug release: increasing 
concentrations yielded faster drug release (irrespective of molecular weight), whereas the 
influence of molecular weight depended on concentration. Polyethylene glycol/polyethylene 
oxide release increased at higher polyethylene glycol/polyethylene oxide concentration 
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(irrespective of molecular weight), and a slower polyethylene glycol/polyethylene oxide 
release was observed for all formulations formulated with high molecular weight polyethylene 
oxide. Smooth extrudates were obtained when processed at 40 and 70°C for polyethylene 
glycol and polyethylene oxide formulations, respectively. Raman analysis revealed that 
metoprolol tartrate was homogeneously distributed in the mini-matrices, independent of 
hydrophilic polymer concentration and molecular weight. Also drug and polymer crystallinity 
were independent of both parameters. An oral dose of 200 mg metoprolol tartrate was 
administered to 6 dogs either as immediate-release preparation (Lopresor® 100 (2 tablets)), 
as sustained-release formulation (Slow-Lopresor® 200 Divitabs®), or as experimental mini-
matrices (varying in hydrophilic polymer concentration). An HPLC-fluorescence method, 
validated according to the ICH-guidelines, was used for determination of drug levels in dog 
plasma. Interference of metoprolol tartrate and alprenolol (internal standard) with 
endogenous compounds was not detected. The calibration curves were linear (R2 = 0.9976 ± 
0.0015; n = 10) in the 0.05 to 3.0 µg/ml concentration range. The recovery of metoprolol 
tartrate after extraction varied between 79.3 and 85.0% depending on the concentration, 
while 85.1% of internal standard was recovered. The method was precise: the coefficients of 
variation for repeatability and intermediate precision ranged from 3.7 to 10.5% and from 1.7 
to 11.6%, respectively. Metoprolol tartrate could be determined with an accuracy between 
91.7 and 125.7%. The limits of detections and quantification were 0.05 µg/ml. The sustained-
release effect of the experimental formulations was limited and relative bioavailabilities (using 
Slow-Lopresor® 200 Divitabs® as reference) of 51.5, 94.4, 131.5, 66.2 and 148.2% were 
obtained for mini-matrices containing 5, 10 and 20% XG, and 5 and 20% PEO 1.000.000, 
respectively. 
 
Chapter 3 demonstrated that drug and polymer release was affected by the concentration 
as well as the molecular weight of polyethylene glycol/polyethylene oxide. Therefore drug and 
polymer release from hot-melt extruded mini-matrices were mathematically modelled in CHAPTER 
4. Drug and polyethylene glycol/polyethylene oxide release mechanism depended on polymer 
content and molecular weight. An increase of the hydrophilic polymer content resulted in higher 
drug and polymer diffusion coefficients; an increase in molecular weight of the hydrophilic polymer 
lowered the diffusion coefficient of drug and polymer. At high polyethylene glycol/polyethylene 
oxide content (≥ 20%) (irrespective of the polymer molecular weight), and at low/intermediate 
polymer content in the case of low/intermediate polymer molecular weight (≤ 100.000 Da), drug 
and polymer release was controlled by diffusion with constant diffusivities (Fick’s second law of 
diffusion). This resulted in a good correlation between theoretical modelling and experimental data 
for these mini-matrices (3 mm diameter, 2 mm height). Based on the drug diffusion coefficients of 
these mini-matrices, the metoprolol tartrate release patterns from cylinders with arbitrary 
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dimensions (variable radius (0.5-6 mm) for constant height (2 mm), variable height (1-32 mm) for 
constant radius (1.5 mm)) could be quantitatively predicted: a smaller radius and shorter length 
increased drug release, whereas a higher radius and longer length decreased drug release. The 
agreement between theoretical calculations and experimental data could be verified in all cases, 
confirming the diffusion-controlled drug release mechanism and proving the validity of the model. 
In contrast, at low/intermediate polyethylene glycol/polyethylene oxide content (1-10%) in case of 
high polymer molecular weight (≥ 1.000.000 Da), drug and polymer release was not only 
controlled by diffusion, resulting in significant deviations between the applied theory (considering 
constant diffusivities) and experimental release profiles for mini-matrices with 3 mm diameter and 
2 mm height. Thus, in these cases the underlying drug and polymer release mechanisms were 
more complex and a new theory was required: a mathematical model was developed, taking into 
account the experimentally determined increase in porosity of the cylinders upon drug and 
polymer release as well as time-dependent drug and polymer mobilities. This model (with more 
realistic conditions for drug and polymer diffusion) could more adequately describe the 
experimentally measured release kinetics, resulting in a better fit between theoretical predictions 
and experimental data. An interesting application of the model is the possibility to quantitatively 
predict the effects of different formulation parameters on the resulting drug and polymer release 
patterns. 
 
The objective of this doctoral thesis was to develop by means of a simple, flexible and 
continuous processing technique (i.e. hot-melt extrusion) a multiparticulate dosage form with zero-
order sustained-release properties. This study demonstrated that the in vitro and in vivo drug 
release kinetics could be varied by selecting a formulation with an appropriate ratio of lipophilic 
and hydrophilic polymers, and by changing the particle size and/or molecular weight of the 
hydrophilic polymer (i.e. xanthan gum and polyethylene oxide). Nevertheless, a few topics can be 
identified for future investigation: 
- Since ethylcellulose was used as the main excipient, it would be of interest to investigate if hot-
melt extrusion of other lipophilic polymers (in combination with hydrophilic polymers) offers distinct 
advantages compared to the ethylcellulose-based mini-matrices. 
- All formulations used in this study were processed using a specific type of laboratory-scale 
extruder. It is known that the equipment type and batch size (due to a difference in energy input 
and heat generation during longer processing times) can affect the material behaviour, thus 
influencing extrudate and matrix quality. Therefore, scale-up would be another challenging step 
when evaluating hot-melt extrusion as processing technique for a multiparticulate dosage form.  
- Future work can also focus on co-extrusion (multiple layers of material are simultaneously 
extruded): incorporation of polymers with different hydration/swelling/release properties in different 
layers could result in a dosage form with zero-order drug release kinetics. 
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‘Hot-melt’ extrusie is een goed ingeburgerde techniek in de polymeer industrie. In de 
farmaceutische sector vindt het zijn toepassing in de ontwikkeling van farmaceutische 
geneesmiddelvormen zoals granules, pellets en tabletten voor gecontroleerde vrijstelling, 
transdermale toedieningsvormen en vaste geneesmiddel/polymeer dispersies of oplossingen. In 
de INLEIDING worden een gedetailleerde beschrijving van het extrusieproces en de verschillende 
types van apparatuur weergegeven, alsook een overzicht van geneesmiddelen en polymeren die  
reeds met behulp van ‘hot-melt’ extrusie werden verwerkt. Dit hoofdstuk vermeld eveneens de 
voordelen van multiparticulaire vormen in vergelijking met ‘single-unit’ systemen, gevolgd door 
een beschrijving van de mogelijke productiemethoden voor deze multiparticulaire vormen. 
Matrices worden vaak aangewend voor de orale, vertraagde vrijgave van geneesmiddelen, maar 
het voornaamste nadeel is dat het vrijstellingsprofiel gekarakteriseerd wordt door een ‘burst 
release’ fenomeen. Aangezien een constante vrijstellingssnelheid van primordiaal belang is voor 
‘sustained-release’ formulaties, is reeds heel wat onderzoek verricht naar nieuwe 
geneesmiddelvormen die gekenmerkt worden door een nulde orde vrijstellingsprofiel. De inleiding 
beschrijft de in de literatuur vermelde strategieën om ‘burst release’ van matrices te beperken of 
zelfs te elimineren. 
 
De DOELSTELLING van dit onderzoekswerk was om een multiparticulaire 
geneesmiddelvorm te ontwikkelen op basis van polymeren, gebruik makende van een 
eenvoudige, flexibele en economisch haalbare productietechniek. De eigenschappen van mini-
matrices, bestaande uit lipofiele en hydrofiele polymeren om de geneesmiddelvrijstelling te sturen 
en geproduceerd via ‘hot-melt’ extrusie, werden geëvalueerd. 
 
HOOFDSTUK 1 beschrijft het formulatie-onderzoek van mini-matrices voor vertraagde 
geneesmiddelvrijstelling. Deze mini-matrices werden geproduceerd via ‘hot-melt’ extrusie, met 
ibuprofen als modelgeneesmiddel en ethylcellulose als vrijstellingsvertragende drager. 
Xanthaangom, een hydrofiel polymeer, werd aan de formulatie toegevoegd om de 
 
 
223
SAMENVATTING EN ALGEMEEN BESLUIT 
 
geneesmiddelvrijstelling te versnellen, vermits de vrijstelling van ibuprofen uit 
ibuprofen/ethylcellulose matrices (60/40, g/g) te traag verliep (20% in 24 u). In het eerste deel van 
hoofdstuk 1 werd aangetoond dat zowel de xanthaangom-concentratie als de deeltjesgrootte van 
xanthaangom het in vitro vrijstellingsprofiel beïnvloedden. Hogere xanthaangom-concentraties 
zorgden voor een snellere geneesmiddelvrijstelling, dit omwille van een hogere wateropname, 
zwelling en erosiesnelheid. Wat betreft de invloed van de deeltjesgrootte van xanthaangom, werd 
er geen verschil in vrijstelling vastgesteld tussen formulaties op basis van 10 en 20% 
xanthaangom. Echter, voor de formulaties op basis van 30% xanthaangom werd de 
geneesmiddelvrijstelling wel beïnvloed door de deeltjesgrootte van het hydrofiele polymeer, omdat 
de grotere xanthaangomdeeltjes gevoeliger zijn voor erosie. Onderzoek naar de porositeit van de 
mini-matrices gaf aan dat de initiële porositeit (≤ 5.5%) onafhankelijk is van de samenstelling 
(xanthaangom-concentratie, xanthaangom-deeltjesgrootte) van de mini-matrices, en aldus niet 
verantwoordelijk kan geacht worden voor verschillen in de vrijstellingsprofielen. 
Geneesmiddelvrijstelling uit de mini-matrices was vooral diffusie-gecontroleerd, nochtans bleek 
ook zwelling een belangrijke rol te spelen in het bekomen van volledige geneesmiddelvrijstelling 
binnen de 24 u. De ibuprofen-vrijstelling werd niet beïnvloed door de hydrodynamische condities 
tijdens de in vitro dissolutietest. De ionensterkte van het dissolutiemedium bleek wel een invloed 
te hebben op de geneesmiddelvrijstelling, vermits de conformatie van xanthaangom afhangt van 
de zoutconcentratie. Het verhogen van de xanthaangom-concentratie leidde tot een hogere 
friabiliteit (≤ 0.32%), dewelke gecorreleerd was met een daling van de hardheid; de invloed van de 
xanthaangom-deeltjesgrootte bleek verwaarloosbaar te zijn. Een stabiliteitsstudie toonde aan dat 
de geneesmiddelvrijstelling, wateropname en hardheid van de xanthaangom-formulaties 
wijzigden gedurende 12 maanden bewaring bij 25°C/60% relatieve vochtigheid en bij 40°C/75% 
relatieve vochtigheid, wat inhoudt dat deze formulaties op een geschikte manier zullen moeten 
verpakt worden. In het tweede deel van dit hoofdstuk werd een orale dosis van 300 mg ibuprofen 
toegediend aan 6 honden, dit onder de vorm van een ‘immediate-release’ preparaat (Junifen®), 
een ‘sustained-release’ preparaat (Ibu-Slow® 600 mg (½ tablet)) of de experimentele formulaties 
(mini-matrices met variërende xanthaangom-concentratie). Via een HPLC-UV methode, 
gevalideerd volgens de ICH-richtlijnen, werden de concentraties aan ibuprofen in hondenplasma 
bepaald. Er werd geen interferentie vastgesteld tussen ibuprofen, de interne standaard en 
endogene plasmacomponenten. De calibratiecurves waren lineair binnen het gehele 
concentratiegebied (R2 = 0.9997 ± 0.0003; n = 10). De recovery van ibuprofen 
(concentratiegebied: 0.25-20 µg/ml) na extractie varieerde tussen 82.4 en 88.9%, terwijl 73.5% 
van de interne standaard (indomethacine) werd teruggevonden. De methode was precies binnen 
dezelfde concentratierange, aangezien de variatiecoëfficiënten voor de herhaalbaarheid en 
intermediaire precisie respectievelijk tussen 2.9 en 8.0% en tussen 4.4 en 12.5% lagen. Ibuprofen 
kon nauwkeurig bepaald worden, vermits een accuraatheid tussen 86.8 en 103.4% verkregen 
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werd. De detectie- en kwantificatielimiet werden vastgelegd op 0.25 µg/ml. Toediening van de 
experimentele formulaties leidde tot een vertraagde ibuprofen-vrijstelling. Echter, het significante 
verschil in in vitro dissolutiesnelheid tussen de 20 en 30% xanthaangom-formulaties werd niet 
teruggevonden in vivo: het verschil in relatieve biologische beschikbaarheid (met Ibu-Slow® 600 
mg als referentie) bleek immers beperkt (respectievelijk 70.6 en 73.8%).  
 
In HOOFDSTUK 2 werden via ‘hot-melt’ extrusie (cylindrische ‘die’: 3 mm) mini-matrices 
met vrijstellingsvertragende eigenschappen geproduceerd, op basis van ethylcellulose als 
vrijstellingsvertragende drager en metoprololtartraat als modelgeneesmiddel dat geen 
weekmakend effect heeft op het dragerpolymeer. Bij mini-matrices geformuleerd op basis 
van triethylcitraat of triacetine (hydrofiele weekmakers) werd een ‘burst release’ vastgesteld, 
terwijl geneesmiddelvrijstelling uit matrices met dibutylsebacaat of diethylftalaat (hydrofobe 
weekmakers) een traag, nulde orde profiel vertoonde. Ondanks het verschil in hydrofiliciteit 
van de weekmakers hadden ze allen hetzelfde weekmakend effect tijdens verwerking. 
Dibutylsebacaat werd geselecteerd als weekmaker voor de verdere formulatie-ontwikkeling 
en de concentratie werd geoptimaliseerd tot 50% (g/g) van de ethylcellulose-concentratie. 
Xanthaangom, een hydrofiel polymeer, werd toegevoegd aan de formulatie om de 
geneesmiddelvrijstelling te versnellen. Wijziging van de xanthaangom-concentratie leidde tot 
een wijziging van de in vitro geneesmiddelvrijstelling: hogere xanthaangom-concentraties (1, 
2.5, 5, 10 and 20%, g/g) gaven een snellere geneesmiddelvrijstelling. Een nulde orde 
vrijstellingskinetiek werd bereikt met 5% (g/g) xanthaangom. Met behulp van X-
straaldiffractie werd vastgesteld dat metoprololtartraat in kristallijne vorm aanwezig was in de 
geëxtrudeerde matrices, onafhankelijk van de xanthaangom-concentratie. De productie van 
de extrudaten was reproduceerbaar, en na een equilibratietijd van 5 min konden extrudaten 
van constante kwaliteit geproduceerd worden. Incorporatie van kneedelementen in de 
schroefconfiguratie liet toe gladde extrudaten te produceren bij een procestemperatuur van 
60°C. Het aantal mengzones en hun lokalisatie in het extrusietoestel hadden geen invloed op 
de mengefficiëntie en de geneesmiddelvrijstelling. Een schroefconfiguratie van louter 
transportzones leidde (bij 60°C) tot extrudaten met een onregelmatig oppervlak en met 
poederzones op het oppervlak (geïdentificeerd als metoprololtartraat via Raman 
spectroscopie). Verhogen van de extrusietemperatuur (70°C) verbeterde de 
oppervlaktestructuur van het extrudaat, doch metoprololtartraat-zones bleven zichtbaar op 
het oppervlak. Raman analyse toonde aan dat metoprololtartraat homogeen verdeeld was in 
de mini-matrices, onafhankelijk van de schroefconfiguratie en procesomstandigheden. 
Simultane wijziging van de poedertoevoersnelheid (6-50 g/min) en de schroefsnelheid (30-
200 tpm) had geen invloed op de extrudaatkwaliteit of de dissolutie-eigenschappen.    
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In HOOFDSTUK 3 werd geopteerd om xanthaangom te vervangen door polyethyleenglycol 
of polyethyleenoxides, omdat van deze polymeren gekend is dat hun zweleigenschappen 
afhangen van hun moleculair gewicht. Er werden mini-matrices met vrijstellingsvertragende 
eigenschappen geproduceerd via ‘hot-melt’ extrusie (diameter 3 mm, hoogte 2 mm), met 
metoprololtartraat als modelgeneesmiddel (30%, g/g) en ethylcellulose als vrijstellingsvertragende 
drager. Polyethyleenglycol of polyethyleenoxide werd toegevoegd aan de formulatie om de 
geneesmiddelvrijstelling te versnellen. Wijziging van de concentratie van het hydrofiele polymeer 
(0, 1, 2.5, 5, 10, 20 en 70%, g/g) en van het moleculair gewicht (6000, 100.000, 1.000.000 en 
7.000.000) wijzigde het in vitro vrijstellingsprofiel: toenemende concentraties gaven een snellere 
geneesmiddelvrijstelling (onafhankelijk van het moleculair gewicht), terwijl de invloed van het 
moleculair gewicht afhing van de concentratie. Polyethyleenglycol/polyethyleenoxide-vrijstelling 
nam toe bij hogere polyethyleenglycol/polyethyleenoxide-concentratie (onafhankelijk van het 
moleculair gewicht), en een tragere polyethyleenglycol/polyethyleenoxide-vrijstelling werd gezien 
voor alle formulaties met polyethyleenoxide met hoog moleculair gewicht. Er werden gladde 
extrudaten bekomen bij een extrusietemperatuur van respectievelijk 40 en 70°C, voor 
polyethyleenglycol- en polyethyleenoxide-formulaties. Raman spectroscopie toonde aan dat 
metoprololtartraat homogeen verdeeld was in de mini-matrices, onafhankelijk van de concentratie 
en het moleculair gewicht van het hydrofiele polymeer. Ook de geneesmiddel- en 
polymeerkristalliniteit bleken onafhankelijk te zijn van deze twee parameters. De biologische 
beschikbaarheid werd bepaald na orale toediening van 200 mg metoprololtartraat aan 6 honden, 
dit onder de vorm van een ‘immediate-release’ preparaat (Lopresor® 100 (2 tabletten)), een 
‘sustained-release’ preparaat (Slow-Lopresor® 200 Divitabs®) of de experimentele formulaties 
(mini-matrices met variërende concentraties van het hydrofiele polymeer). Voor de bepaling van 
het geneesmiddelgehalte in hondenplasma werd gebruik gemaakt van een HPLC-fluorescentie 
methode die gevalideerd was in overeenstemming met de ICH-richtlijnen. Er werd geen 
interferentie waargenomen van metoprololtartraat en alprenolol (interne standaard) met endogene 
componenten. De calibratiecurves waren lineair (R2 = 0.9976 ± 0.0015; n = 10) in een 
concentratiegebied van 0.05 tot 3.0 µg/ml. De recovery van metoprololtartraat na extractie 
varieerde afhankelijk van de concentratie tussen 79.3 en 85.0%, terwijl 85.1% van de interne 
standaard werd gerecupereerd. De methode was exact: de variatiecoëfficiënten voor de 
herhaalbaarheid en intermediaire precisie varieerden respectievelijk van 3.7 tot 10.5% en van 1.7 
tot 11.6%. Metoprololtartraat kon accuraat bepaald worden, aangezien een nauwkeurigheid 
tussen 91.7 en 125.7% behaald werd. De detectie- en kwantificatielimiet bedroegen 0.05 µg/ml. 
Het vrijstellingsvertragend effect van de experimentele formulaties bleek echter beperkt. Een 
relatieve biologische beschikbaarheid (met Slow-Lopresor® 200 Divitabs® als referentie) van 
respectievelijk 51.5, 94.4, 131.5, 66.2 en 148.2% werd bekomen met mini-matrices op basis van 
5, 10 en 20% xanthaangom, en 5 en 20% PEO 1.000.000.  
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Hoofdstuk 3 toonde aan dat geneesmiddel- en polymeervrijstelling beïnvloed werden door 
zowel de concentratie als het moleculair gewicht van polyethyleenglycol/polyethyleenoxide. Om 
deze reden werd in HOOFDSTUK 4 de geneesmiddel- en polymeervrijstelling uit de geëxtrudeerde 
mini-matrices wiskundig gemodelleerd. Het geneesmiddel- en 
polyethyleenglycol/polyethyleenoxide-vrijstellingsmechanisme was afhankelijk van de 
polymeerconcentratie en het moleculair gewicht. Het verhogen van de concentratie hydrofiel 
polymeer resulteerde in hogere geneesmiddel- en polymeer-diffusiecoëfficiënten. Een stijging van 
het moleculair gewicht leidde tot een daling van de diffusiecoëfficiënt van geneesmiddel en 
polymeer. Bij hoge polyethyleenglycol/polyethyleenoxide-concentratie (≥ 20%) (onafhankelijk van 
het moleculair gewicht van het polymeer), en bij lage/intermediaire polymeerconcentratie in geval 
van laag/intermediair moleculair gewicht (≤ 100.000 Da), werd de geneesmiddel- en de 
polymeervrijstelling gecontroleerd door diffusie (tweede wet van Fick). Voor deze mini-matrices (3 
mm diameter, 2 mm hoogte) resulteerde dit in een goede correlatie tussen theoretische 
modellering en experimentele data. Op basis van de geneesmiddel-diffusiecoëfficiënten van deze 
mini-matrices, kon de vrijstelling van metoprololtartraat uit cilinders met willekeurige afmetingen 
(variabele diameter (0.5-6 mm) met constante hoogte (2 mm), variabele hoogte (1-32 mm) met 
constante diameter (1.5 mm)) kwantitatief voorspeld worden: een kleine diameter en een kleine 
lengte versnellen de geneesmiddelvrijstelling, terwijl een grote diameter en een grote lengte de 
geneesmiddelvrijstelling vertragen. Er werd in alle gevallen overeenstemming tussen de 
theoretische berekeningen en de experimentele data vastgesteld, waardoor het diffusie-
gecontroleerde vrijstellingsmechanisme en de validiteit van het model kon worden bevestigd. 
Daarentegen, bij lage/intermediaire polyethyleenglycol/polyethyleenoxide-concentratie (1-10%) in 
geval van hoog moleculair gewicht (≥ 1.000.000 Da) werd de geneesmiddel- en 
polymeervrijstelling niet enkel en alleen door diffusie gecontroleerd, waardoor er significante 
afwijkingen waren tussen theoretische (uitgaande van constante diffusie) en experimentele 
vrijstellingsprofielen voor mini-matrices van 3 mm diameter en 2 mm hoogte. Dus, in deze 
gevallen bleek het geneesmiddel- en polymeervrijstellingsmechanisme complexer te zijn en was 
een nieuwe theorie noodzakelijk: er werd een mathematisch model ontwikkeld dat rekening hield 
met de experimenteel vastgestelde toename in porositeit van de cilinders tijdens geneesmiddel- 
en polymeervrijstelling, en met de tijdsafhankelijke geneesmiddel- en polymeermobiliteit.  Dit 
model (met meer realistische condities voor geneesmiddel- en polymeerdiffusie) kon de 
experimenteel vastgestelde vrijstellingskinetieken adequater beschrijven, waardoor een betere 
overeenkomst tussen de theoretische voorspellingen en de experimentele data werd bekomen. 
Een interessante toepassing van dit model is de mogelijkheid om het effect van verschillende 
formulatieparameters op de geneesmiddel- en polymeervrijstellingspatronen kwantitatief te gaan 
voorspellen. 
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 Het objectief van deze doctoraatsthesis was het ontwikkelen van een multiparticulaire 
geneesmiddelvorm met een vertraagd, nulde orde vrijstellingsprofiel, met behulp van een 
eenvoudige, flexibele en continue productietechniek, nl. ‘hot-melt’ extrusie. Dit onderzoek toonde 
aan dat de in vitro en in vivo vrijstellingskinetiek kan aangepast worden door selectie van een 
formulatie met een geschikte ratio van lipofiele en hydrofiele polymeren, en door wijziging van de 
deeltjesgrootte en/of moleculair gewicht van het hydrofiel polymeer (xanthaangom en 
polyethyleenoxide). Verder onderzoek zou zich kunnen richten op volgende onderwerpen: 
- Vermits dit onderzoek steeds werkte met ethylcellulose als dragerpolymeer zou het interessant 
kunnen zijn om na te gaan of ‘hot-melt’ extrusie van andere lipofiele polymeren (in combinatie van 
hydrofiele polymeren) duidelijke voordelen biedt ten opzichte van mini-matrices op basis van 
ethylcellulose.  
- Alle formulaties onderzocht tijdens dit doctoraatswerk werden geproduceerd met een specifiek 
type ‘lab-scale’ extruder. Het is echter bekend dat toesteltype en batchgrootte (omwille van een 
verschil in energietoevoer en warmte-ontwikkeling tijdens de langere procestijden) het gedrag van 
het materiaal kan beïnvloeden, en aldus ook de extrudaat- en matrixkwaliteit. Daardoor zou 
procesopschaling een uitdagende stap kunnen vormen in de evaluatie van ‘hot-melt’ extrusie als 
productietechniek voor multiparticulaire geneesmiddelvormen. 
- Toekomstig werk kan ook focussen op co-extrusie (meerdere lagen van materiaal worden 
simultaan geëxtrudeerd): incorporatie van polymeren met verschillende hydratatie-, zwelling- en 
vrijstellingseigenschappen in verschillende lagen zou kunnen resulteren in een 
geneesmiddelvorm met nulde orde kinetiek. 
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